

COVID-19 spike protein pathogenicity research library

Compiled by Dr. Martin Wucher, MSC Dent Sc (eq DDS), Erik Sass, et al.

Doi: [10.5281/zenodo.14269255](https://doi.org/10.5281/zenodo.14269255)

Last updated December 26, 2024. Corresponding author: eriksass@gmail.com

Originally part of the outer coat of the SARS-CoV2 virus, where it functions as a “key” to “unlock” (infect) cells, spike proteins are also produced in large amounts by the mRNA “vaccines,” triggering a short-lived immune response in the form of antibodies. However, a growing body of evidence has shown that the spike protein is harmful by itself, independent of the rest of the virus.

The following (I. Alphabetical List) collects over 300 (**n=320**) peer-reviewed scientific studies confirming that the spike protein is highly pathogenic on its own; most *in vitro* studies cited here used recombinant spike proteins or spike proteins in pseudoviral vectors, and produced pathological effects not reliant on the SARS-CoV2 viral machinery.

The second section (II. Categories) organizes the research into broad categories including affected tissues and organ systems, mechanisms, and evidence from clinical pathology. Because these areas overlap, many articles appear more than once in the second section.

This compilation originated with Dr. Wucher's contribution to [TOXIC SHOT: Facing the Dangers of the COVID "Vaccines,"](#) (Chapter 4: The Spike Protein Is Harmful By Itself).

Please note a separate research collection of over 100 peer-reviewed papers (**n=130**) addresses mRNA “vaccine” biodistribution, persistence, and adjuvant toxicity here: <https://zenodo.org/records/14559625>

I. ALPHABETICAL LIST (n=320)

1. Abdi A et al., “Biomed Interaction of SARS-CoV-2 with cardiomyocytes: Insight into the underlying molecular mechanisms of cardiac injury and pharmacotherapy,” *Pharmacother.* 2022, 146: 112518. doi: [10.1016/j.biopha.2021.112518](https://doi.org/10.1016/j.biopha.2021.112518)
2. Aboudounya MM and RJ Heads, “COVID-19 and Toll-Like Receptor 4 (TLR4): SARS-CoV-2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation,” *Mediators Inflamm.* 2021, 8874339. doi: <https://doi.org/10.1155/2021/8874339>
3. Acevedo-Whitehouse K and R Bruno, “Potential health risks of mRNA-based vaccine therapy: A hypothesis,” *Med. Hypotheses* 2023, 171: 111015. doi: <https://doi.org/10.1016/j.mehy.2023.111015>

4. Ahn WM et al., "SARS-CoV-2 Spike Protein Stimulates Macropinocytosis in Murine and Human Macrophages via PKC-NADPH Oxidase Signaling," *Antioxidants* 2024, 13, 2: 175. doi: <https://doi.org/10.3390/antiox13020175>
5. Ait-Belkacem I et al., "SARS-CoV-2 spike protein induces a differential monocyte activation that may contribute to age bias in COVID-19 severity," *Sci. Rep.* 2022, 12: 20824. doi: <https://doi.org/10.1038/s41598-022-25259-2>
6. Aksenova AY et al., "The increased amyloidogenicity of Spike RBD and pH-dependent binding to ACE2 may contribute to the transmissibility and pathogenic properties of SARS-CoV-2 omicron as suggested by in silico study," *Int. J. Mol. Sci.* 2022, 23, 21: 13502. doi: <https://doi.org/10.3390/ijms232113502>
7. Al-Kuraishy HM et al., "Changes in the Blood Viscosity in Patients With SARS-CoV-2 Infection," *Front. Med.* 2022, 9: 876017. doi: [10.3389/fmed.2022.876017](https://doi.org/10.3389/fmed.2022.876017)
8. Al-Kuraishy HM et al., "Hemolytic anemia in COVID-19," *Ann. Hematol.* 2022, 101: 1887–1895. doi: [10.1007/s00277-022-04907-7](https://doi.org/10.1007/s00277-022-04907-7)
9. Albornoz EA et al., "SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein," *Mol. Psychiatr.* 2023, 28: 2878–2893. doi: <https://doi.org/10.1038/s41380-022-01831-0>
10. Almehdi AM et al., "SARS-CoV-2 Spike Protein: Pathogenesis, Vaccines, and Potential Therapies," *Infection* 2021, 49, 5: 855–876. doi: <https://doi.org/10.1007/s15010-021-01677-8>
11. Angeli F et al., "COVID-19, vaccines and deficiency of ACE2 and other angiotensinases. Closing the loop on the 'Spike effect'," *Eur J. Intern. Med.* 2022, 103: 23–28. doi: [10.1016/j.ejim.2022.06.015](https://doi.org/10.1016/j.ejim.2022.06.015)
12. Angeli F et al., "The spike effect of acute respiratory syndrome coronavirus 2 and coronavirus disease 2019 vaccines on blood pressure," *Eur. J. Intern. Med.* 2022, 109: 12-21. doi: [10.1016/j.ejim.2022.12.004](https://doi.org/10.1016/j.ejim.2022.12.004)
13. Ao Z et al., "SARS-CoV-2 Delta spike protein enhances the viral fusogenicity and inflammatory cytokine production," *iScience* 2022, 25, 8: 104759. doi: [10.1016/j.isci.2022.104759](https://doi.org/10.1016/j.isci.2022.104759)
14. Appelbaum K et al., "SARS-CoV-2 spike-dependent platelet activation in COVID-19 vaccine-induced thrombocytopenia," *Blood Adv.* 2022, 6: 2250–2253. doi: [10.1182/bloodadvances.2021005050](https://doi.org/10.1182/bloodadvances.2021005050)
15. Arjsri P et al., "Hesperetin from root extract of *Clerodendrum petasites* S. Moore inhibits SARS-CoV-2 spike protein S1 subunit-induced Nlrp3 inflammasome in A549 lung cells via modulation of the Akt/Mapk/Ap-1 pathway," *Int. J. Mol. Sci.* 2022, 23, 18: 10346. doi: <https://doi.org/10.3390/ijms231810346>
16. Asandei A et al., "Non-Receptor-Mediated Lipid Membrane Permeabilization by the SARS-CoV-2 Spike Protein S1 Subunit," *ACS Appl. Mater. Interfaces* 2020, 12, 50: 55649–55658. doi: <https://doi.org/10.1021/acsami.0c17044>
17. Avolio E et al., "The SARS-CoV-2 Spike Protein Disrupts Human Cardiac Pericytes Function through CD147 Receptor-Mediated Signalling: A Potential Non-infective Mechanism of COVID-19

- Microvascular Disease,” *Clin. Sci.* 2021, 135, 24: 2667–2689, doi: <https://doi.org/10.1042/CS20210735>
18. Baldari CT et al., “Emerging Roles of SARS-CoV-2 Spike-ACE2 in Immune Evasion and Pathogenesis,” *Trends Immunol.* 2023, 44, 6. doi: <https://doi.org/10.1016/j.it.2023.04.001>
 19. Balzanelli MG et al., “The Role of SARS-CoV-2 Spike Protein in Long-term Damage of Tissues and Organs, the Underestimated Role of Retrotransposons and Stem Cells, a Working Hypothesis,” *Endocr Metab Immune Disord Drug Targets* 2025, 25, 2: 85-98. doi: [10.2174/0118715303283480240227113401](https://doi.org/10.2174/0118715303283480240227113401)
 20. Bansal S et al., “Cutting Edge: Circulating Exosomes with COVID Spike Protein Are Induced by BNT162b2 (Pfizer-BioNTech) Vaccination prior to Development of Antibodies: A Novel Mechanism for Immune Activation by mRNA Vaccines,” *J. Immunol.* 2021, 207, 10: 2405–2410. doi: <https://doi.org/10.4049/jimmunol.2100637>
 21. Barhoumi T et al., “SARS-CoV-2 coronavirus Spike protein-induced apoptosis, inflammatory, and oxidative stress responses in THP-1-like-macrophages: potential role of angiotensin-converting enzyme inhibitor (perindopril),” *Front Immunol.* 2021, 12: 728896. doi: <https://doi.org/10.3389/fimmu.2021.728896>
 22. Barreda D et al., “SARS-CoV-2 Spike Protein and Its Receptor Binding Domain Promote a Proinflammatory Activation Profile on Human Dendritic Cells,” *Cells* 2021, 10, 12: 3279. doi: <https://doi.org/10.3390/cells10123279>
 23. Baumeier C et al., “Intramyocardial Inflammation after COVID-19 Vaccination: An Endomyocardial Biopsy-Proven Case Series,” *Int. J. Mol. Sci.* 2022, 23: 6940. doi: <https://doi.org/10.3390/ijms23136940>
 24. Bellavite P et al., “Immune response and molecular mechanisms of cardiovascular adverse effects of spike proteins from SARS-coV-2 and mRNA vaccines,” *Biomedicines* 2023, 11, 2: 451. doi: <https://doi.org/10.3390/biomedicines11020451>
 25. Bellucci M et al., “Post-SARS-CoV-2 infection and post-vaccine-related neurological complications share clinical features and the same positivity to anti-ACE2 antibodies,” *Front. Immunol.* 2024, 15 (Sec. Multiple Sclerosis and Neuroimmunology). doi: <https://doi.org/10.3389/fimmu.2024.1398028>
 26. Bhargavan B and GD Kanmogne, “SARS-CoV-2 spike proteins and cell–cell communication inhibits TFPI and induces thrombogenic factors in human lung microvascular endothelial cells and neutrophils: implications for COVID-19 coagulopathy pathogenesis,” *Int. J. Mol. Sci.* 2022, 23, 18: 10436. doi: <https://doi.org/10.3390/ijms231810436>
 27. Bhattacharyya S and JK Tobacman, “SARS-CoV-2 spike protein-ACE2 interaction increases carbohydrate sulfotransferases and reduces N-acetylgalactosamine-4-sulfatase by p38 MAPK,” *Signal Transduct Target Ther* 2024, 9, 39. doi: <https://doi.org/10.1038/s41392-024-01741-3>
 28. Biancatelli RMLC et al., “The SARS-CoV-2 spike protein subunit S1 induces COVID-19-like acute lung injury in Kappa18-hACE2 transgenic mice and barrier dysfunction in human endothelial cells,” *Am. J. Physiol. Lung Cell. Mol. Physiol.* 2021, 321, L477–L484. doi: <https://doi.org/10.1152/ajplung.00223.2021>

29. Biering SB et al., "SARS-CoV-2 Spike Triggers Barrier Dysfunction and Vascular Leak via Integrins and TGF- β Signaling," *Nat. Commun.* 2022, 13: 7630. doi: <https://doi.org/10.1038/s41467-022-34910-5>
30. Bocquet-Garcon A, "Impact of the SARS-CoV-2 Spike Protein on the Innate Immune System: A Review," *Cureus* 2024, 16, 3: e57008. doi: [10.7759/cureus.57008](https://doi.org/10.7759/cureus.57008)
31. Boretti A, "PQQ Supplementation and SARS-CoV-2 Spike Protein-Induced Heart Inflammation," *Nat. Prod. Commun.* 2022, 17, 1934578x221080929. doi: <https://doi.org/10.1177/1934578X221080929>
32. Boros LG et al., "Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination," *Pharmacol Res Perspect* 2024, 12, 3: e1218. doi: <https://doi.org/10.1002/prp2.1218>
33. Bortolotti D et al., "SARS-CoV-2 Spike 1 Protein Controls Natural Killer Cell Activation via the HLA-E/NKG2A Pathway," *Cells* 2020, 9, 9: 1975. doi: <https://doi.org/10.3390/cells9091975>
34. Boschi C et al., "SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects," *Int. J. Biol. Macromol.* 2022, 23, 24: 15480. doi: <https://doi.org/10.3390/ijms232415480>
35. Brady M et al., "Spike protein multiorgan tropism suppressed by antibodies targeting SARS-CoV-2," *Comm. Biol.* 2021, 4, 1318. doi: <https://doi.org/10.1038/s42003-021-02856-x>
36. Braga L et al., "Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia," *Nature* 2021, 594: 88–93. doi: <https://doi.org/10.1038/s41586-021-03491-6>
37. Buoninfante A et al., "Myocarditis associated with COVID-19 vaccination," *npj Vaccines* 2024, 122. doi: <https://doi.org/10.1038/s41541-024-00893-1>
38. Burkhardt A, "Pathology Conference: Vaccine-Induced Spike Protein Production in the Brain, Organs etc., now Proven," *Report24.news*. 2022, <https://report24.news/pathologie-konferenz-impfinduzierte-spike-produktion-in-gehirn-u-a-organen-nun-erwiesen/>
39. Burnett FN et al., "SARS-CoV-2 Spike Protein Intensifies Cerebrovascular Complications in Diabetic hACE2 Mice through RAAS and TLR Signaling Activation," *Int. J. Mol. Sci.* 2023, 24, 22: 16394. doi: <https://doi.org/10.3390/ijms242216394>
40. Buzhdygan TP et al., "The SARS-CoV-2 Spike Protein Alters Barrier Function in 2D Static and 3D Microfluidic in-Vitro Models of the Human Blood-Brain Barrier," *Neurobiol. Dis.* 2020, 146, 105131. doi: <https://doi.org/10.1016/j.nbd.2020.105131>
41. Bye AP et al., "Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets," *Blood* 2021, 138, 6: 1481–9. doi: <https://doi.org/10.1182/blood.2021011871>
42. Cao JB et al., "Mast cell degranulation-triggered by SARS-CoV-2 induces tracheal-bronchial epithelial inflammation and injury," *Viol. Sin.* 2024, 39, 2: 309-318. doi: <https://doi.org/10.1016/j.virs.2024.03.001>
43. Cao S et al., "Spike Protein Fragments Promote Alzheimer's Amyloidogenesis," *ACS Appl. Mater. Interfaces* 2023, 15, 34: 40317-40329. doi: <https://doi.org/10.1021/acsami.3c09815>

44. Cao X et al., "Spike protein of SARS-CoV-2 activates macrophages and contributes to induction of acute lung inflammation in male mice," *FASEB J.* 2021, 35, e21801. doi: <https://doi.org/10.1096/fj.202002742RR>
45. Cao X et al., "The SARS-CoV-2 spike protein induces long-term transcriptional perturbations of mitochondrial metabolic genes, causes cardiac fibrosis, and reduces myocardial contractile in obese mice," *Mol. Metab.* 2023, 74, 101756. doi: <https://doi.org/10.1016/j.molmet.2023.101756>
46. Caohuy H et al., "Inflammation in the COVID-19 airway is due to inhibition of CFTR signaling by the SARS-CoV-2 spike protein," *Sci. Rep.* 2024, 14: 16895. doi: <https://doi.org/10.1038/s41598-024-66473-4>
47. Carnevale R et al., "Toll-Like Receptor 4-Dependent Platelet-Related Thrombosis in SARS-CoV-2 Infection," *Circ. Res.* 2023, 132, 3: 290–305, doi: <https://doi.org/10.1161/CIRCRESAHA.122.321541>
48. Cattin-Ortolá J et al., "Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate expression at the cell surface and syncytia formation," *Nat Commun* 2021, 12, 1: 5333. doi: <https://doi.org/10.1038/s41467-021-25589-1>
49. Chang MH et al., "SARS-CoV-2 Spike Protein 1 Causes Aggregation of α -Synuclein via Microglia-Induced Inflammation and Production of Mitochondrial ROS: Potential Therapeutic Applications of Metformin," *Biomedicines* 2024, 12, 6: 1223. doi: <https://doi.org/10.3390/biomedicines12061223>
50. Chaves JCS et al., "Differential Cytokine Responses of APOE3 and APOE4 Blood-brain Barrier Cell Types to SARS-CoV-2 Spike Proteins," *J. Neuroimmune Pharmacol.* 2024, 19, 22. doi: <https://doi.org/10.1007/s11481-024-10127-9>
51. Cheng MH et al., "Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation," *Proc Natl Acad Sci* 2020, 117: 25254–25262. doi: <https://doi.org/10.1073/pnas.201072211>
52. Cheung CCL et al., "Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19," *Gut* 2022, 71, 1: 226–9. doi: <https://doi.org/10.1136/gutjnl-2021-324280>
53. Chiok K et al., "Proinflammatory Responses in SARS-CoV-2 and Soluble Spike Glycoprotein S1 Subunit Activated Human Macrophages," *Viruses* 2023, 15, 3: 754. doi: <https://doi.org/10.3390/v15030754>
54. Chittasupho C et al., "Inhibition of SARS-CoV-2-Induced NLRP3 Inflammasome-Mediated Lung Cell Inflammation by Triphala-Loaded Nanoparticle Targeting Spike Glycoprotein S1," *Pharmaceutics* 2024, 16, 6: 751. <https://doi.org/10.3390/pharmaceutics16060751>
55. Chittasupho C et al., "Targeting spike glycoprotein S1 mediated by NLRP3 inflammasome machinery and the cytokine releases in A549 lung epithelial cells by nanocurcumin," *Pharmaceutics* (Basel) 2023, 16, 6: 862. doi: <https://doi.org/10.3390/ph16060862>
56. Choi JY et al., "SARS-CoV-2 spike S1 subunit protein-mediated increase of beta-secretase 1 (BACE1) impairs human brain vessel cells," *Biochem. Biophys. Res. Commun.* 2022, 625, 20: 66–71. doi: <https://doi.org/10.1016/j.bbrc.2022.07.113>

57. Clemens DJ et al., "SARS-CoV-2 spike protein-mediated cardiomyocyte fusion may contribute to increased arrhythmic risk in COVID-19," *PLoS One* 2023, 18, 3: e0282151. doi: <https://doi.org/10.1371/journal.pone.0282151>
58. Clough E et al., "Mitochondrial Dynamics in SARS-COV2 Spike Protein Treated Human Microglia: Implications for Neuro-COVID," *Journal of Neuroimmune Pharmacology* 2021, 16, 4: 770–784. doi: <https://doi.org/10.1007/s11481-021-10015-6>
59. Colmenero I et al., "SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases," *Br J Dermatol.* 2020, 183: 729-737. doi: <https://doi.org/10.1111/bjd.19327/>
60. Coly M, et al., "Subacute monomelic radiculoplexus neuropathy following Comirnaty(c) (Pfizer-BioNTech COVID-19) vaccination: A case report," *Revue Neurologique* 2023, 179, 6: 636-639. doi: <https://doi.org/10.1016/j.neurol.2023.02.063>
61. Corpetti C et al., "Cannabidiol inhibits SARS-Cov-2 spike (S) protein-induced cytotoxicity and inflammation through a PPAR γ -dependent TLR4/NLRP3/Caspase-1 signaling suppression in Caco-2 cell line," *Phytother. Res.* 2021, 35, 12: 6893–6903. doi: <https://doi.org/10.1002/ptr.7302>
62. Correa Y et al., "SARS-CoV-2 spike protein removes lipids from model membranes and interferes with the capacity of high-density lipoprotein to exchange lipids," *J. Colloid Interface Sci.* 2021, 602: 732-739. doi: <https://doi.org/10.1016/j.jcis.2021.06.056>
63. Cory TJ et al., "Metformin Suppresses Monocyte Immunometabolic Activation by SARS-CoV-2 Spike Protein Subunit 1," *Front. Immunol.* 2021, 12 (Sec. Cytokines and Soluble Mediators in Immunity): 733921. doi: <https://doi.org/10.3389/fimmu.2021.733921>
64. Cosentino M and Franca Marino, "Understanding the Pharmacology of COVID- 19 mRNA Vaccines: Playing Dice with the Spike?" *Int. J. Mol. Sci.* 2022, 23, 18: 10881. doi: <https://doi.org/10.3390/ijms231810881>
65. Cossenza LC et al., "Inhibitory effects of SARS-CoV-2 spike protein and BNT162b2 vaccine on erythropoietin-induced globin gene expression in erythroid precursor cells from patients with β -thalassemia," *Exp. Hematol.* 2024, 129, 104128. doi: <https://doi.org/10.1016/j.exphem.2023.11.002>
66. Craddock V et al., "Persistent circulation of soluble and extracellular vesicle-linked Spike protein in individuals with postacute sequelae of COVID-19," *J Med. Virol.* 2023, 95, 2: e28568. doi: <https://doi.org/10.1002/jmv.28568>
67. Das T et al., "N-glycosylation of the SARS-CoV-2 spike protein at Asn331 and Asn343 is involved in spike-ACE2 binding, virus entry, and regulation of IL-6," *Microbiol. Immunol.* 2024, 68, 5: 165-178. doi: <https://doi.org/10.1111/1348-0421.13121>
68. De Michele M et al., "Evidence of SARS-CoV-2 Spike Protein on Retrieved Thrombi from COVID-19 Patients," *Journal of Hematology Oncology* 2022, 15, 108. doi: <https://doi.org/10.1186/s13045-022-01329-w>

69. De Michele M et al., "Vaccine-induced immune thrombotic thrombocytopenia: a possible pathogenic role of ChAdOx1 nCoV-19 vaccine-encoded soluble SARS-CoV-2 spike protein," *Haematologica* 2022, 107, 7: 1687–92. doi: <https://doi.org/10.3324/haematol.2021.280180>
70. De Sousa PMB et al., "Fatal Myocarditis following COVID-19 mRNA Immunization: A Case Report and Differential Diagnosis Review," *Vaccines* 2024, 12, 2: 194. doi: <https://doi.org/10.3390/vaccines12020194>
71. Del Re A et al., "Intranasal delivery of PEA-producing *Lactobacillus paracasei* F19 alleviates SARS-CoV-2 spike protein-induced lung injury in mice," *Transl. Med. Commun.* 2024, 9, 9. doi: <https://doi.org/10.1186/s41231-024-00167-x>
72. Del Re A et al., "Ultramicronized Palmitoylethanolamide Inhibits NLRP3 Inflammasome Expression and Pro-Inflammatory Response Activated by SARS-CoV-2 Spike Protein in Cultured Murine Alveolar Macrophages," *Metabolites* 2021, 11, 9: 592. doi: <https://doi.org/10.3390/metabo11090592>
73. Delgado JF et al., "SARS-CoV-2 spike protein vaccine-induced immune imprinting reduces nucleocapsid protein antibody response in SARS-CoV-2 infection," *J. Immunol. Res.* 2022: 8287087. doi: <https://doi.org/10.1155/2022/8287087>
74. DeOre BJ et al., "SARS-CoV-2 Spike Protein Disrupts Blood-Brain Barrier Integrity via RhoA Activation," *J Neuroimmune Pharmacol.* 2021, 16, 4: 722-728. doi: <https://doi.org/10.1007/s11481-021-10029-0>
75. Devaux CA and L. Camoin-Jau, "Molecular mimicry of the viral spike in the SARS-CoV-2 vaccine possibly triggers transient dysregulation of ACE2, leading to vascular and coagulation dysfunction similar to SARS-CoV-2 infection," *Viruses* 2023, 15, 5: 1045. doi: <https://doi.org/10.3390/v15051045>
76. Dissook S et al., "Luteolin-rich fraction from *Perilla frutescens* seed meal inhibits spike glycoprotein S1 of SARS-CoV-2-induced NLRP3 inflammasome lung cell inflammation via regulation of JAK1/STAT3 pathway: A potential anti-inflammatory compound against inflammation-induced long-COVID," *Front. Med.* 2023, 9: 1072056. doi: <https://doi.org/10.3389/fmed.2022.1072056>
77. Duarte C, "Age-dependent effects of the recombinant spike protein/SARS-CoV-2 on the M-CSF- and IL-34-differentiated macrophages in vitro," *Biochem. Biophys. Res. Commun.* 2021, 546: 97–102. doi: <https://doi.org/10.1016/j.bbrc.2021.01.104>
78. Erdogan MA, "Prenatal SARS-CoV-2 Spike Protein Exposure Induces Autism-Like Neurobehavioral Changes in Male Neonatal Rats," *J Neuroimmune Pharmacol.* 2023, 18, 4 :573-591. doi: [10.1007/s11481-023-10089-4](https://doi.org/10.1007/s11481-023-10089-4)
79. Erickson MA et al., "Blood-brain barrier penetration of non-replicating SARS-CoV-2 and S1 variants of concern induce neuroinflammation which is accentuated in a mouse model of Alzheimer's disease," *Brain Behav Immun* 2023, 109: 251-268. doi: <https://doi.org/10.1016/j.bbi.2023.01.010>
80. Fajloun Z et al., "SARS-CoV-2 or Vaccinal Spike Protein can Induce Mast Cell Activation Syndrome (MCAS)," *Infect Disord Drug Targets*, 2025, 25, 1: e300424229561. doi: [10.2174/0118715265319896240427045026](https://doi.org/10.2174/0118715265319896240427045026)

81. Ferrer MD et al., "Nitrite Attenuates the In Vitro Inflammatory Response of Immune Cells to the SARS-CoV-2 S Protein without Interfering in the Antioxidant Enzyme Activation," *Int. J. Mol. Sci.* 2024, 25, 5: 3001. <https://doi.org/10.3390/ijms25053001>
82. Fertig TE et al., "Beyond the injection site: identifying the cellular targets of mRNA vaccines," *J Cell Ident* 2024, 3, 1. doi: [10.47570/joci.2024.004](https://doi.org/10.47570/joci.2024.004)
83. Fertig TE et al., "Vaccine mRNA Can Be Detected in Blood at 15 Days Post Vaccination," *Biomedicines* 2022, 10, 7: 1538. doi: <https://doi.org/10.3390/biomedicines10071538>
84. Fontes-Dantas FL, "SARS-CoV-2 Spike Protein Induces TLR4-Mediated Long- Term Cognitive Dysfunction Recapitulating Post-COVID-19 Syndrome in Mice," *Cell Reports* 2023, 42, 3: 112189. doi: <https://doi.org/10.1016/j.celrep.2023.112189>
85. Forsyth CB et al., "The SARS-CoV-2 S1 spike protein promotes MAPK and NF-kB activation in human lung cells and inflammatory cytokine production in human lung and intestinal epithelial cells," *Microorganisms* 2022, 10, 10: 1996. doi: <https://doi.org/10.3390/microorganisms10101996>
86. Forte E, "Circulating spike protein may contribute to myocarditis after COVID-19 vaccination," *Nat. Cardiovasc. Res.* 2023, 2: 100. doi: <https://doi.org/10.1038/s44161-023-00222-0>
87. Frank MG et al., "Exploring the immunogenic properties of SARS-CoV-2 structural proteins: PAMP:TLR signaling in the mediation of the neuroinflammatory and neurologic sequelae of COVID-19," *Brain Behav Immun* 2023, 111. doi: <https://doi.org/10.1016/j.bbi.2023.04.009>
88. Frank MG et al., "SARS-CoV-2 Spike S1 Subunit Induces Neuroinflammatory, Microglial and Behavioral Sickness Responses: Evidence of PAMP-Like Properties," *Brain Behav. Immun.* 2022, 100: 267277. doi: <https://doi.org/10.1016/j.bbi.2021.12.007>
89. Frank MG et al., "SARS-CoV-2 S1 subunit produces a protracted priming of the neuroinflammatory, physiological, and behavioral responses to a remote immune challenge: A role for corticosteroids," *Brain Behav. Immun.* 2024, 121: 87-103. doi: <https://doi.org/10.1016/j.bbi.2024.07.034>
90. Fraser ME et al., "SARS-CoV-2 Spike Protein and Viral RNA Persist in the Lung of Patients With Post-COVID Lung Disease (abstract)," *Am J Respir Crit Care Med* 2024, 209: A4193. doi: https://doi.org/10.1164/ajrccm-conference.2024.209.1_MeetingAbstracts.A4193
91. Freeborn J, "Misfolded Spike Protein Could Explain Complicated COVID-19 Symptoms," *Medical News Today*, May 26, 2022, <https://www.medicalnewstoday.com/articles/misfolded-spike-protein-could-explain-complicated-covid-19-symptoms>
92. Freitas RS et al., "SARS-CoV-2 Spike antagonizes innate antiviral immunity by targeting interferon regulatory factor 3," *Front Cell Infect Microbiol.* 2021, 11: 789462. doi: <https://doi.org/10.3389/fcimb.2021.789462>
93. Frühbeck G et al., "FNDC4 and FNDC5 reduce SARS-CoV-2 entry points and spike glycoprotein S1-induced pyroptosis, apoptosis, and necroptosis in human adipocytes," *Cell Mol Immunol.* 2021, 18, 10: 2457–9. doi: <https://doi.org/10.1038/s41423-021-00762-0>

94. Gamblicher T et al., "SARS-CoV-2 spike protein is present in both endothelial and eccrine cells of a chilblain-like skin lesion," *J Eur Acad Dermatol Venereol.* 2020, 1, 10: e187-e189. doi: <https://doi.org/10.1111/jdv.16970>
95. Gao X et al., "Spike-Mediated ACE2 Down-Regulation Was Involved in the Pathogenesis of SARS-CoV-2 Infection," *Journal of Infection* 2022, 85, 4: 418–427, doi: [10.1016/j.jinf.2022.06.030](https://doi.org/10.1016/j.jinf.2022.06.030)
96. Gasparello J et al., "Sulforaphane inhibits the expression of interleukin-6 and interleukin-8 induced in bronchial epithelial IB3-1 cells by exposure to the SARS-CoV-2 Spike protein," *Phytomedicine* 2021, 87: 153583. doi: <https://doi.org/10.1016/j.phymed.2021.153583>
97. Gawaz A et al., "SARS-CoV-2-Induced Vasculitic Skin Lesions Are Associated with Massive Spike Protein Depositions in Autophagosomes," *J Invest Dermatol.* 2024, 144, 2: 369-377.e4. doi: <https://doi.org/10.1016/j.jid.2023.07.018>
98. Ghazanfari D et al., "Mechanistic insights into SARS-CoV-2 spike protein induction of the chemokine CXCL10," *Sci. Rep.* 2024, 14: 11179. doi: <https://doi.org/10.1038/s41598-024-61906-6>
99. Goh D et al., "Case report: Persistence of residual antigen and RNA of the SARS-CoV-2 virus in tissues of two patients with long COVID," *Front. Immunol.* 2022, 13 (Sec. Viral Immunology). doi: <https://doi.org/10.3389/fimmu.2022.939989>
100. Golob-Schwarzl N et al., "SARS-CoV-2 spike protein functionally interacts with primary human conjunctival epithelial cells to induce a pro-inflammatory response," *Eye* 2022, 36: 2353–5. doi: <https://doi.org/10.1038/s41433-022-02066-7>
101. Gracie NP et al., "Cellular signalling by SARS-CoV-2 spike protein," *Microbiology Australia* 2024, 45, 1: 13-17. doi: <https://doi.org/10.1071/MA24005>
102. Greenberger JS et al., "SARS-CoV-2 Spike Protein Induces Oxidative Stress and Senescence in Mouse and Human Lung," *In Vivo* 2024, 38, 4: 1546-1556; doi: <https://doi.org/10.21873/invivo.13605>
103. Grishma K and Das Sarma, "The Role of Coronavirus Spike Protein in Inducing Optic Neuritis in Mice: Parallels to the SARS-CoV-2 Virus," *J Neuroophthalmol* 2024, 44, 3: 319-329. Doi: [10.1097/WNO.0000000000002234](https://doi.org/10.1097/WNO.0000000000002234)
104. Grobbelaar LM et al., "SARS-CoV-2 Spike Protein S1 Induces Fibrin(ogen) Resistant to Fibrinolysis: Implications for Microclot Formation in COVID-19," *Bioscience Reports* 2021, 41, 8: BSR20210611. doi: <https://doi.org/10.1042/BSR20210611>
105. Gu T et al., "Cytokine Signature Induced by SARS-CoV-2 Spike Protein in a Mouse Model," *Front. Immunol.* 2021 (Sec. Inflammation). doi: <https://doi.org/10.3389/fimmu.2020.621441>
106. Guo X et al., "Regulation of proinflammatory molecules and tissue factor by SARS-CoV-2 spike protein in human placental cells: implications for SARS-CoV-2 pathogenesis in pregnant women," *Front Immunol* 2022, 13: 876555–876555. <https://doi.org/10.3389/fimmu.2022.876555>
107. Guo Y and V Kanamarlapudi, "Molecular Analysis of SARS-CoV-2 Spike Protein-Induced Endothelial Cell Permeability and vWF Secretion," *Int. J. Mol. Sci.* 2023, 24, 6: 5664. <https://doi.org/10.3390/ijms24065664>

108. Gussow AB et al., "Genomic Determinants of Pathogenicity in SARS-CoV-2 and Other Human Coronaviruses," *PNAS* 2020, 117, 26: 15193–15199. doi: <https://doi.org/10.1073/pnas.2008176117>
109. Halma MTJ et al., "Exploring autophagy in treating SARS-CoV-2 spike protein-related pathology," *Endocrinol Metab (EnM)* 2024, 14: 100163. doi: <https://doi.org/10.1016/j.endmts.2024.100163>
110. Halma MTJ et al., "Strategies for the Management of Spike Protein-Related Pathology," *Microorganisms* 2023, 11, 5: 1308, doi: <https://doi.org/10.3390/microorganisms11051308>
111. Hano S et al., "A case of persistent, confluent maculopapular erythema following a COVID-19 mRNA vaccination is possibly associated with the intralesional spike protein expressed by vascular endothelial cells and eccrine glands in the deep dermis," *J Dermatol* 2023, 50, 9: 1208-1212. doi: <https://doi.org/10.1111/1346-8138.16816>
112. Heath SP et al., "SARS-CoV-2 Spike Protein Exacerbates Thromboembolic Cerebrovascular Complications in Humanized ACE2 Mouse Model," *Transl Stroke Res.* 2024. doi: <https://doi.org/10.1007/s12975-024-01301-5>
113. Heil M, "Self-DNA driven inflammation in COVID-19 and after mRNA-based vaccination: lessons for non-COVID-19 pathologies," *Front. Immunol.*, 2023, 14. doi: <https://doi.org/10.3389/fimmu.2023.1259879>
114. Huang X et al., "Sars-Cov-2 Spike Protein-Induced Damage of hiPSC-Derived Cardiomyocytes," *Adv. Biol.* 2022, 6, 7: e2101327. doi: <https://doi.org/10.1002/adbi.202101327>
115. Hulscher N et al., "Autopsy findings in cases of fatal COVID-19 vaccine-induced myocarditis," *ESC Heart Failure* 2024. doi: <https://doi.org/10.1002/ehf2.14680>
116. Huynh TV et al., "Spike Protein Impairs Mitochondrial Function in Human Cardiomyocytes: Mechanisms Underlying Cardiac Injury in COVID-19," *Cells* 2023, 12, 877. doi: <https://doi.org/10.3390/cells12060877>
117. Huynh TV et al., "Spike Protein of SARS-CoV-2 Activates Cardiac Fibrogenesis through NLRP3 Inflammasomes and NF-κB Signaling," *Cells* 2024, 13, 16: 1331: doi: <https://doi.org/10.3390/cells13161331>
118. Iba T and JH Levy, "The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia," *Trends Cardiovasc Med.* 2022, 32, 1: 1-9. doi: <https://doi.org/10.1016/j.tcm.2021.08.012>
119. Idrees D and Vijay Kumar, "SARS-CoV-2 Spike Protein Interactions with Amyloidogenic Proteins: Potential Clues to Neurodegeneration," *Biochem Biophys Res Commun.* 2021, 554 : 94–98, doi: <https://doi.org/10.1016/j.bbrc.2021.03.100>
120. Imig JD, "SARS-CoV-2 spike protein causes cardiovascular disease independent of viral infection," *Clin Sci (Lond)* 2022, 136, 6: 431–434. doi: <https://doi.org/10.1042/CS20220028>
121. Irrgang P et al., "Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination," *Sci. Immunol.* 2022, 8, 79. doi: [10.1126/sciimmunol.ade2798](https://doi.org/10.1126/sciimmunol.ade2798)

122. Jana S et al., "Cell-free hemoglobin does not attenuate the effects of SARS-CoV-2 spike protein S1 subunit in pulmonary endothelial cells," *Int. J. Mol. Sci.* 2021, 22, 16: 9041. doi: <https://doi.org/10.3390/ijms22169041>
123. Jiang Q et al., "SARS-CoV-2 spike S1 protein induces microglial NLRP3-dependent neuroinflammation and cognitive impairment in mice," *Exp. Neurol.* 2025, 383: 115020. doi: <https://doi.org/10.1016/j.expneurol.2024.115020>
124. Johnson EL et al., "The S1 spike protein of SARS-CoV-2 upregulates the ERK/MAPK signaling pathway in DC-SIGN-expressing THP-1 cells," *Cell Stress Chaperones* 2024, 29, 2: 227-234. doi: <https://doi.org/10.1016/j.cstres.2024.03.002>
125. Jugler C et al, "SARS-CoV-2 Spike Protein-Induced Interleukin 6 Signaling Is Blocked by a Plant-Produced Anti-Interleukin 6 Receptor Monoclonal Antibody," *Vaccines* 2021, 9, 11: 1365. <https://doi.org/10.3390/vaccines9111365>
126. Kammala AK et al., "In vitro mRNA-S maternal vaccination induced altered immune regulation at the maternal-fetal interface," *Am. J. Reprod. Immunol.* 2024, 91, 5: e13861. doi: <https://doi.org/10.1111/aji.13861>
127. Kanduc D, "From Anti-SARS-CoV-2 Immune Responses to COVID-19 via Molecular Mimicry," *Antibodies* 2020, 9, 3: 33. doi: <https://doi.org/10.3390/antib9030033>
128. Kanduc D and Y Shoenfeld, "Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine," *Immunol Res* 2020, 68: 310-313. doi: <https://doi.org/10.1007/s12026-020-09152-6>
129. Karrow NA et al., "Maternal COVID-19 Vaccination and Its Potential Impact on Fetal and Neonatal Development," *Vaccines* 2021, 9: 1351. doi: <https://doi.org/10.3390/vaccines9111351>
130. Karwaciak I et al., "Nucleocapsid and Spike Proteins of the Coronavirus Sars-Cov-2 Induce Il6 in Monocytes and Macrophages—Potential Implications for Cytokine Storm Syndrome," *Vaccines* 2021, 9(1), 54: 1–10. doi: <https://doi.org/10.3390/vaccines9010054>
131. Kato Y et al., "TRPC3-Nox2 Protein Complex Formation Increases the Risk of SARS-CoV-2 Spike Protein-Induced Cardiomyocyte Dysfunction through ACE2 Upregulation," *Int. J. Mol. Sci.* 2023, 24, 1: 102. doi: <https://doi.org/10.3390/ijms24010102>
132. Kawano H et al., "Fulminant Myocarditis 24 Days after Coronavirus Disease Messenger Ribonucleic Acid Vaccination," *Intern. Med.* 2022, 61, 15: 2319-2325. doi: <https://doi.org/10.2169/internalmedicine.9800-22>
133. Ken W et al., "Low dose radiation therapy attenuates ACE2 depression and inflammatory cytokines induction by COVID-19 viral spike protein in human bronchial epithelial cells," *Int J Radiat Biol.* 2022, 98, 10: 1532-1541. doi: <https://doi.org/10.1080/09553002.2022.2055806>
134. Kent SJ et al., "Blood Distribution of SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine in Humans," *ACS Nano* 2024, 18, 39: 27077-27089. doi: <https://doi.org/10.1021/acsnano.4c11652>
135. Khaddaj-Mallat R et al., "SARS-CoV-2 deregulates the vascular and immune functions of brain pericytes via Spike protein," *Neurobiol. Dis.* 2021, 161, 105561. doi: <https://doi.org/10.1016/j.nbd.2021.105561>

136. Khan S et al., "SARS-CoV-2 Spike Protein Induces Inflammation via TLR2-Dependent Activation of the NF- κ B Pathway," *eLife* 2021, 10: e68563. doi: <https://doi.org/10.7554/elife.68563>
137. Kim ES et al., "Spike Proteins of SARS-CoV-2 Induce Pathological Changes in Molecular Delivery and Metabolic Function in the Brain Endothelial Cells," *Viruses*, 2021, 13, 10. doi: <https://doi.org/10.3390/v13102021>
138. Kim MJ et al., "The SARS-CoV-2 spike protein induces lung cancer migration and invasion in a TLR2-dependent manner," *Cancer Commun* (London), 2023, 44, 2: 273–277. doi: <https://doi.org/10.1002/cac2.12485>
139. Kim SY et al., "Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions," *Antivir Res.* 2020, 181: 104873. doi: <https://doi.org/10.1016/j.antiviral.2020.104873>
140. Kircheis R, "Coagulopathies after Vaccination against SARS-CoV-2 May Be Derived from a Combined Effect of SARS-CoV-2 Spike Protein and Adenovirus Vector-Triggered Signaling Pathways," *Int. J. Mol. Sci.* 2021, 22, 19: 10791. <https://doi.org/10.3390/ijms221910791>
141. Kircheis R and O Planz, "Could a Lower Toll-like Receptor (TLR) and NF- κ B Activation Due to a Changed Charge Distribution in the Spike Protein Be the Reason for the Lower Pathogenicity of Omicron?" *Int. J. Mol. Sci.* 2022, 23, 11: 5966. doi: <https://doi.org/10.3390/ijms23115966>
142. Ko CJ et al., "Discordant anti-SARS-CoV-2 spike protein and RNA staining in cutaneous pernioitic lesions suggests endothelial deposition of cleaved spike protein," *J. Cutan Pathol* 2021, 48, 1: 47–52. doi: <https://doi.org/10.1111/cup.13866>
143. Kowarz E et al., "Vaccine-induced COVID-19 mimicry syndrome," *eLife* 2022, 11: e74974. doi: <https://doi.org/10.7554/eLife.74974>
144. Krauson AM et al., "Duration of SARS-CoV-2 mRNA vaccine persistence and factors associated with cardiac involvement in recently vaccinated patients," *npj Vaccines*, 8, 141. doi: <https://doi.org/10.1038/s41541-023-00742-7>
145. Kucia M et al., "An evidence that SARS-Cov-2/COVID-19 spike protein (SP) damages hematopoietic stem/progenitor cells in the mechanism of pyroptosis in Nlrp3 inflammasome-dependent manner," *Leukemia* 2021, 35: 3026-3029. doi: <https://doi.org/10.1038/s41375-021-01332-z>
146. Kuhn CC et al., "Direct Cryo-ET observation of platelet deformation induced by SARS-CoV-2 spike protein," *Nat. Commun.* (2023) 14, 620. doi: <https://doi.org/10.1038/s41467-023-36279-5>
147. Kulkoviene G et al., "Differential Mitochondrial, Oxidative Stress and Inflammatory Responses to SARS-CoV-2 Spike Protein Receptor Binding Domain in Human Lung Microvascular, Coronary Artery Endothelial and Bronchial Epithelial Cells," *Int. J. Mol. Sci.* 2024, 25, 6: 3188. doi: <https://doi.org/10.3390/ijms25063188>
148. Kumar N et al., "SARS-CoV-2 spike protein S1-mediated endothelial injury and pro-inflammatory state Is amplified by dihydrotestosterone and prevented by mineralocorticoid antagonism," *Viruses* 2021, 13, 11: 2209. Doi: <https://doi.org/10.3390/v13112209>
149. Kyriakopoulos AM et al., "Mitogen Activated Protein Kinase (MAPK) Activation, p53, and Autophagy Inhibition Characterize the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-

- CoV-2) Spike Protein Induced Neurotoxicity,” *Cureus* 2022, 14, 12: e32361. doi: [10.7759/cureus.32361](https://doi.org/10.7759/cureus.32361)
150. Lazebnik Y, “Cell fusion as a link between the SARS-CoV-2 spike protein, COVID-19 complications, and vaccine side effects,” *Oncotarget* 2021, 12, 25: 2476-2488. doi: <https://doi.org/10.18632/oncotarget.28088>
151. Lehmann KJ, “Impact of SARS-CoV-2 Spikes on Safety of Spike-Based COVID-19 Vaccinations,” *Immunome Res.* 2024, 20, 2: 1000267. doi: [10.35248/1745-7580.24.20.267](https://doi.org/10.35248/1745-7580.24.20.267)
152. Lehmann KJ, “SARS-CoV-2-Spike Interactions with the Renin-Angiotensin-Aldosterone System – Consequences of Adverse Reactions of Vaccination,” *J Biol Today’s World* 2023, 12/4: 001-013. <https://doi.org/10.31219/osf.io/27g5h>
153. Lehmann KJ, “Suspected Causes of the Specific Intolerance Profile of Spike-Based Covid-19 Vaccines,” *Med. Res. Arch* 2024, 12, 9. doi: [10.18103/mra.v12i9.5704](https://doi.org/10.18103/mra.v12i9.5704)
154. Lei Y et al., “SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2,” *Circ. Res.* 2021, 128, 9: 1323–1326. doi: <https://doi.org/10.1161/CIRCRESAHA.121.318902>
155. Lesgard JF et al., “Toxicity of SARS-CoV-2 Spike Protein from the Virus and Produced from COVID-19 mRNA or Adenoviral DNA Vaccines,” *Arch Microbiol Immun* 2023, 7, 3: 121-138. doi: [10.26502/ami.936500110](https://doi.org/10.26502/ami.936500110)
156. Letarov AV et al., “Free SARS-CoV-2 Spike Protein S1 Particles May Play a Role in the Pathogenesis of COVID-19 Infection,” *Biochemistry (Moscow)* 2021, 86: 257–261. doi: <https://doi.org/10.1134/S0006297921030032>
157. Li C. et al., “Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model,” *Clin. Infect. Dis.* 2022, 74, 11: 1933-1950. doi: <https://doi.org/10.1093/cid/ciab707>
158. Li F et al., “SARS-CoV-2 Spike Promotes Inflammation and Apoptosis Through Autophagy by ROS-Suppressed PI3K/AKT/mTOR Signaling,” *Biochim Biophys Acta BBA - Mol Basis Dis* 2021, 1867: 166260. doi: <https://doi.org/10.1016/j.bbadis.2021.166260>
159. Li K et al., “SARS-CoV-2 Spike protein promotes vWF secretion and thrombosis via endothelial cytoskeleton-associated protein 4 (CKAP4),” *Signal Transduct Targ Ther* 2022, 7, 332. doi: <https://doi.org/10.1038/s41392-022-01183-9>
160. Li T et al., “Platelets Mediate Inflammatory Monocyte Activation by SARS-CoV-2 Spike Protein,” *J. Clin. Invest.* 2022, 132, 4: e150101. doi: [10.1172/JCI150101](https://doi.org/10.1172/JCI150101)
161. Li Z et al., “SARS-CoV-2 pathogenesis in the gastrointestinal tract mediated by Spike-induced intestinal inflammation,” *Precis. Clin. Med.* 2024, 7, 1: pbad034. doi: <https://doi.org/10.1093/pcmedi/pbad034>
162. Liang S et al., “SARS-CoV-2 spike protein induces IL-18-mediated cardiopulmonary inflammation via reduced mitophagy,” *Signal Transduct Target Ther* 2023, 8, 103. doi: <https://doi.org/10.1038/s41392-023-01368-w>

163. Lin X et al., "Transplacental transmission of the COVID-19 vaccine messenger RNA: evidence from placental, maternal, and cord blood analyses postvaccination," *Am J Obstet Gynecol* 2024, 92, 4: e13934. doi: <https://doi.org/10.1111/aji.13934>
164. Lin Z, "More than a key—the pathological roles of SARS-CoV-2 spike protein in COVID-19 related cardiac injury," *Sports Med Health Sci* 2023, 6, 3: 209-220. doi: <https://doi.org/10.1016/j.smhs.2023.03.004>
165. Liu T et al., "RS-5645 attenuates inflammatory cytokine storm induced by SARS-CoV-2 spike protein and LPS by modulating pulmonary microbiota," *Int J Biol Sci*. 2021, 17, 13: 3305–3319. doi: [10.7150/ijbs.63329](https://doi.org/10.7150/ijbs.63329)
166. Liu X et al., "SARS-CoV-2 spike protein-induced cell fusion activates the cGAS-STING pathway and the interferon response," *Sci Signal*. 2022, 15, 729: eabg8744. doi: [10.1126/scisignal.abg8744](https://doi.org/10.1126/scisignal.abg8744)
167. Loh D, "The potential of melatonin in the prevention and attenuation of oxidative hemolysis and myocardial injury from cd147 SARS-CoV-2 spike protein receptor binding," *Melatonin Research* 2020, 3, 3: 380-416. doi: <https://doi.org/10.32794/mr11250069>
168. Loh JT et al., "Dok3 restrains neutrophil production of calprotectin during TLR4 sensing of SARS-CoV-2 spike protein," *Front. Immunol*. 2022, 13 (Sec. Molecular Innate Immunity). doi: <https://doi.org/10.3389/fimmu.2022.996637>
169. Lu J and PD Sun, "High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity," *J. Biol. Chem* 2020, 295, 52: p18579-18588. doi: [10.1074/jbc.RA120.015303](https://doi.org/10.1074/jbc.RA120.015303)
170. Luchini A et al., "Lipid bilayer degradation induced by SARS-CoV-2 spike protein as revealed by neutron reflectometry," *Sci. Rep*. 2021, 11: 14867. doi: <https://doi.org/10.1038/s41598-021-93996-x>
171. Luo Y et al., "SARS-Cov-2 spike induces intestinal barrier dysfunction through the interaction between CEACAM5 and Galectin-9," *Front. Immunol.*, 2024, 15. doi: <https://doi.org/10.3389/fimmu.2024.1303356>
172. Lykhmus O et al., "Immunization with 674–685 fragment of SARS-Cov-2 spike protein induces neuroinflammation and impairs episodic memory of mice," *Biochem. Biophys. Res. Commun*. 2022, 622: 57–63. doi: <https://doi.org/10.1016/j.bbrc.2022.07.016>
173. Ma G et al., "SARS-CoV-2 Spike protein S2 subunit modulates γ -secretase and enhances amyloid- β production in COVID-19 neuropathy," *Cell Discov* 2022, 8, 99. doi: <https://doi.org/10.1038/s41421-022-00458-3>
174. Maeda Y et al., "Differential Ability of Spike Protein of SARS-CoV-2 Variants to Downregulate ACE2," *Int. J. Mol. Sci*. 2024, 25, 2: 1353. doi: <https://doi.org/10.3390/ijms25021353>
175. Magen E et al., "Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis," *Vaccines* 2022, 10: 1135. doi: <https://doi.org/10.3390/vaccines10071135>
176. Magro C et al., "Disruption of the blood-brain barrier is correlated with spike endocytosis by ACE2 + endothelia in the CNS microvasculature in fatal COVID-19. Scientific commentary on 'Detection of blood-brain barrier disruption in brains of patients with COVID-19, but no evidence of brain

- penetration by SARS-CoV-2,” *Acta Neuropathol.* 2024, 147, 1: 47. doi: <https://doi.org/10.1007/s00401-023-02681-y>
177. Magro C et al., “The histologic and molecular correlates of COVID-19 vaccine-induced changes in the skin,” *Clin. Dermatol.* 2021, 39, 6: 966-984. doi: <https://doi.org/10.1016/j.clindermatol.2021.07.011>
178. Marrone L et al., “Tirofiban prevents the effects of SARS-CoV-2 spike protein on macrophage activation and endothelial cell death,” *Heliyon* 2024, 10, 15: e35341. doi: [10.1016/j.heliyon.2024.e35341](https://doi.org/10.1016/j.heliyon.2024.e35341)
179. Martin-Navarro L et al., “In situ detection of vaccine mRNA in the cytoplasm of hepatocytes during COVID-19 vaccine-related hepatitis,” *J. Hepatol.* 2023, 78, 1: e20-e22. doi: [10.1016/j.jhep.2022.08.039](https://doi.org/10.1016/j.jhep.2022.08.039)
180. Martinez-Marmol R et al., “SARS-CoV-2 infection and viral fusogens cause neuronal and glial fusion that compromises neuronal activity,” *Sci. Adv.* 2023, 9, 23. doi: [10.1126/sciadv.adg2248](https://doi.org/10.1126/sciadv.adg2248)
181. Matschke J et al., “Neuropathology of patients with COVID-19 in Germany: a post-mortem case series,” *Lancet Neurol.* 2020, 19, 11: 919-929. doi: [10.1016/S1474-4422\(20\)30308-2](https://doi.org/10.1016/S1474-4422(20)30308-2)
182. Matsuzawa Y et al., “Impact of Renin–Angiotensin–Aldosterone System Inhibitors on COVID-19,” *Hypertens Res.* 2022, 45, 7: 1147–1153. doi: <https://doi.org/10.1038/s41440-022-00922-3>
183. Maugeri M et al., “Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells,” *Nat Commun* 2019, 10: 4333. doi: <https://doi.org/10.1038/s41467-019-12275-6>
184. Maugeri N et al., “Unconventional CD147-Dependent Platelet Activation Elicited by SARS-CoV-2 in COVID-19,” *J. Thromb. Haemost.* 2021, 20, 2: 434–448. doi: <https://doi.org/10.1111/jth.15575>
185. Mayordomo-Colunga J et al., “SARS-CoV-2 spike protein in intestinal cells of a patient with coronavirus disease 2019 multisystem inflammatory syndrome,” *J Pediatr.* 2022, 243: 214-18e215. doi: <https://doi.org/10.1016/j.jpeds.2021.11.058>
186. Mercado-Gómez M et al., “The spike of SARS-CoV-2 promotes metabolic rewiring in hepatocytes,” *Commun. Biol.* 2022, 5, 827. doi: <https://doi.org/10.1038/s42003-022-03789-9>
187. Meyer K et al., “SARS-CoV-2 Spike Protein Induces Paracrine Senescence and Leukocyte Adhesion in Endothelial Cells,” *J. Virol.* 2021, 95, e0079421. doi: <https://doi.org/10.1128/jvi.00794-21>
188. Miller GM et al., “SARS-CoV-2 and SARS-CoV-2 Spike protein S1 subunit Trigger Proinflammatory Response in Macrophages in the Absence of Productive Infection,” *J. Immunol.* 2023, 210 (1_Supplement): 71.30. doi: <https://doi.org/10.4049/jimmunol.210.Supp.71.30>
189. Mishra R and AC Banerjee, “SARS-CoV-2 Spike targets USP33-IRF9 axis via exosomal miR-148a to activate human microglia,” *Front. Immunol.* 2021, 12: 656700. doi: <https://doi.org/10.3389/fimmu.2021.656700>

190. Mörz M, "A Case Report: Multifocal Necrotizing Encephalitis and Myocarditis after BNT162b2 mRNA Vaccination against COVID-19," *Vaccines* 2022, 10, 10: 1651. doi: <https://doi.org/10.3390/vaccines10101651>
191. Moutal A et al., "SARS-CoV-2 Spike protein co-opts VEGF-A/Neuropilin-1 receptor signaling to induce analgesia," *Pain* 2020, 162, 1: 243–252. doi: [10.1097/j.pain.0000000000002097](https://doi.org/10.1097/j.pain.0000000000002097)
192. Munavilli GG et al., "COVID-19/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to hyaluronic acid dermal fillers: a challenging clinical conundrum in diagnosis and treatment," *Arch. Dermatol. Res.* 2022, 314: 1-15. doi: <https://doi.org/10.1007/s00403-021-02190-6>
193. Nahalka J, "1-L Transcription of SARS-CoV-2 Spike Protein S1 Subunit," *Int. J. Mol. Sci.* 2024, 25, 8: 4440. doi: <https://doi.org/10.3390/ijms25084440>
194. Nascimento RR et al., "SARS-CoV-2 Spike protein triggers gut impairment since mucosal barrier to innermost layers: From basic science to clinical relevance," *Mucosal Immunol.* 2024, 17, 4: 565-583. doi: <https://doi.org/10.1016/j.mucimm.2024.03.00>
195. Nguyen V, "The Spike Protein of SARS-CoV-2 Impairs Lipid Metabolism and Increases Susceptibility to Lipotoxicity: Implication for a Role of Nrf2," *Cells* 2022, 11, 12: 1916. doi: <https://doi.org/10.3390/cells11121916>
196. Niu C et al., "SARS-CoV-2 spike protein induces the cytokine release syndrome by stimulating T cells to produce more IL-2," *Front. Immunol.* 2024, 15: 1444643. doi: <https://doi.org/10.3389/fimmu.2024.1444643>
197. Norris B et al., "Evaluation of Glutathione in Spike Protein of SARS-CoV-2 Induced Immunothrombosis and Cytokine Dysregulation," *Antioxidants* 2024, 13, 3: 271. doi: <https://doi.org/10.3390/antiox13030271>
198. Nunez-Castilla J et al., "Potential autoimmunity resulting from molecular mimicry between SARS-CoV-2 spike and human proteins," *Viruses* 2022, 14, 7: 1415. doi: <https://doi.org/10.3390/v14071415>
199. Nuovo JG et al., "Endothelial Cell Damage Is the Central Part of COVID-19 and a Mouse Model Induced by Injection of the S1 Subunit of the Spike Protein," *Ann. Diagn. Pathol.* 2021, 51, 151682. doi: <https://doi.org/10.1016/j.anndiagpath.2020.151682>
200. Nyein CM et al., "Severe *de novo* liver injury after Moderna vaccination – not always autoimmune hepatitis," *J. Hepatol.* 2022, 77, 2: 556-558. Doi: [10.1016/j.jhep.2022.03.041](https://doi.org/10.1016/j.jhep.2022.03.041)
201. Nyström S, "Amyloidogenesis of SARS-CoV-2 Spike Protein," *J. Am. Chem. Soc.* 2022, 144, 8945–8950. doi: <https://doi.org/10.1021/jacs.2c03925>
202. Ogata AF et al., "Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients," *Clin. Infect. Dis.* 2022, 75, 4: 715–718. doi: <https://doi.org/10.1093/cid/ciab465>
203. Ogata AF et al., "Ultra-Sensitive Serial Profiling of SARS-CoV-2 Antigens and Antibodies in Plasma to Understand Disease Progression in COVID-19 Patients with Severe Disease," *Clin. Chem.* 2020, 66, 12: 1562-1572. doi: <https://doi.org/10.1093/clinchem/hvaa213>

204. Oh J et al., "SARS-CoV-2 Spike Protein Induces Cognitive Deficit and Anxiety-Like Behavior in Mouse via Non-cell Autonomous Hippocampal Neuronal Death," *Scientific Reports* 2022, 12, 5496. doi: <https://doi.org/10.1038/s41598-022-09410-7>
205. Oka N et al., "SARS-CoV-2 S1 protein causes brain inflammation by reducing intracerebral acetylcholine production," *iScience* 2023, 26, 6: 106954. doi: [10.1016/j.isci.2023.106954](https://doi.org/10.1016/j.isci.2023.106954)
206. Olajide OA et al., "Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone," *Inflammation* 2021, 44: 1865–1877. doi: <https://doi.org/10.1007/s10753-021-01464-5>
207. Olajide OA et al., "SARS-CoV-2 spike glycoprotein S1 induces neuroinflammation in BV-2 microglia," *Mol. Neurobiol.* 2022, 59: 445-458. doi: <https://doi.org/10.1007/s12035-021-02593-6>
208. Onnis A et al., "SARS-CoV-2 Spike protein suppresses CTL-mediated killing by inhibiting immune synapse assembly," *J Exp Med* 2023, 220, 2: e20220906. doi: <https://doi.org/10.1084/jem.20220906>
209. Palestra F et al., "SARS-CoV-2 Spike Protein Activates Human Lung Macrophages," *Int. J. Mol. Sci.* 2023, 24, 3: 3036. doi: <https://doi.org/10.3390/ijms24033036>
210. Pallas RM, "Innate and adaptative immune mechanisms of COVID-19 vaccines. Serious adverse events associated with SARS-CoV-2 vaccination: A systematic review," *Vacunas (English ed.)* 2024, 25, 2: 285.e1-285.e94. doi: <https://doi.org/10.1016/j.vacune.2024.05.002>
211. Panigrahi S et al., "SARS-CoV-2 Spike Protein Destabilizes Microvascular Homeostasis," *Microbiol Spectr.* 2021, 9, 3: e0073521. doi: <https://doi.org/10.1128/Spectrum.00735-21>
212. Parcial ALN et al., "SARS-CoV-2 Is Persistent in Placenta and Causes Macroscopic, Histopathological, and Ultrastructural Changes," *Viruses* 2022, 14, 9: 1885. doi: <https://doi.org/10.3390/v14091885>
213. Park C et al., "Murine alveolar Macrophages Rapidly Accumulate intranasally Administered SARS-CoV-2 Spike Protein leading to neutrophil Recruitment and Damage," *Elife* 2024, 12: RP86764. doi: <https://doi.org/10.7554/eLife.86764.3>
214. Park YJ et al., "D-dimer and CoV-2 spike-immune complexes contribute to the production of PGE2 and proinflammatory cytokines in monocytes," *PLoS Pathog.* 2022, 18, 4: e1010468. doi: <https://doi.org/10.1371/journal.ppat.1010468>
215. Park YJ et al., "Pyrogenic and inflammatory mediators are produced by polarized M1 and M2 macrophages activated with D-dimer and SARS-CoV-2 spike immune complexes," *Cytokine* 2024, 173: 156447. doi: <https://doi.org/10.1016/j.cyto.2023.156447>
216. Parry PL et al., "'Spikeopathy': COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA," *Biomedicine* 2023, 11, 8: 2287. doi: <https://doi.org/10.3390/biomedicines11082287>
217. Passariello M et al., "Interactions of Spike-RBD of SARS-CoV-2 and Platelet Factor 4: New Insights in the Etiopathogenesis of Thrombosis," *Int. J. Mol. Sci.* 2021, 22, 16: 8562. doi: <https://doi.org/10.3390/ijms22168562>

218. Pateev I et al., "Biodistribution of RNA Vaccines and of Their Products: Evidence from Human and Animal Studies," *Biomedicines* 2024, 12, 1: 59. doi: <https://doi.org/10.3390/biomedicines12010059>
219. Patra T et al., "SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells," *PLoS Pathog.* 2020, 16: e1009128. doi: <https://doi.org/10.1371/journal.ppat.1009128>
220. Patterson BK et al., "Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection," *Front. Immunol.* 12 (Sec. Viral Immunology). doi: <https://doi.org/10.3389/fimmu.2021.746021>
221. Peluso MJ et al., "Plasma-based antigen persistence in the post-acute phase of COVID-19," *Lancet* 2024, 24, 6: E345-E347. doi: [10.1016/S1473-3099\(24\)00211-1](https://doi.org/10.1016/S1473-3099(24)00211-1)
222. Peluso MJ et al., "SARS-CoV-2 and mitochondrial proteins in neural-derived exosomes of COVID-19," *Ann Neurol* 2022, 91, 6: 772-781. doi: <https://doi.org/10.1002/ana.26350>
223. Pence B, "Recombinant SARS-CoV-2 Spike Protein Mediates Glycolytic and Inflammatory Activation in Human Monocytes," *Innov Aging* 2020, 4, sp. 1: 955. doi: <https://doi.org/10.1093/geroni/igaa057.3493>
224. Perico L et al., "SARS-CoV-2 and the spike protein in endotheliopathy," *Trends Microbiol.* 2024, 32, 1: 53-67. doi: [10.1016/j.tim.2023.06.004](https://doi.org/10.1016/j.tim.2023.06.004)
225. Perico L et al., "SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation," *Front. Immunol.* 2022, 13, 827146. doi: <https://doi.org/10.3389/fimmu.2022.827146>
226. Petrova J et al., "SARS-CoV-2 spike protein aggregation is triggered by bacterial lipopolysaccharide," *FEBS Lett.* 2022, 596: 2566–2575. doi: <https://doi.org/10.1002/1873-3468.14490>
227. Petrosino S and N Matende, "Elimination/Neutralization of COVID-19 Vaccine-Produced Spike Protein: Scoping Review," *Mathews Journal of Nutrition & Dietetics* 2024, 7, 2. doi: <https://doi.org/10.30654/MJND.10034>
228. Petrovszki D et al., "Penetration of the SARS-CoV-2 Spike Protein across the Blood-Brain Barrier, as Revealed by a Combination of a Human Cell Culture Model System and Optical Biosensing," *Biomedicines* 2022, 10, 1: 188. doi: <https://doi.org/10.3390/biomedicines10010188>
229. Petruk G et al., "SARS-CoV-2 spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity," *J. Mol. Cell Biol.* (2020) 12: 916-932. doi: <https://doi.org/10.1093/jmcb/mjaa067>
230. Prieto-Villalobos J et al., "SARS-CoV-2 spike protein S1 activates Cx43 hemichannels and disturbs intracellular Ca²⁺ dynamics," *Biol Res.* 2023, 56, 1: 56. doi: <https://doi.org/10.1186/s40659-023-00468-9>
231. Puthia MTL et al., "Experimental model of pulmonary inflammation induced by SARS-CoV-2 spike protein and endotoxin," *ACS Pharmacol Transl Sci.* 2022, 5, 3: 141–8. doi: <https://doi.org/10.1021/acspsci.1c00219>

232. Raghavan S et al., "SARS-CoV-2 Spike Protein Induces Degradation of Junctional Proteins That Maintain Endothelial Barrier Integrity," *Front. Cardiovasc. Med.* 2021, 8, 687783. doi: <https://doi.org/10.3389/fcvm.2021.687783>
233. Rahman M et al., "Differential Effect of SARS-CoV-2 Spike Glycoprotein 1 on Human Bronchial and Alveolar Lung Mucosa Models: Implications for Pathogenicity," *Viruses* 2021, 13, 12: 2537. doi: <https://doi.org/10.3390/v13122537>
234. Rajah MM et al., "SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced spike-mediated syncytia formation," *EMBO J.* 2021, 40: e108944. doi: <https://doi.org/10.15252/embj.2021108944>
235. Ratajczak MZ et al., "SARS-CoV-2 Entry Receptor ACE2 Is Expressed on Very Small CD45⁺ Precursors of Hematopoietic and Endothelial Cells and in Response to Virus Spike Protein Activates the Nlrp3 Inflammasome," *Stem Cell Rev Rep.* 2021, 17, 1: 266-277. doi: <https://doi.org/10.1007/s12015-020-10010-z>
236. Rhea EM et al., "The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice," *Nature Neuroscience* 2021, 24, 3: 368-378. doi: <https://doi.org/10.1038/s41593-020-00771-8>
237. Rivas MN et al., "COVID-19-associated multisystem inflammatory syndrome in children (MIS-C): A novel disease that mimics toxic shock syndrome—the superantigen hypothesis," *J Allergy Clin Immunol* 2021, 147, 1: 57-59. doi: [10.1016/j.jaci.2020.10.008](https://doi.org/10.1016/j.jaci.2020.10.008)
238. Rivas MN et al., "Multisystem Inflammatory Syndrome in Children and Long COVID: The SARS-CoV-2 Viral Superantigen Hypothesis," *Front Immunol.* 2022, 13 (Sec. Molecular Innate Immunity) doi: <https://doi.org/10.3389/fimmu.2022.941009>
239. Robles JP et al., "The Spike Protein of SARS-CoV-2 Induces Endothelial Inflammation through Integrin $\alpha 5\beta 1$ and NF- κ B Signaling," *J. Biol. Chem.* 2022, 298, 3: 101695. doi: <https://doi.org/10.1016/j.jbc.2022.101695>
240. Roden AC et al., "Comparison of In Situ Hybridization, Immunohistochemistry, and Reverse Transcription-Droplet Digital Polymerase Chain Reaction for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Testing in Tissue," *Arch Pathol Lab Med* 2021, 145, 7: 785-796. doi: <https://doi.org/10.5858/arpa.2021-0008-SA>
241. Rodriguez Y et al., "Autoinflammatory and autoimmune conditions at the crossroad of COVID-19," *J. Autoimmun.* 2020, 114: 102506. doi: <https://doi.org/10.1016/j.jaut.2020.102506>
242. Rong Z et al., "Persistence of spike protein at the skull-meninges-brain axis may contribute to the neurological sequelae of COVID-19," *Cell Host Microbe* 2024, 26: S1931-3128(24)00438-4. doi: [10.1016/j.chom.2024.11.007](https://doi.org/10.1016/j.chom.2024.11.007)
243. Ropa J et al., "Human Hematopoietic Stem, Progenitor, and Immune Cells Respond Ex Vivo to SARS-CoV-2 Spike Protein," *Stem Cell Rev Rep.* 2021, 17, 1: 253-265. doi: <https://doi.org/10.1007/s12015-020-10056-z>
244. Rotoli BM et al., "Endothelial cell activation by SARS-CoV-2 spike S1 protein: A crosstalk between endothelium and innate immune cells," *Biomedicines* 2021, 9, 9: 1220. doi: <https://doi.org/10.3390/biomedicines9091220>

245. Roytenberg R et al., "Thymidine phosphorylase mediates SARS-CoV-2 spike protein enhanced thrombosis in K18-hACE2TG mice," *Thromb. Res.* 2024, 244, 8: 109195. doi: [10.1016/j.thromres.2024.109195](https://doi.org/10.1016/j.thromres.2024.109195)
246. Ruben ML et al., "The SARS-CoV-2 spike protein subunit S1 induces COVID-19-like acute lung injury in K18-hACE2 transgenic mice and barrier dysfunction in human endothelial cells," *Am J Physiol Lung Cell Mol Physiol.* 2021, 321, 2: L477-L484. doi: <https://doi.org/10.1152/ajplung.00223.2021>
247. Russo A, et al., "Implication of COVID-19 on Erythrocytes Functionality: Red Blood Cell Biochemical Implications and Morpho-Functional Aspects," *Int. J. Mol. Sci.* 2022, 23, 4: 2171. doi: <https://doi.org/10.3390/ijms23042171>
248. Ryu JK et al., "Fibrin drives thromboinflammation and neuropathology in COVID-19," *Nature* 2024, 633: 905-913. doi: <https://doi.org/10.1038/s41586-024-07873-4>
249. Rzymiski P and Andrzej Fal, "To aspirate or not to aspirate? Considerations for the COVID-19 vaccines," *Pharmacol. Rep* 2022, 74: 1223–1227. doi: <https://doi.org/10.1007/s43440-022-00361-4>
250. Saadi F et al., "Spike glycoprotein is central to coronavirus pathogenesis-parallel between m-CoV and SARS-CoV-2," *Ann Neurosci.* 2021, 28 (3-4): 201–218. doi: <https://doi.org/10.1177/09727531211023755>
251. Sacco K et al., "Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19," *Nat. Med.* 2022, 28: 1050-1062. doi: <https://doi.org/10.1038/s41591-022-01724-3>
252. Samsudin S et al., "SARS-CoV-2 spike protein as a bacterial lipopolysaccharide delivery system in an overzealous inflammatory cascade," *J. Mol. Biol.* 2022, 14, 9: mjac058. <https://doi.org/10.1093/jmcb/mjac058>
253. Sandelius A et al., "Biodistribution of lipid nanoparticle, eGFP mRNA and translated protein following subcutaneous administration in mouse," *Bioanalysis* 2024, 16, 14: 721-733. doi: <https://doi.org/10.1080/17576180.2024.2360361>
254. Sano H et al., "A case of persistent, confluent maculopapular erythema following a COVID-19 mRNA vaccination is possibly associated with the intralesional spike protein expressed by vascular endothelial cells and eccrine glands in the deep dermis," *J. Dermatol.* 2023, 50: 1208–1212. doi: <https://doi.org/10.1111/1346-8138.16816>
255. Sano S et al., "SARS-CoV-2 spike protein found in the acrosyringium and eccrine gland of repetitive miliaria-like lesions in a woman following mRNA vaccination," *J. Dermatol.* 2024, 51, 9: e293-e295. doi: <https://doi.org/10.1111/1346-8138.17204>
256. Santonja C et al., "COVID-19 chilblain-like lesion: immunohistochemical demonstration of SARS-CoV-2 spike protein in blood vessel endothelium and sweat gland epithelium in a polymerase chain reaction-negative patient," *Br J Dermatol.* 2020, 183, 4: 778-780. doi: <https://doi.org/10.1111/bjd.19338>
257. Satta S et al., "An engineered nano-liposome-human ACE2 decoy neutralizes SARS-CoV-2 Spike protein-induced inflammation in both murine and human macrophages," *Theranostics* 2022, 12, 6: 2639–2657. doi: [10.7150/thno.66831](https://doi.org/10.7150/thno.66831)

258. Sattar S et al., "Nuclear translocation of spike mRNA and protein is a novel feature of SARS-CoV-2," 2023 *Front. Microbiol.* 2023, 14 (Sec. Virology). doi: <https://doi.org/10.3389/fmicb.2023.1073789>
259. Scheim DE, "A Deadly Embrace: Hemagglutination Mediated by SARS-CoV-2 Spike Protein at its 22 N-Glycosylation Sites, Red Blood Cell Surface Sialoglycoproteins, and Antibody," *Int. J. Mol. Sci.* 2022, 23, 5, 2558. doi: <https://doi.org/10.3390/ijms23052558>
260. Scheim DE et al., "Sialylated Glycan Bindings from SARS-CoV-2 Spike Protein to Blood and Endothelial Cells Govern the Severe Morbidities of COVID-19," *Int. J. Mol. Sci.* 2023, 24, 23:17039. doi: <https://doi.org/10.3390/ijms242317039>
261. Scholkmann F and CA May, "COVID-19, post-acute COVID-19 syndrome (PACS, 'long COVID') and post-COVID-19 vaccination syndrome (PCVS, 'post-COVIDvac-syndrome'): Similarities and differences," *Pathol Res Pract.* 2023, 246: 154497. doi: <https://doi.org/10.1016/j.prp.2023.154497>
262. Schreckenber R et al., "Cardiac side effects of RNA-based SARS-CoV-2 vaccines: Hidden cardiotoxic effects of mRNA-1273 and BNT162b2 on ventricular myocyte function and structure," *Br. J. Pharmacol.* 2024, 181, 3: 345-361. doi: <https://doi.org/10.1111/bph.16262>
263. Schroeder JT and AP Bieneman, "The S1 Subunit of the SARS-CoV-2 Spike protein activates human monocytes to produce cytokines linked to COVID-19: relevance to galectin-3," *Front Immunol.* 2022, 13: 831763. doi: <https://doi.org/10.3389/fimmu.2022.831763>
264. Schultheiss C et al., "Liquid biomarkers of macrophage dysregulation and circulating spike protein illustrate the biological heterogeneity in patients with post-acute sequelae of COVID-19," *J Med Virol* 2023, 95, 1: e28364. doi: <https://doi.org/10.1002/jmv.28364>
265. Segura-Villalobos D et al., "Jacareubin inhibits TLR4-induced lung inflammatory response caused by the RBD domain of SARS-CoV-2 Spike protein," *Pharmacol. Rep.* 2022, 74: 1315-1325. doi: <https://doi.org/10.1007/s43440-022-00398-5>
266. Semmarath W et al., "Cyanidin-3-O-glucoside and Peonidin-3-O-glucoside-Rich Fraction of Black Rice Germ and Bran Suppresses Inflammatory Responses from SARS-CoV-2 Spike Glycoprotein S1-Induction In Vitro in A549 Lung Cells and THP-1 Macrophages via Inhibition of the NLRP3 Inflammasome Pathway," *Nutrients* 2022, 14, 13: 2738. doi: <https://doi.org/10.3390/nu14132738>
267. Sharma VK et al., "Nanocurcumin Potently Inhibits SARS-CoV-2 Spike Protein-Induced Cytokine Storm by Deactivation of MAPK/NF- κ B Signaling in Epithelial Cells," *ACS Appl. Bio Mater.* 2022, 5, 2: 483-491. doi: <https://doi.org/10.1021/acsabm.1c00874>
268. Shirato K and Takako Kizaki, "SARS-CoV-2 Spike Protein S1 Subunit Induces Pro-inflammatory Responses via Toll-Like Receptor 4 Signaling in Murine and Human Macrophages," *Heliyon* 2021, 7, 2: e06187. doi: <https://doi.org/10.1016/j.heliyon.2021.e06187>
269. Singh N and Anuradha Bharara Singh, "S2 Subunit of SARS-nCoV-2 Interacts with Tumor Suppressor Protein p53 and BRCA: An in Silico Study," *Transl. Oncol.* 2020, 13, 10: 100814, doi: <https://doi.org/10.1016/j.tranon.2020.100814>
270. Singh RD, "The spike protein of sars-cov-2 induces heme oxygenase-1: pathophysiologic implications," *Biochim Biophys Acta, Mol Basis Dis* 2022, 1868, 3: 166322. doi: <https://doi.org/10.1016/j.bbadis.2021.166322>

271. Sirsendu J et al., "Cell-Free Hemoglobin Does Not Attenuate the Effects of SARS-CoV-2 Spike Protein S1 Subunit in Pulmonary Endothelial Cells," *Int. J. Mol. Sci.*, 2021, 22, 16: 9041. doi: <https://doi.org/10.3390/ijms22169041>
272. Soares CD et al., "Oral vesiculobullous lesions as an early sign of COVID-19: immunohistochemical detection of SARS-CoV-2 spike protein," *Br. J. Dermatol.* 2021, 184, 1: e6. doi: <https://doi.org/10.1111/bjd.19569>
273. Solis O et al., "The SARS-CoV-2 spike protein binds and modulates estrogen receptors," *Sci. Adv.* 2022, 8, 48: eadd4150. doi: [10.1126/sciadv.add4150](https://doi.org/10.1126/sciadv.add4150)
274. Stern B et al., "SARS-CoV-2 spike protein induces endothelial dysfunction in 3D engineered vascular networks," *J. Biomed. Mater. Res. A.* 2023, 112, 4: 524-533. doi: <https://doi.org/10.1002/jbm.a.37543>
275. Sui Y et al., "SARS-CoV-2 Spike Protein Suppresses ACE2 and Type I Interferon Expression in Primary Cells From Macaque Lung Bronchoalveolar Lavage," *Front. Immunol.* 2021, 12. doi: <https://doi.org/10.3389/fimmu.2021.658428>
276. Sun Q et al., "SARS-coV-2 spike protein S1 exposure increases susceptibility to angiotensin II-induced hypertension in rats by promoting central neuroinflammation and oxidative stress," *Neurochem. Res.* 2023, 48, 3016–3026. doi: <https://doi.org/10.1007/s11064-023-03949-1>
277. Sung PS et al., "CLEC5A and TLR2 Are Critical in SARS-CoV-2-Induced NET Formation and Lung Inflammation," *J. Biomed. Sci.* 2002, 29, 52. doi: <https://doi.org/10.1186/s12929-022-00832-z>
278. Suprewicz L et al., "Blood-brain barrier function in response to SARS-CoV-2 and its spike protein," *Neurol. Neurochir Pol.* 2023, 57: 14–25. doi: [10.5603/PJNNS.a2023.0014](https://doi.org/10.5603/PJNNS.a2023.0014)
279. Suprewicz L et al., "Recombinant human plasma gelsolin reverses increased permeability of the blood-brain barrier induced by the spike protein of the SARS-CoV-2 virus," *J Neuroinflammation* 2022, 19, 1: 282, doi: <https://doi.org/10.1186/s12974-022-02642-4>
280. Suzuki YJ et al., "SARS-CoV-2 spike protein-mediated cell signaling in lung vascular cells," *Vascul. Pharmacol.* 2021, 137: 106823. doi: <https://doi.org/10.1016/j.vph.2020.106823>
281. Suzuki YJ and SG Gychka, "SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines," *Vaccines* 2021, 9, 1, 36. doi: <https://doi.org/10.3390/vaccines9010036>
282. Swank Z, et al. "Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae," *Clin. Infect. Dis.* 2023, 76, 3: e487–e490. doi: <https://doi.org/10.1093/cid/ciac722>
283. Tetz G and Victor Tetz, "Prion-Like Domains in Spike Protein of SARS-CoV-2 Differ across Its Variants and Enable Changes in Affinity to ACE2," *Microorganisms* 2022, 10, 2: 280, doi: <https://doi.org/10.3390/microorganisms10020280>
284. Theobald SJ et al., "Long-lived macrophage reprogramming drives spike protein-mediated inflammasome activation in COVID-19," *EMBO Mol. Med.* 2021, 13: e14150. doi: <https://doi.org/10.15252/emmm.202114150>

285. Theoharides TC, "Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome?" *Mol. Neurobiol.* 2022, 59, 3: 1850–1861. doi: <https://doi.org/10.1007/s12035-021-02696-0>
286. Theoharides TC and P Conti, "Be Aware of SARS-CoV-2 Spike Protein: There Is More Than Meets the Eye," *J. Biol. Reg. Homeost. Agents* 2021, 35, 3: 833–838 doi: [10.23812/THEO_EDIT_3_21](https://doi.org/10.23812/THEO_EDIT_3_21)
287. Theuerkauf SA et al., "Quantitative assays reveal cell fusion at minimal levels of SARS-CoV-2 spike protein and fusion from without," *iScience* 2021, 24, 3: 102170. doi: <https://doi.org/10.1016/j.isci.2021.102170>
288. Tillman TS et al., "SARS-CoV-2 Spike Protein Downregulates Cell Surface $\alpha 7nAChR$ through a Helical Motif in the Spike Neck," *ACS Chem. Neurosci.* 2023, 14, 4: 689–698. doi: <https://doi.org/10.1021/acscchemneuro.2c00610>
289. Trougakos IP et al., "Adverse Effects of COVID-19 mRNA Vaccines: The Spike Hypothesis," *Trends Mol. Med.* 2022, 28, 7: 542–554. doi: [10.1016/j.molmed.2022.04.007](https://doi.org/10.1016/j.molmed.2022.04.007)
290. Tyrkalska SD et al., "Differential proinflammatory activities of spike proteins of SARS-CoV-2 variants of concern," *Sci. Adv.* 2022, 8, 37: eabo0732. doi: [10.1126/sciadv.abo0732](https://doi.org/10.1126/sciadv.abo0732)
291. Vargas-Castro R et al., "Calcitriol prevents SARS-CoV spike-induced inflammation in human trophoblasts through downregulating *ACE2* and *TMPRSS2* expression," *J Steroid Biochem Mol Biol* 2025, 245: 106625. doi: <https://doi.org/10.1016/j.jsbmb.2024.106625>
292. Vettori M et al., "Effects of Different Types of Recombinant SARS-CoV-2 Spike Protein on Circulating Monocytes' Structure," *Int. J. Mol. Sci.* 2023, 24, 11: 9373. doi: <https://doi.org/10.3390/ijms24119373>
293. Villacampa A et al., "SARS-CoV-2 S protein activates NLRP3 inflammasome and deregulates coagulation factors in endothelial and immune cells," *Cell Commun. Signal.* 2024, 22, 38. doi: <https://doi.org/10.1186/s12964-023-01397-6>
294. Visvabharathy L et al., "Case report: Treatment of long COVID with a SARS-CoV-2 antiviral and IL-6 blockade in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence," *Front. Med.* 2022, 9 (Sec. Infectious Diseases – Surveillance). doi: <https://doi.org/10.3389/fmed.2022.1003103>
295. Vojdani A and D Kharrazian, "Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases," *Clin Immunol.* 2020, 217: 108480. doi: <https://doi.org/10.1016/j.clim.2020.108480>
296. Vojdani A et al., "Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases," *Front. Immunol.* 2021, 11 (Sec. Autoimmune and Autoinflammatory Disorders). doi: <https://doi.org/10.3389/fimmu.2020.617089>
297. Wang J et al., "SARS-CoV-2 Spike Protein S1 Domain Accelerates α -Synuclein Phosphorylation and Aggregation in Cellular Models of Synucleinopathy," *Mol Neurobiol.* 2024, 61, 4:2446–2458. doi: <https://doi.org/10.1007/s12035-023-03726-9>
298. Wu H et al., "Molecular evidence suggesting the persistence of residual SARS-CoV-2 and immune responses in the placentas of pregnant patients recovered from COVID-19," *Cell Prolif.* 2021, 54, 9: e13091. doi: <https://doi.org/10.1111/cpr.13091>

299. Wu ML et al., "Mast cell activation triggered by SARS-CoV-2 causes inflammation in brain microvascular endothelial cells and microglia," *Front. Cell. Infect. Microbiol.*, 2024, 14. doi: <https://doi.org/10.3389/fcimb.2024.1358873>
300. Yamamoto M et al., "Persistent varicella zoster virus infection following mRNA COVID-19 vaccination was associated with the presence of encoded spike protein in the lesion," *J. Cutan Immunol. Allergy*. 2022:1–6. doi: <https://doi.org/10.1002/cia2.12278>
301. Yeung-Luk BH et al., "SARS-CoV-2 infection alters mitochondrial and cytoskeletal function in human respiratory epithelial cells mediated by expression of spike protein," *mBio* 2023, 14, 4: e00820-23. doi: <https://doi.org/10.1128/mbio.00820-23>
302. Yilmaz A et al., "Differential proinflammatory responses of colon epithelial cells to SARS-CoV-2 spike protein and *Pseudomonas aeruginosa* lipopolysaccharide," *Turk J Biochem*. 2024. doi: <https://doi.org/10.1515/tjb-2024-0144>
303. Yonker LM et al., "Circulating Spike Protein Detected in Post-COVID-19 mRNA Vaccine Myocarditis," *Circulation* 2023, 147, 11. doi: <https://doi.org/10.1161/CIRCULATIONAHA.122.061025>
304. Yonker LM et al., "Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier," *J Clin Invest*. 2021, 131, 14: e149633. doi: <https://doi.org/10.1172/JCI149633>
305. Youn JY et al., "Therapeutic application of estrogen for COVID-19: Attenuation of SARS-CoV-2 spike protein and IL-6 stimulated, ACE2-dependent NOX2 activation, ROS production and MCP-1 upregulation in endothelial cells," *Redox Biol*. 2021, 46: 102099. doi: <https://doi.org/10.1016/j.redox.2021.102099>
306. Youn YJ et al., "Nucleocapsid and spike proteins of SARS-CoV-2 drive neutrophil extracellular trap formation," *Immune Netw*. 2021, 21, 2: e16. doi: <https://doi.org/10.4110/in.2021.21.e16>
307. Yu J et al., "Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition," *Blood* 2020, 136, 18: 2080–2089. doi: <https://doi.org/10.1182/blood.2020008248>
308. Zaki H and S Khan, "SARS-CoV-2 spike protein induces inflammatory molecules through TLR2 in macrophages and monocytes," *J. Immunol*. 2021, 206 (1_supplement): 62.07. doi: <https://doi.org/10.4049/jimmunol.206.Supp.62.07>
309. Zaki H and S Khan, "TLR2 senses spike protein of SARS-CoV-2 to trigger inflammation," *J. Immunol*. 2022, 208 (1_Supplement): 125.30. doi: <https://doi.org/10.4049/jimmunol.208.Supp.125.30>
310. Zekri-Nechar K et al., "Spike Protein Subunits of SARS-CoV-2 Alter Mitochondrial Metabolism in Human Pulmonary Microvascular Endothelial Cells: Involvement of Factor Xa," *Dis. Markers* 2022: 1118195. doi: <https://doi.org/10.1155/2022/1118195>
311. Zeng FM et al., "SARS-CoV-2 spike spurs intestinal inflammation via VEGF production in enterocytes," *EMBO Mol Med*. 2022, 14: e14844. doi: <https://doi.org/10.15252/emmm.202114844>

312. Zhang Q et al., "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) and spike (S) proteins antagonize host type I interferon response," *Front Cell Infect Microbiol* 2021, 11: 766922. doi: <https://doi.org/10.3389/fcimb.2021.766922>
313. Zhang RG et al., "SARS-CoV-2 spike protein receptor binding domain promotes IL-6 and IL-8 release via ATP/P2Y₂ and ERK1/2 signaling pathways in human bronchial epithelia," *Mol. Immunol.* 2024, 167: 53-61. doi: <https://doi.org/10.1016/j.molimm.2024.02.005>
314. Zhang S et al., "SARS-CoV-2 Binds Platelet ACE2 to Enhance Thrombosis in COVID-19," *J. Hematol. Oncol.* 2020, 13, 120. doi: <https://doi.org/10.1186/s13045-020-00954-7>
315. Zhang Z et al., "SARS-CoV-2 spike protein dictates syncytium-mediated lymphocyte elimination," *Cell Death Differ.* 2021, 28: 2765–2777. doi: <https://doi.org/10.1038/s41418-021-00782-3>
316. Zhao Y et al., "SARS-CoV-2 spike protein interacts with and activates TLR4," *Cell Res.* 2021, 31: 818–820. doi: <https://doi.org/10.1038/s41422-021-00495-9>
317. Zheng Y et al., "SARS-CoV-2 Spike Protein Causes Blood Coagulation and Thrombosis by Competitive Binding to Heparan Sulfate," *Int. J. Biol. Macromol.* 2021, 193: 1124–1129, doi: <https://doi.org/10.1016/j.ijbiomac.2021.10.112>
318. Zhu G et al., "SARS-CoV-2 spike protein-induced host inflammatory response signature in human corneal epithelial cells," *Mol. Med. Rep.* 2021, 24: 584. doi: <https://doi.org/10.3892/mmr.2021.12223>
319. Zollner A et al., "Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases," *Gastroenterology* 2022, 163, 2: 495-506.e8. doi: <https://doi.org/10.1053/j.gastro.2022.04.037>
320. Zurlow M et al., "The anti-SARS-CoV-2 BNT162b2 vaccine suppresses mithramycin-induced erythroid differentiation and expression of embryo-fetal globin genes in human erythroleukemia K562 cells." *Exp Cell Res* 2023, 433, 2: 113853. doi: <https://doi.org/10.1016/j.yexcr.2023.113853>

II. CATEGORIES

- A. General/Overview (32)**
- B. ACE2 (19)**
- C. Amyloid, prion-like properties (12)**
- D. Autoimmune (7)**
- E. Blood pressure/hypertension (2)**
- F. CD147 (13)**
- G. Cell membrane permeability, barrier dysfunction (13)**
- H. Cerebral, cerebrovascular, neurologic, blood-brain barrier, cognitive (24)**
- I. Clinical pathology (22)**
- J. Clotting, platelets, hemoglobin (30)**
- K. Cytokines, chemokines, interferon, interleukins (27)**
- L. Endothelial (25)**
- M. Gastrointestinal (8)**
- N. Immune dysfunction (5)**
- O. Macrophages, monocytes, neutrophils (28)**
- P. MAPK/NF-kB (10)**
- Q. Mast cells (3)**
- R. Microglia (6)**
- S. Microvascular (8)**
- T. MIS-C, pediatric (7)**
- U. Mitochondria/metabolism (9)**
- V. Myocarditis, cardiac, cardiomyopathy (22)**
- W. NLRP3 (15)**
- X. Ocular, ophthalmic, conjunctival (3)**
- Y. Other cell signaling (16)**
- Z. PASC, post COVID, long COVID (20)**
- AA. Pregnancy, fetal, placenta (7)**
- BB. Pulmonary, respiratory (28)**
- CC. Renin-Angiotensin-Aldosterone System (3)**
- DD. Senescence/aging (3)**
- EE. Stem cells (3)**
- FF. Syncytia/cell fusion (10)**
- GG. Therapeutics (37)**
- HH. Toll-like receptors (TLRs) (15)**

A. General/Overview

1. Acevedo-Whitehouse K and R Bruno, "Potential health risks of mRNA-based vaccine therapy: A hypothesis," *Med. Hypotheses* 2023, 171: 111015. doi: <https://doi.org/10.1016/j.mehy.2023.111015>
2. Almehti AM et al., "SARS-CoV-2 Spike Protein: Pathogenesis, Vaccines, and Potential Therapies," *Infection* 2021, 49, 5: 855–876. doi: <https://doi.org/10.1007/s15010-021-01677-8>

3. Baldari CT et al., "Emerging Roles of SARS-CoV-2 Spike-ACE2 in Immune Evasion and Pathogenesis," *Trends Immunol.* 2023, 44, 6. doi: <https://doi.org/10.1016/j.it.2023.04.001>
4. Bansal S et al., "Cutting Edge: Circulating Exosomes with COVID Spike Protein Are Induced by BNT162b2 (Pfizer-BioNTech) Vaccination prior to Development of Antibodies: A Novel Mechanism for Immune Activation by mRNA Vaccines," *J. Immunol.* 2021, 207, 10: 2405–2410. doi: <https://doi.org/10.4049/jimmunol.2100637>
5. Bellucci M et al., "Post-SARS-CoV-2 infection and post-vaccine-related neurological complications share clinical features and the same positivity to anti-ACE2 antibodies," *Front. Immunol.* 2024, 15 (Sec. Multiple Sclerosis and Neuroimmunology). doi: <https://doi.org/10.3389/fimmu.2024.1398028>
6. Boros LG et al., "Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination," *Pharmacol Res Perspect* 2024, 12, 3: e1218. doi: <https://doi.org/10.1002/prp2.1218>
7. Brady M et al., "Spike protein multiorgan tropism suppressed by antibodies targeting SARS-CoV-2," *Comm. Biol.* 2021, 4, 1318. doi: <https://doi.org/10.1038/s42003-021-02856-x>
8. Cosentino M and Franca Marino, "Understanding the Pharmacology of COVID-19 mRNA Vaccines: Playing Dice with the Spike?" *Int. J. Mol. Sci.* 2022, 23, 18: 10881. doi: <https://doi.org/10.3390/ijms231810881>
9. Fertig TE et al., "Beyond the injection site: identifying the cellular targets of mRNA vaccines," *J Cell Ident* 2024, 3, 1. doi: [10.47570/joci.2024.004](https://doi.org/10.47570/joci.2024.004)
10. Fertig TE et al., "Vaccine mRNA Can Be Detected in Blood at 15 Days Post Vaccination," *Biomedicines* 2022, 10, 7: 1538. doi: <https://doi.org/10.3390/biomedicines10071538>
11. Gussow AB et al., "Genomic Determinants of Pathogenicity in SARS-CoV-2 and Other Human Coronaviruses," *PNAS* 117, 2020, 26: 15193–15199. doi: <https://doi.org/10.1073/pnas.2008176117>
12. Halma MTJ et al., "Strategies for the Management of Spike Protein-Related Pathology," *Microorganisms* 2023, 11, 5: 1308, doi: <https://doi.org/10.3390/microorganisms11051308>
13. Kent SJ et al., "Blood Distribution of SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine in Humans," *ACS Nano* 2024, 18, 39: 27077-27089. doi: <https://doi.org/10.1021/acsnano.4c11652>
14. Kowarz E et al., "Vaccine-induced COVID-19 mimicry syndrome," *eLife* 2022, 11: e74974. doi: <https://doi.org/10.7554/eLife.74974>
15. Lehmann KJ, "Impact of SARS-CoV-2 Spikes on Safety of Spike-Based COVID-19 Vaccinations," *Immunome Res.* 2024, 20, 2: 1000267. doi: [10.35248/1745-7580.24.20.267](https://doi.org/10.35248/1745-7580.24.20.267)
16. Lehmann KJ, "Suspected Causes of the Specific Intolerance Profile of Spike-Based Covid-19 Vaccines," *Med. Res. Arch* 2024, 12, 9. doi: [10.18103/mra.v12i9.5704](https://doi.org/10.18103/mra.v12i9.5704)
17. Lesgard JF et al., "Toxicity of SARS-CoV-2 Spike Protein from the Virus and Produced from COVID-19 mRNA or Adenoviral DNA Vaccines," *Arch Microbiol Immun* 2023, 7, 3: 121- 138. doi: [10.26502/ami.936500110](https://doi.org/10.26502/ami.936500110)

18. Letarov AV et al., “Free SARS-CoV-2 Spike Protein S1 Particles May Play a Role in the Pathogenesis of COVID-19 Infection,” *Biochemistry (Moscow)* 2021, 86, 257–261. doi: <https://doi.org/10.1134/S0006297921030032>
19. Nuovo JG et al., “Endothelial Cell Damage Is the Central Part of COVID-19 and a Mouse Model Induced by Injection of the S1 Subunit of the Spike Protein,” *Ann. Diagn. Pathol.* 2021, 51, 151682. doi: <https://doi.org/10.1016/j.anndiagpath.2020.151682>
20. Pallas RM, “Innate and adaptative immune mechanisms of COVID-19 vaccines. Serious adverse events associated with SARS-CoV-2 vaccination: A systematic review,” *Vacunas (English ed.)* 2024, 25, 2: 285.e1-285.e94. doi: <https://doi.org/10.1016/j.vacune.2024.05.002>
21. Parry PL et al., “‘Spikeopathy’: COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA,” *Biomedicine* 2023, 11, 8: 2287. doi: <https://doi.org/10.3390/biomedicines11082287>
22. Pateev I et al., “Biodistribution of RNA Vaccines and of Their Products: Evidence from Human and Animal Studies,” *Biomedicines* 2024, 12, 1: 59. doi: <https://doi.org/10.3390/biomedicines12010059>
23. Peluso MJ et al., “Plasma-based antigen persistence in the post-acute phase of COVID-19,” *Lancet* 2024, 24, 6: E345-E347. doi: [10.1016/S1473-3099\(24\)00211-1](https://doi.org/10.1016/S1473-3099(24)00211-1)
24. Rzymiski P and Andrzej Fal, “To aspirate or not to aspirate? Considerations for the COVID-19 vaccines,” *Pharmacol. Rep* 2022, 74: 1223–1227. doi: <https://doi.org/10.1007/s43440-022-00361-4>
25. Saadi F et al., “Spike glycoprotein is central to coronavirus pathogenesis-parallel between m-CoV and SARS-CoV-2,” *Ann Neurosci.* 2021, 28 (3-4): 201–218. doi: <https://doi.org/10.1177/09727531211023755>
26. Sacco K et al., “Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19,” *Nat. Med.* 2022, 28: 1050-1062. doi: <https://doi.org/10.1038/s41591-022-01724-3>
27. Scholkmann F and CA May, “COVID-19, post-acute COVID-19 syndrome (PACS, ‘long COVID’) and post-COVID-19 vaccination syndrome (PCVS, ‘post-COVIDvac-syndrome’): Similarities and differences,” *Pathol Res Pract.* 2023, 246: 154497. doi: <https://doi.org/10.1016/j.prp.2023.154497>
28. Swank Z, et al. “Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae,” *Clin. Infect. Dis* 2023, 76, 3: e487–e490. doi: <https://doi.org/10.1093/cid/ciac722>
29. Theoharides TC, “Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome?” *Mol. Neurobiol.* 2022, 59, 3: 1850–1861, doi: <https://doi.org/10.1007/s12035-021-02696-0>
30. Theoharides TC and P. Conti, “Be Aware of SARS-CoV-2 Spike Protein: There Is More Than Meets the Eye,” *J Biol Reg Homeostat Agents* 2021, 35, 3: 833–838 doi: [10.23812/THEO_EDIT_3_21](https://doi.org/10.23812/THEO_EDIT_3_21)
31. Trougakos IP et al., “Adverse Effects of COVID-19 mRNA Vaccines: The Spike Hypothesis,” *Trends Mol Med.* 2022, 28, 7: 542–554. doi: [10.1016/j.molmed.2022.04.007](https://doi.org/10.1016/j.molmed.2022.04.007)
32. Tyrkalska SD et al., “Differential proinflammatory activities of spike proteins of SARS-CoV-2 variants of concern,” *Sci. Adv.* 2022, 8, 37: eabo0732. doi: [10.1126/sciadv.abo0732](https://doi.org/10.1126/sciadv.abo0732)

B. ACE2

1. Aboudounya MM and RJ Heads, "COVID-19 and Toll-Like Receptor 4 (TLR4): SARS-CoV-2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation," *Mediators Inflamm.* 2021, 8874339. doi: <https://doi.org/10.1155/2021/8874339>
2. Aksenova AY et al., "The increased amyloidogenicity of Spike RBD and pH-dependent binding to ACE2 may contribute to the transmissibility and pathogenic properties of SARS-CoV-2 omicron as suggested by in silico study," *Int J Mol Sci.* 2022, 23, 21: 13502. doi: <https://doi.org/10.3390/ijms232113502>
3. Angeli F et al., "COVID-19, vaccines and deficiency of ACE2 and other angiotensinases. Closing the loop on the 'Spike effect'," *Eur J. Intern. Med.* 2022, 103: 23–28. doi: [10.1016/j.ejim.2022.06.015](https://doi.org/10.1016/j.ejim.2022.06.015)
4. Baldari CT et al., "Emerging Roles of SARS-CoV-2 Spike-ACE2 in Immune Evasion and Pathogenesis," *Trends Immunol.* 2023, 44, 6. doi: <https://doi.org/10.1016/j.it.2023.04.001>
5. Bellucci M et al., "Post-SARS-CoV-2 infection and post-vaccine-related neurological complications share clinical features and the same positivity to anti-ACE2 antibodies," *Front. Immunol.* 2024, 15 (Sec. Multiple Sclerosis and Neuroimmunology). doi: <https://doi.org/10.3389/fimmu.2024.1398028>
6. Devaux CA and L. Camoin-Jau, "Molecular mimicry of the viral spike in the SARS-CoV-2 vaccine possibly triggers transient dysregulation of ACE2, leading to vascular and coagulation dysfunction similar to SARS-CoV-2 infection," *Viruses* 2023, 15, 5: 1045. doi: <https://doi.org/10.3390/v15051045>
7. Gao X et al., "Spike-Mediated ACE2 Down-Regulation Was Involved in the Pathogenesis of SARS-CoV-2 Infection," *J. Infect.* 2022, 85, 4: 418–427. doi: [10.1016/j.jinf.2022.06.030](https://doi.org/10.1016/j.jinf.2022.06.030)
8. Kato Y et al., "TRPC3-Nox2 Protein Complex Formation Increases the Risk of SARS-CoV-2 Spike Protein-Induced Cardiomyocyte Dysfunction through ACE2 Upregulation," *Int. J. Mol. Sci.* 2023, 24, 1: 102. doi: <https://doi.org/10.3390/ijms24010102>
9. Ken W et al., "Low dose radiation therapy attenuates ACE2 depression and inflammatory cytokines induction by COVID-19 viral spike protein in human bronchial epithelial cells," *Int J Radiat Biol.* 2022, 98, 10: 1532-1541. doi: <https://doi.org/10.1080/09553002.2022.2055806>
10. Lei Y et al., "SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2," *Circulation Research* 2021, 128, 9: 1323–1326. doi: <https://doi.org/10.1161/CIRCRESAHA.121.318902>
11. Lu J and PD Sun, "High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity," *J. Biol. Chem* 2020, 295, 52: p18579-18588. doi: [10.1074/jbc.RA120.015303](https://doi.org/10.1074/jbc.RA120.015303)
12. Maeda Y et al., "Differential Ability of Spike Protein of SARS-CoV-2 Variants to Downregulate ACE2," *Int. J. Mol. Sci.* 2024, 25, 2: 1353. doi: <https://doi.org/10.3390/ijms25021353>
13. Magro N et al., "Disruption of the blood-brain barrier is correlated with spike endocytosis by ACE2 + endothelia in the CNS microvasculature in fatal COVID-19. Scientific commentary on 'Detection of blood-brain barrier disruption in brains of patients with COVID-19, but no evidence of brain penetration by SARS-CoV-2'," *Acta Neuropathol.* 2024, 147, 1: 47. doi: <https://doi.org/10.1007/s00401-023-02681-y>

14. Satta S et al., "An engineered nano-liposome-human ACE2 decoy neutralizes SARS-CoV-2 Spike protein-induced inflammation in both murine and human macrophages," *Theranostics* 2022, 12, 6: 2639–2657. doi: [10.7150/thno.66831](https://doi.org/10.7150/thno.66831)
15. Sui Y et al., "SARS-CoV-2 Spike Protein Suppresses ACE2 and Type I Interferon Expression in Primary Cells From Macaque Lung Bronchoalveolar Lavage," *Front. Immunol.* 2021, 12. doi: <https://doi.org/10.3389/fimmu.2021.658428>
16. Tetz G and Victor Tetz, "Prion-Like Domains in Spike Protein of SARS-CoV-2 Differ across Its Variants and Enable Changes in Affinity to ACE2," *Microorganisms* 2025, 10, 2: 280. doi: <https://doi.org/10.3390/microorganisms10020280>
17. Vargas-Castro R et al., "Calcitriol prevents SARS-CoV spike-induced inflammation in human trophoblasts through downregulating ACE2 and TMPRSS2 expression," *J Steroid Biochem Mol Biol* 2025, 245: 106625. doi: <https://doi.org/10.1016/j.jsbmb.2024.106625>
18. Youn JY et al., "Therapeutic application of estrogen for COVID-19: Attenuation of SARS-CoV-2 spike protein and IL-6 stimulated, ACE2-dependent NOX2 activation, ROS production and MCP-1 upregulation in endothelial cells," *Redox Biol.* 2021, 46: 102099. doi: <https://doi.org/10.1016/j.redox.2021.102099>
19. Zhang S et al., "SARS-CoV-2 Binds Platelet ACE2 to Enhance Thrombosis in COVID-19," *J. Hematol. Oncol.* 2020, 13, 120: 120. doi: <https://doi.org/10.1186/s13045-020-00954-7>

C. Amyloid, prion-like properties

1. Aksenova AY et al., "The increased amyloidogenicity of Spike RBD and pH-dependent binding to ACE2 may contribute to the transmissibility and pathogenic properties of SARS-CoV-2 omicron as suggested by in silico study," *Int. J. Mol. Sci.* 2022, 23, 21: 13502. doi: <https://doi.org/10.3390/ijms232113502>
2. Cao S et al., "Spike Protein Fragments Promote Alzheimer's Amyloidogenesis," *ACS Appl. Mater. Interfaces* 2023, 15, 34: 40317-40329. doi: <https://doi.org/10.1021/acsami.3c09815>
3. Freeborn J, "Misfolded Spike Protein Could Explain Complicated COVID-19 Symptoms," *Medical News Today*, May 26, 2022, <https://www.medicalnewstoday.com/articles/misfolded-spike-protein-could-explain-complicated-covid-19-symptoms>
4. Idrees D and Vijay Kumar, "SARS-CoV-2 Spike Protein Interactions with Amyloidogenic Proteins: Potential Clues to Neurodegeneration," *Biochemical and Biophysical Research Communications* 2021, 554 : 94–98. doi: <https://doi.org/10.1016/j.bbrc.2021.03.100>
5. Ma G et al., "SARS-CoV-2 Spike protein S2 subunit modulates γ -secretase and enhances amyloid- β production in COVID-19 neuropathy," *Cell Discov* 2022, 8, 99. doi: <https://doi.org/10.1038/s41421-022-00458-3>
6. Nahalka J, "1-L Transcription of SARS-CoV-2 Spike Protein S1 Subunit," *Int. J. Mol. Sci.* 2024, 25, 8: 4440. doi: <https://doi.org/10.3390/ijms25084440>

7. Nyström S, "Amyloidogenesis of SARS-CoV-2 Spike Protein," *J. Am. Chem. Soc.* 2022, 144, 8945–8950. doi: <https://doi.org/10.1021/jacs.2c03925>
8. Petrlova J et al., "SARS-CoV-2 spike protein aggregation is triggered by bacterial lipopolysaccharide," *FEBS Lett.* 2022, 596:2566–2575. doi: <https://doi.org/10.1002/1873-3468.14490>
9. Petruk G et al., "SARS-CoV-2 spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity," *J. Mol. Cell Biol.* 2020, 12: 916-932. doi: <https://doi.org/10.1093/jmcb/mjaa067>
10. Rong Z et al., "Persistence of spike protein at the skull-meninges-brain axis may contribute to the neurological sequelae of COVID-19," *Cell Host Microbe* 2024, 26: S1931-3128(24)00438-4. doi: [10.1016/j.chom.2024.11.007](https://doi.org/10.1016/j.chom.2024.11.007)
11. Tetz G and Victor Tetz, "Prion-Like Domains in Spike Protein of SARS-CoV-2 Differ across Its Variants and Enable Changes in Affinity to ACE2," *Microorganisms* 2022, 10, 2: 280, doi: <https://doi.org/10.3390/microorganisms10020280>
12. Wang J et al., "SARS-CoV-2 Spike Protein S1 Domain Accelerates α -Synuclein Phosphorylation and Aggregation in Cellular Models of Synucleinopathy," *Mol Neurobiol.* 2024, 61, 4: 2446-2458. doi: <https://doi.org/10.1007/s12035-023-03726-9>

D. Autoimmune

1. Heil M, "Self-DNA driven inflammation in COVID-19 and after mRNA-based vaccination: lessons for non-COVID-19 pathologies," *Front. Immunol.*, 2023, 14. doi: <https://doi.org/10.3389/fimmu.2023.1259879>
2. Kanduc D, "From Anti-SARS-CoV-2 Immune Responses to COVID-19 via Molecular Mimicry," *Antibodies* 2020, 9, 3: 33. doi: <https://doi.org/10.3390/antib9030033>
3. Kanduc D and Y Shoenfeld, "Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine," *Immunol Res* 2020, 68: 310-313. doi: <https://doi.org/10.1007/s12026-020-09152-6>
4. Nunez-Castilla J et al., "Potential autoimmunity resulting from molecular mimicry between SARS-CoV-2 spike and human proteins," *Viruses* 2022, 14, 7: 1415. <https://doi.org/10.3390/v14071415>
5. Rodriguez Y et al., "Autoinflammatory and autoimmune conditions at the crossroad of COVID-19," *J. Autoimmun.* 2020, 114: 102506. doi: <https://doi.org/10.1016/j.jaut.2020.102506>
6. Vojdani A and D Kharratian, "Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases," *Clin Immunol.* 2020, 217: 108480. doi: <https://doi.org/10.1016/j.clim.2020.108480>
7. Vojdani A et al., "Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases," *Front. Immunol.* 2021, 11 (Sec. Autoimmune and Autoinflammatory Disorders). doi: <https://doi.org/10.3389/fimmu.2020.617089>

E. Blood pressure/hypertension

1. Angeli F et al., "The spike effect of acute respiratory syndrome coronavirus 2 and coronavirus disease 2019 vaccines on blood pressure," *Eur J Intern Med.* 2023, 109: 12-21. doi: [10.1016/j.ejim.2022.12.004](https://doi.org/10.1016/j.ejim.2022.12.004)
2. Sun Q et al., "SARS-coV-2 spike protein S1 exposure increases susceptibility to angiotensin II-induced hypertension in rats by promoting central neuroinflammation and oxidative stress," *Neurochem. Res.* 2023, 48, 3016–3026. doi: <https://doi.org/10.1007/s11064-023-03949-1>

F. CD147

1. Avolio E et al., "The SARS-CoV-2 Spike Protein Disrupts Human Cardiac Pericytes Function through CD147 Receptor-Mediated Signalling: A Potential Non-infective Mechanism of COVID-19 Microvascular Disease," *Clin. Sci.* 2021, 135, 24: 2667–2689. doi: <https://doi.org/10.1042/CS20210735>
2. Loh D, "The potential of melatonin in the prevention and attenuation of oxidative hemolysis and myocardial injury from cd147 SARS-CoV-2 spike protein receptor binding," *Melatonin Research* 2020, 3, 3: 380-416. doi: <https://doi.org/10.32794/mr11250069>
3. Maugeri N et al., "Unconventional CD147-Dependent Platelet Activation Elicited by SARS-CoV-2 in COVID-19," *J. Thromb. Haemost.* 2021, 20, 2: 434–448. doi: <https://doi.org/10.1111/jth.15575>

G. Cell membrane permeability, barrier dysfunction

1. Asandei A et al., "Non-Receptor-Mediated Lipid Membrane Permeabilization by the SARS-CoV-2 Spike Protein S1 Subunit," *ACS Appl. Mater. Interfaces* 2020, 12, 50: 55649–55658. doi: <https://doi.org/10.1021/acsami.0c17044>
2. Biancatelli RMLC, et al. "The SARS-CoV-2 spike protein subunit S1 induces COVID-19-like acute lung injury in Kappa18-hACE2 transgenic mice and barrier dysfunction in human endothelial cells," *Am. J. Physiol. Lung Cell. Mol. Physiol.* 2021, 321: L477–L484. doi: <https://doi.org/10.1152/ajplung.00223.2021>
3. Biering SB et al., "SARS-CoV-2 Spike Triggers Barrier Dysfunction and Vascular Leak via Integrins and TGF- β Signaling," *Nat. Commun.* 2022, 13: 7630. doi: <https://doi.org/10.1038/s41467-022-34910-5>
4. Buzhdygan TP et al., "The SARS-CoV-2 Spike Protein Alters Barrier Function in 2D Static and 3D Microfluidic in-Vitro Models of the Human Blood-Brain Barrier," *Neurobiol. Dis.* 2020, 146: 105131. doi: <https://doi.org/10.1016/j.nbd.2020.105131>
5. Chaves JCS et al., "Differential Cytokine Responses of APOE3 and APOE4 Blood-brain Barrier Cell Types to SARS-CoV-2 Spike Proteins," *J. Neuroimmune Pharmacol.* 2024, 19, 22. doi: <https://doi.org/10.1007/s11481-024-10127-9>
6. Correa Y et al., "SARS-CoV-2 spike protein removes lipids from model membranes and interferes with the capacity of high-density lipoprotein to exchange lipids," *J. Colloid Interface Sci.* 2021, 602: 732-739. doi: <https://doi.org/10.1016/j.jcis.2021.06.056>

7. DeOre BJ et al., "SARS-CoV-2 Spike Protein Disrupts Blood-Brain Barrier Integrity via RhoA Activation," *J Neuroimmune Pharmacol.* 2021, 16, 4:722-728. Doi: <https://doi.org/10.1007/s11481-021-10029-0>
8. Guo Y and V Kanamarlapudi, "Molecular Analysis of SARS-CoV-2 Spike Protein-Induced Endothelial Cell Permeability and vWF Secretion," *Int. J. Mol. Sci.* 2023, 24, 6: 5664. doi: <https://doi.org/10.3390/ijms24065664>
9. Luchini A et al., "Lipid bilayer degradation induced by SARS-CoV-2 spike protein as revealed by neutron reflectometry," *Sci. Rep.* 2021, 11: 14867. doi: <https://doi.org/10.1038/s41598-021-93996-x>
10. Luo Y et al., "SARS-Cov-2 spike induces intestinal barrier dysfunction through the interaction between CEACAM5 and Galectin-9," *Front. Immunol.* 2024, 15. doi: <https://doi.org/10.3389/fimmu.2024.1303356>
11. Magro N et al., "Disruption of the blood-brain barrier is correlated with spike endocytosis by ACE2 + endothelia in the CNS microvasculature in fatal COVID-19. Scientific commentary on 'Detection of blood-brain barrier disruption in brains of patients with COVID-19, but no evidence of brain penetration by SARS-CoV-2'," *Acta Neuropathol.* 2024, 147, 1: 47. doi: <https://doi.org/10.1007/s00401-023-02681-y>
12. Raghavan S et al., "SARS-CoV-2 Spike Protein Induces Degradation of Junctional Proteins That Maintain Endothelial Barrier Integrity," *Front. Cardiovasc. Med.* 2021, 8, 687783. doi: <https://doi.org/10.3389/fcvm.2021.687783>
13. Ruben ML et al., "The SARS-CoV-2 spike protein subunit S1 induces COVID-19-like acute lung injury in K18-hACE2 transgenic mice and barrier dysfunction in human endothelial cells," *Am J Physiol Lung Cell Mol Physiol.* 2021, 321, 2: L477-L484. doi: <https://doi.org/10.1152/ajplung.00223.2021>

H. Cerebral, cerebrovascular, neurologic, blood-brain barrier, cognitive

1. Bellucci M et al., "Post-SARS-CoV-2 infection and post-vaccine-related neurological complications share clinical features and the same positivity to anti-ACE2 antibodies," *Front. Immunol.* 2024, 15 (Sec. Multiple Sclerosis and Neuroimmunology). doi: <https://doi.org/10.3389/fimmu.2024.1398028>
2. Burnett FN et al., "SARS-CoV-2 Spike Protein Intensifies Cerebrovascular Complications in Diabetic hACE2 Mice through RAAS and TLR Signaling Activation," *Int. J. Mol. Sci.* 2023, 24, 22: 16394. doi: <https://doi.org/10.3390/ijms242216394>
3. Choi JY et al., "SARS-CoV-2 spike S1 subunit protein-mediated increase of beta-secretase 1 (BACE1) impairs human brain vessel cells," *Biochem. Biophys. Res. Commun.* 2022, 625, 20: 66-71. doi: <https://doi.org/10.1016/j.bbrc.2022.07.113>
4. Clough E et al., "Mitochondrial Dynamics in SARS-COV2 Spike Protein Treated Human Microglia: Implications for Neuro-COVID," *J. Neuroimmune Pharmacol.* 2021, 4, 16: 770-784. doi: <https://doi.org/10.1007/s11481-021-10015-6>
5. Coly M, et al., "Subacute monomelic radiculoplexus neuropathy following Comirnaty(c) (Pfizer-BioNTech COVID-19) vaccination: A case report," *Revue Neurologique* 2023, 179, 6: 636-639. doi: <https://doi.org/10.1016/j.neurol.2023.02.063>

6. DeOre BJ et al., "SARS-CoV-2 Spike Protein Disrupts Blood-Brain Barrier Integrity via RhoA Activation," *J Neuroimmune Pharmacol.* 2021, 16, 4: 722-728. Doi: <https://doi.org/10.1007/s11481-021-10029-0>
7. Erdogan MA, "Prenatal SARS-CoV-2 Spike Protein Exposure Induces Autism-Like Neurobehavioral Changes in Male Neonatal Rats," *J Neuroimmune Pharmacol.* 2023, 18, 4: 573-591. doi: [10.1007/s11481-023-10089-4](https://doi.org/10.1007/s11481-023-10089-4)
8. Erickson MA et al., "Blood-brain barrier penetration of non-replicating SARS-CoV-2 and S1 variants of concern induce neuroinflammation which is accentuated in a mouse model of Alzheimer's disease," *Brain Behav Immun* 2023, 109: 251-268. doi: <https://doi.org/10.1016/j.bbi.2023.01.010>
9. Fontes-Dantas FL, "SARS-CoV-2 Spike Protein Induces TLR4-Mediated Long- Term Cognitive Dysfunction Recapitulating Post-COVID-19 Syndrome in Mice," *Cell Reports* 2023, 42, 3: 112189. doi: <https://doi.org/10.1016/j.celrep.2023.112189>
10. Frank MG et al., "Exploring the immunogenic properties of SARS-CoV-2 structural proteins: PAMP:TLR signaling in the mediation of the neuroinflammatory and neurologic sequelae of COVID-19," *Brain Behav Immun* 2023, 111. doi: <https://doi.org/10.1016/j.bbi.2023.04.009>
11. Frank MG et al., "SARS-CoV-2 S1 subunit produces a protracted priming of the neuroinflammatory, physiological, and behavioral responses to a remote immune challenge: A role for corticosteroids," *Brain Behav. Immun.* 2024, 121: 87-103. doi: <https://doi.org/10.1016/j.bbi.2024.07.034>
12. Heath SP et al., "SARS-CoV-2 Spike Protein Exacerbates Thromboembolic Cerebrovascular Complications in Humanized ACE2 Mouse Model," *Transl Stroke Res.* 2024. doi: <https://doi.org/10.1007/s12975-024-01301-5>
13. Khaddaj-Mallat R et al., "SARS-CoV-2 deregulates the vascular and immune functions of brain pericytes via Spike protein," *Neurobiol. Dis.* 2021, 161, 105561. doi: <https://doi.org/10.1016/j.nbd.2021.105561>
14. Kim ES et al., "Spike Proteins of SARS-CoV-2 Induce Pathological Changes in Molecular Delivery and Metabolic Function in the Brain Endothelial Cells," *Viruses* 2021, 13, 10: 2021. doi: <https://doi.org/10.3390/v13102021>
15. Lykhmus O et al., "Immunization with 674–685 fragment of SARS-Cov-2 spike protein induces neuroinflammation and impairs episodic memory of mice," *Biochem. Biophys. Res. Commun.* 2022, 622: 57–63. doi: <https://doi.org/10.1016/j.bbrc.2022.07.016>
16. Magro N et al., "Disruption of the blood-brain barrier is correlated with spike endocytosis by ACE2 + endothelia in the CNS microvasculature in fatal COVID-19. Scientific commentary on 'Detection of blood-brain barrier disruption in brains of patients with COVID-19, but no evidence of brain penetration by SARS-CoV-2'," *Acta Neuropathol.* 2024, 147, 1: 47. doi: <https://doi.org/10.1007/s00401-023-02681-y>
17. Oh J et al., "SARS-CoV-2 Spike Protein Induces Cognitive Deficit and Anxiety-Like Behavior in Mouse via Non-cell Autonomous Hippocampal Neuronal Death," *Scientific Reports* 2022, 12, 5496. doi: <https://doi.org/10.1038/s41598-022-09410-7>
18. Oka N et al., "SARS-CoV-2 S1 protein causes brain inflammation by reducing intracerebral acetylcholine production," *iScience* 2023, 26, 6: 106954. doi: [10.1016/j.isci.2023.106954](https://doi.org/10.1016/j.isci.2023.106954)

19. Peluso MJ et al., "SARS-CoV-2 and mitochondrial proteins in neural-derived exosomes of COVID-19," *Ann Neurol* 2022, 91, 6: 772-781. doi: <https://doi.org/10.1002/ana.26350>
20. Petrovski D et al., "Penetration of the SARS-CoV-2 Spike Protein across the Blood-Brain Barrier, as Revealed by a Combination of a Human Cell Culture Model System and Optical Biosensing," *Biomedicines* 2022, 10, 1: 188. doi: <https://doi.org/10.3390/biomedicines10010188>
21. Rong Z et al., "Persistence of spike protein at the skull-meninges-brain axis may contribute to the neurological sequelae of COVID-19," *Cell Host Microbe* 2024, 26: S1931-3128(24)00438-4. doi: [10.1016/j.chom.2024.11.007](https://doi.org/10.1016/j.chom.2024.11.007)
22. Suprewicz L et al., "Blood-brain barrier function in response to SARS-CoV-2 and its spike protein," *Neurol. Neurochir Pol.* 2023, 57: 14–25. doi: [10.5603/PJNNS.a2023.0014](https://doi.org/10.5603/PJNNS.a2023.0014)
23. Suprewicz L et al., "Recombinant human plasma gelsolin reverses increased permeability of the blood-brain barrier induced by the spike protein of the SARS-CoV-2 virus," *J Neuroinflammation* 2022, 19, 1: 282, doi: <https://doi.org/10.1186/s12974-022-02642-4>
24. Wu ML et al., "Mast cell activation triggered by SARS-CoV-2 causes inflammation in brain microvascular endothelial cells and microglia," *Front. Cell. Infect. Microbiol.*, 2024, 14. doi: <https://doi.org/10.3389/fcimb.2024.1358873>

I. Clinical pathology

1. Baumeier C et al., "Intramyocardial Inflammation after COVID-19 Vaccination: An Endomyocardial Biopsy-Proven Case Series," *Int. J. Mol. Sci.* 2022, 23: 6940. doi: <https://doi.org/10.3390/ijms23136940>
2. Burkhardt A, "Pathology Conference: Vaccine-Induced Spike Protein Production in the Brain, Organs etc., now Proven," *Report24.news.* 2022, <https://report24.news/pathologie-konferenz-impfinduzierte-spike-produktion-in-gehirn-u-a-organen-nun-erwiesen/>
3. Craddock V et al., "Persistent circulation of soluble and extracellular vesicle-linked Spike protein in individuals with postacute sequelae of COVID-19," *J Med. Virol.* 2023, 95, 2: e28568. doi: <https://doi.org/10.1002/jmv.28568>
4. De Michele M et al., "Evidence of SARS-CoV-2 Spike Protein on Retrieved Thrombi from COVID-19 Patients," *J. Hematol. Oncol.* 2022, 15, 108. doi: <https://doi.org/10.1186/s13045-022-01329-w>
5. De Sousa PMB et al., "Fatal Myocarditis following COVID-19 mRNA Immunization: A Case Report and Differential Diagnosis Review," *Vaccines* 2024, 12, 2: 194. doi: <https://doi.org/10.3390/vaccines12020194>
6. Gamblicher T et al., "SARS-CoV-2 spike protein is present in both endothelial and eccrine cells of a chilblain-like skin lesion," *J Eur Acad Dermatol Venereol.* 2020, 1, 10: e187-e189. doi: <https://doi.org/10.1111/jdv.16970>
7. Gawaz A et al., "SARS-CoV-2-Induced Vasculitic Skin Lesions Are Associated with Massive Spike Protein Depositions in Autophagosomes," *J Invest Dermatol.* 2024, 144, 2: 369-377.e4. doi: <https://doi.org/10.1016/j.jid.2023.07.018>

8. Hulscher N et al., "Autopsy findings in cases of fatal COVID-19 vaccine-induced myocarditis," *ESC Heart Failure* 2024. doi: <https://doi.org/10.1002/ehf2.14680>
9. Ko CJ et al., "Discordant anti-SARS-CoV-2 spike protein and RNA staining in cutaneous pernioic lesions suggests endothelial deposition of cleaved spike protein," *J. Cutan Pathol* 2021, 48, 1: 47–52. doi: <https://doi.org/10.1111/cup.13866>
10. Magen E et al., "Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis," *Vaccines* 2022, 10: 1135. doi: <https://doi.org/10.3390/vaccines10071135>
11. Magro N et al., "Disruption of the blood-brain barrier is correlated with spike endocytosis by ACE2 + endothelia in the CNS microvasculature in fatal COVID-19. Scientific commentary on 'Detection of blood-brain barrier disruption in brains of patients with COVID-19, but no evidence of brain penetration by SARS-CoV-2'," *Acta Neuropathol.* 2024, 147, 1: 47. doi: <https://doi.org/10.1007/s00401-023-02681-y>
12. Matschke J et al., "Neuropathology of patients with COVID-19 in Germany: a post-mortem case series," *Lancet Neurol.* 2020, 19, 11: 919-929. doi: [10.1016/S1474-4422\(20\)30308-2](https://doi.org/10.1016/S1474-4422(20)30308-2)
13. Mörz M, "A Case Report: Multifocal Necrotizing Encephalitis and Myocarditis after BNT162b2 mRNA Vaccination against COVID-19," *Vaccines* 2022, 10, 10: 1651. doi: <https://doi.org/10.3390/vaccines10101651>
14. Rong Z et al., "Persistence of spike protein at the skull-meninges-brain axis may contribute to the neurological sequelae of COVID-19," *Cell Host Microbe* 2024, 26: S1931-3128(24)00438-4. doi: [10.1016/j.chom.2024.11.007](https://doi.org/10.1016/j.chom.2024.11.007)
15. Sano H et al., "A case of persistent, confluent maculopapular erythema following a COVID-19 mRNA vaccination is possibly associated with the intralesional spike protein expressed by vascular endothelial cells and eccrine glands in the deep dermis," *J. Dermatol.* 2023, 50: 1208–1212. doi: <https://doi.org/10.1111/1346-8138.16816>
16. Sano S et al., "SARS-CoV-2 spike protein found in the acrosyringium and eccrine gland of repetitive miliaria-like lesions in a woman following mRNA vaccination," *J. Dermatol.* 2024, 51, 9: e293-e295. doi: <https://doi.org/10.1111/1346-8138.17204>
17. Santonja C et al., "COVID-19 chilblain-like lesion: immunohistochemical demonstration of SARS-CoV-2 spike protein in blood vessel endothelium and sweat gland epithelium in a polymerase chain reaction-negative patient," *Br J Dermatol.* 2020, 183, 4: 778-780. doi: <https://doi.org/10.1111/bjd.19338>
18. Soares CD et al., "Oral vesiculobullous lesions as an early sign of COVID-19: immunohistochemical detection of SARS-CoV-2 spike protein," *Br. J. Dermatol.* 2021, 184, 1: e6. doi: <https://doi.org/10.1111/bjd.19569>
19. Wu H et al., "Molecular evidence suggesting the persistence of residual SARS-CoV-2 and immune responses in the placentas of pregnant patients recovered from COVID-19," *Cell Prolif.* 2021, 54, 9: e13091. doi: <https://doi.org/10.1111/cpr.13091>

20. Yamamoto M et al., “Persistent varicella zoster virus infection following mRNA COVID-19 vaccination was associated with the presence of encoded spike protein in the lesion,” *J. Cutan Immunol. Allergy*. 2022; 1-6. doi: <https://doi.org/10.1002/cia2.12278>
21. Yonker LM et al., “Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis,” *Circulation* 2023, 147, 11. doi: <https://doi.org/10.1161/CIRCULATIONAHA.122.061025>
22. Yonker LM et al., “Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier,” *J Clin Invest*. 2021, 131, 14: e149633. doi: <https://doi.org/10.1172/JCI149633>

J. Clotting, platelets, hemoglobin

1. Al-Kuraishy HM et al., “Changes in the Blood Viscosity in Patients With SARS-CoV-2 Infection,” *Front. Med*. 2022, 9: 876017. doi: [10.3389/fmed.2022.876017](https://doi.org/10.3389/fmed.2022.876017)
2. Al-Kuraishy HM et al., “Hemolytic anemia in COVID-19,” *Ann. Hematol*. 2022, 101: 1887–1895. doi: [10.1007/s00277-022-04907-7](https://doi.org/10.1007/s00277-022-04907-7)
3. Appelbaum K et al., “SARS-CoV-2 spike-dependent platelet activation in COVID-19 vaccine-induced thrombocytopenia,” *Blood Adv*. 2022, 6: 2250–2253. doi: [10.1182/bloodadvances.2021005050](https://doi.org/10.1182/bloodadvances.2021005050)
4. Boschi C et al., “SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects,” *Int. J. Biol. Macromol*. 2022, 23, 24: 15480, doi: <https://doi.org/10.3390/ijms232415480>
5. Bye AP et al., “Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets,” *Blood* 2021, 138, 6: 1481–9. doi: <https://doi.org/10.1182/blood.2021011871>
6. Carnevale R et al., “Toll-Like Receptor 4-Dependent Platelet-Related Thrombosis in SARS-CoV-2 Infection,” *Circ. Res*. 2023, 132, 3: 290–305, doi: <https://doi.org/10.1161/CIRCRESAHA.122.321541>
7. Cossenza LC et al., “Inhibitory effects of SARS-CoV-2 spike protein and BNT162b2 vaccine on erythropoietin-induced globin gene expression in erythroid precursor cells from patients with β -thalassemia,” *Exp. Hematol*. 2024, 129, 104128. doi: <https://doi.org/10.1016/j.exphem.2023.11.002>
8. De Michele M et al., “Vaccine-induced immune thrombotic thrombocytopenia: a possible pathogenic role of ChAdOx1 nCoV-19 vaccine-encoded soluble SARS-CoV-2 spike protein,” *Haematologica* 2022, 107, 7: 1687–92. <https://doi.org/10.3324/haematol.2021.280180>
9. Grobbelaar LM et al., “SARS-CoV-2 Spike Protein S1 Induces Fibrin(ogen) Resistant to Fibrinolysis: Implications for Microclot Formation in COVID-19,” *Bioscience Reports* 2021, 41, 8: BSR20210611. doi: <https://doi.org/10.1042/BSR20210611>
10. Heath SP et al., “SARS-CoV-2 Spike Protein Exacerbates Thromboembolic Cerebrovascular Complications in Humanized ACE2 Mouse Model,” *Transl Stroke Res*. 2024. doi: <https://doi.org/10.1007/s12975-024-01301-5>
11. Iba T and JH Levy, “The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia,” *Trends Cardiovasc Med*. 2022, 32, 1: 1-9. doi: <https://doi.org/10.1016/j.tcm.2021.08.012>

12. Huynh TV et al., "Spike Protein of SARS-CoV-2 Activates Cardiac Fibrogenesis through NLRP3 Inflammasomes and NF- κ B Signaling," *Cells* 2024, 13, 16: 1331. doi: <https://doi.org/10.3390/cells13161331>
13. Iba T and JH Levy, "The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia," *Trends Cardiovasc Med.* 2022, 32, 1: 1-9. doi: <https://doi.org/10.1016/j.tcm.2021.08.012>
14. Jana S et al., "Cell-free hemoglobin does not attenuate the effects of SARS-CoV-2 spike protein S1 subunit in pulmonary endothelial cells," *Int. J. Mol. Sci.* 2021, 22, 16: 9041. doi: <https://doi.org/10.3390/ijms22169041>
15. Kim SY et al., "Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions," *Antivir Res.* 2020, 181: 104873. doi: <https://doi.org/10.1016/j.antiviral.2020.104873>
16. Kircheis R, "Coagulopathies after Vaccination against SARS-CoV-2 May Be Derived from a Combined Effect of SARS-CoV-2 Spike Protein and Adenovirus Vector-Triggered Signaling Pathways," *Int. J. Mol. Sci.* 2021, 22, 19: 10791. <https://doi.org/10.3390/ijms221910791>
17. Kuhn CC et al. "Direct Cryo-ET observation of platelet deformation induced by SARS-CoV-2 spike protein," *Nat. Commun.* 2023, 14, 620. doi: <https://doi.org/10.1038/s41467-023-36279-5>
18. Li T et al., "Platelets Mediate Inflammatory Monocyte Activation by SARS-CoV-2 Spike Protein," *J. Clin. Invest.* 2022, 132, 4: e150101. doi: [10.1172/JCI150101](https://doi.org/10.1172/JCI150101)
19. Maugeri N et al., "Unconventional CD147-Dependent Platelet Activation Elicited by SARS-CoV-2 in COVID-19," *J. Thromb. Haemost.* 2021, 20, 2: 434-448, doi: <https://doi.org/10.1111/jth.15575>
20. Passariello M et al., "Interactions of Spike-RBD of SARS-CoV-2 and Platelet Factor 4: New Insights in the Etiopathogenesis of Thrombosis," *Int. J. Mol. Sci.* 2021, 22, 16: 8562. doi: <https://doi.org/10.3390/ijms22168562>
21. Perico L et al., "SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation," *Front. Immunol.* 2022, 13, 827146. doi: <https://doi.org/10.3389/fimmu.2022.827146>
22. Roytenberg R et al., "Thymidine phosphorylase mediates SARS-CoV-2 spike protein enhanced thrombosis in K18-hACE2TG mice," *Thromb. Res.* 2024, 244, 8: 109195. doi: [10.1016/j.thromres.2024.109195](https://doi.org/10.1016/j.thromres.2024.109195)
23. Russo A, et al., "Implication of COVID-19 on Erythrocytes Functionality: Red Blood Cell Biochemical Implications and Morpho-Functional Aspects," *Int. J. Mol. Sci.* 2022, 23, 4: 2171. doi: <https://doi.org/10.3390/ijms23042171>
24. Ryu JK et al., "Fibrin drives thromboinflammation and neuropathology in COVID-19," *Nature* 2024, 633: 905-913. doi: <https://doi.org/10.1038/s41586-024-07873-4>
25. Scheim, DE. "A Deadly Embrace: Hemagglutination Mediated by SARS-CoV-2 Spike Protein at its 22 N-Glycosylation Sites, Red Blood Cell Surface Sialoglycoproteins, and Antibody," *Int. J. Mol. Sci.* 2022, 23, 5: 2558. doi: <https://doi.org/10.3390/ijms23052558>

26. Scheim DE et al., "Sialylated Glycan Bindings from SARS-CoV-2 Spike Protein to Blood and Endothelial Cells Govern the Severe Morbidities of COVID-19," *Int. J. Mol. Sci.* 2023, 24, 23: 17039. doi: <https://doi.org/10.3390/ijms242317039>
27. Sirsendu J et al., "Cell-Free Hemoglobin Does Not Attenuate the Effects of SARS-CoV-2 Spike Protein S1 Subunit in Pulmonary Endothelial Cells," *Int. J. Mol. Sci.*, 2021, 22, 16: 9041. doi: <https://doi.org/10.3390/ijms22169041>
28. Zhang S et al., "SARS-CoV-2 Binds Platelet ACE2 to Enhance Thrombosis in COVID-19," *J. Hematol. Oncol.* 2020, 13, 120: 120. doi: <https://doi.org/10.1186/s13045-020-00954-7>
29. Zhang Z et al., "SARS-CoV-2 spike protein dictates syncytium-mediated lymphocyte elimination," *Cell Death Differ.* 2021, 28, 2765–2777. doi: <https://doi.org/10.1038/s41418-021-00782-3>
30. Zheng Y et al., "SARS-CoV-2 Spike Protein Causes Blood Coagulation and Thrombosis by Competitive Binding to Heparan Sulfate," *Int. J. Biol. Macromol.* 2021, 193: 1124–1129. doi: <https://doi.org/10.1016/j.ijbiomac.2021.10.112>

K. Cytokines, chemokines, inteferon, interleukins

1. Ao Z et al., "SARS-CoV-2 Delta spike protein enhances the viral fusogenicity and inflammatory cytokine production," *iScience* 2022, 25, 8: 104759. doi: [10.1016/j.isci.2022.104759](https://doi.org/10.1016/j.isci.2022.104759)
2. Chaves JCS et al., "Differential Cytokine Responses of APOE3 and APOE4 Blood–brain Barrier Cell Types to SARS-CoV-2 Spike Proteins," *J. Neuroimmune Pharmacol.* 2024, 19, 22. doi: <https://doi.org/10.1007/s11481-024-10127-9>
3. Chittasupho C et al., "Targeting spike glycoprotein S1 mediated by NLRP3 inflammasome machinery and the cytokine releases in A549 lung epithelial cells by nanocurcumin," *Pharmaceuticals* (Basel) 2023, 16, 6: 862. doi: <https://doi.org/10.3390/ph16060862>
4. Das T et al., "N-glycosylation of the SARS-CoV-2 spike protein at Asn331 and Asn343 is involved in spike-ACE2 binding, virus entry, and regulation of IL-6," *Microbiol. Immunol.* 2024, 68, 5: 165-178. doi: <https://doi.org/10.1111/1348-0421.13121>
5. Duarte C, "Age-dependent effects of the recombinant spike protein/SARS-CoV-2 on the M-CSF- and IL-34-differentiated macrophages in vitro," *Biochem. Biophys. Res. Commun.* 2021, 546: 97–102. doi: <https://doi.org/10.1016/j.bbrc.2021.01.104>
6. Forsyth CB et al., "The SARS-CoV-2 S1 spike protein promotes MAPK and NF-κB activation in human lung cells and inflammatory cytokine production in human lung and intestinal epithelial cells," *Microorganisms* 2022, 10, 10: 1996. doi: <https://doi.org/10.3390/microorganisms10101996>
7. Freitas RS et al., "SARS-CoV-2 Spike antagonizes innate antiviral immunity by targeting interferon regulatory factor 3," *Front Cell Infect Microbiol.* 2021, 11: 789462. doi: <https://doi.org/10.3389/fcimb.2021.789462>
8. Gasparello J et al., "Sulforaphane inhibits the expression of interleukin-6 and interleukin-8 induced in bronchial epithelial IB3-1 cells by exposure to the SARS-CoV-2 Spike protein," *Phytomedicine* 2021, 87: 153583. doi: <https://doi.org/10.1016/j.phymed.2021.153583>

9. Ghazanfari D et al., "Mechanistic insights into SARS-CoV-2 spike protein induction of the chemokine CXCL10," *Sci. Rep.* 2024, 14: 11179. doi: <https://doi.org/10.1038/s41598-024-61906-6>
10. Gracie NP et al., "Cellular signalling by SARS-CoV-2 spike protein," *Microbiology Australia* 2024, 45, 1: 13-17. doi: <https://doi.org/10.1071/MA24005>
11. Gu T et al., "Cytokine Signature Induced by SARS-CoV-2 Spike Protein in a Mouse Model," *Front. Immunol.*, 2021 (Sec. Inflammation). doi: <https://doi.org/10.3389/fimmu.2020.621441>
12. Jugler C et al, "SARS-CoV-2 Spike Protein-Induced Interleukin 6 Signaling Is Blocked by a Plant-Produced Anti-Interleukin 6 Receptor Monoclonal Antibody," *Vaccines* 2021, 9, 11: 1365. <https://doi.org/10.3390/vaccines9111365>
13. Liang S et al., "SARS-CoV-2 spike protein induces IL-18-mediated cardiopulmonary inflammation via reduced mitophagy," *Signal Transduct Target Ther* 2023, 8, 103. doi: <https://doi.org/10.1038/s41392-023-01368-w>
14. Liu T et al., "RS-5645 attenuates inflammatory cytokine storm induced by SARS-CoV-2 spike protein and LPS by modulating pulmonary microbiota," *Int. J. Biol. Sci.* 2021, 17, 13: 3305–3319. doi: [10.7150/ijbs.63329](https://doi.org/10.7150/ijbs.63329)
15. Liu X et al., "SARS-CoV-2 spike protein-induced cell fusion activates the cGAS-STING pathway and the interferon response," *Sci Signal.* 2022, 15, 729: eabg8744. doi: [10.1126/scisignal.abg8744](https://doi.org/10.1126/scisignal.abg8744)
16. Niu C et al., "SARS-CoV-2 spike protein induces the cytokine release syndrome by stimulating T cells to produce more IL-2," *Front. Immunol.* 2024, 15: 1444643. doi: <https://doi.org/10.3389/fimmu.2024.1444643>
17. Norris B et al., "Evaluation of Glutathione in Spike Protein of SARS-CoV-2 Induced Immunothrombosis and Cytokine Dysregulation," *Antioxidants* 2024, 13, 3: 271. doi: <https://doi.org/10.3390/antiox13030271>
18. Olajide OA et al., "Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone," *Inflammation* 2021, 44: 1865–1877. doi: <https://doi.org/10.1007/s10753-021-01464-5>
19. Park YJ et al., "D-dimer and CoV-2 spike-immune complexes contribute to the production of PGE2 and proinflammatory cytokines in monocytes," *PLoS Pathog.*, 2022, 18, 4: e1010468. doi: <https://doi.org/10.1371/journal.ppat.1010468>
20. Patra T et al., "SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells," *PLoS Pathog.* 2020, 16: e1009128. doi: <https://doi.org/10.1371/journal.ppat.1009128>
21. Samsudin S et al., "SARS-CoV-2 spike protein as a bacterial lipopolysaccharide delivery system in an overzealous inflammatory cascade," *J. Mol. Biol.* 2022, 14, 9: mjac058. doi: <https://doi.org/10.1093/jmcb/mjac058>
22. Schroeder JT and AP Bieneman, "The S1 Subunit of the SARS-CoV-2 Spike protein activates human monocytes to produce cytokines linked to COVID-19: relevance to galectin-3," *Front Immunol.* 2022, 13: 831763. doi: <https://doi.org/10.3389/fimmu.2022.831763>

23. Sharma VK et al., "Nanocurcumin Potently Inhibits SARS-CoV-2 Spike Protein-Induced Cytokine Storm by Deactivation of MAPK/NF- κ B Signaling in Epithelial Cells," *ACS Appl. Bio Mater.* 2022, 5, 2: 483–491. doi: <https://doi.org/10.1021/acsabm.1c00874>
24. Sui Y et al., "SARS-CoV-2 Spike Protein Suppresses ACE2 and Type I Interferon Expression in Primary Cells From Macaque Lung Bronchoalveolar Lavage," *Front. Immunol.* 2021, 12. doi: <https://doi.org/10.3389/fimmu.2021.658428>
25. Youn JY et al., "Therapeutic application of estrogen for COVID-19: Attenuation of SARS-CoV-2 spike protein and IL-6 stimulated, ACE2-dependent NOX2 activation, ROS production and MCP-1 upregulation in endothelial cells," *Redox Biol.* 2021, 46: 102099. doi: <https://doi.org/10.1016/j.redox.2021.102099>
26. Zhang Q et al., "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) and spike (S) proteins antagonize host type I interferon response," *Front Cell Infect Microbiol* 2021, 11: 766922. doi: <https://doi.org/10.3389/fcimb.2021.766922>
27. Zhang RG et al., "SARS-CoV-2 spike protein receptor binding domain promotes IL-6 and IL-8 release via ATP/P2Y₂ and ERK1/2 signaling pathways in human bronchial epithelia," *Mol. Immunol.* 2024, 167: 53-61. doi: <https://doi.org/10.1016/j.molimm.2024.02.005>

L. Endothelial

1. Bhargavan B and GD Kanmogne, "SARS-CoV-2 spike proteins and cell-cell communication inhibits TFPI and induces thrombogenic factors in human lung microvascular endothelial cells and neutrophils: implications for COVID-19 coagulopathy pathogenesis," *Int. J. Mol. Sci.* 2022, 23, 18: 10436. doi: <https://doi.org/10.3390/ijms231810436>
2. Biancatelli RMLC, et al. "The SARS-CoV-2 spike protein subunit S1 induces COVID-19-like acute lung injury in Kappa18-hACE2 transgenic mice and barrier dysfunction in human endothelial cells," *Am. J. Physiol. Lung Cell. Mol. Physiol.* 2021, 321: L477–L484. doi: <https://doi.org/10.1152/ajplung.00223.2021>
3. Gamblicher T et al., "SARS-CoV-2 spike protein is present in both endothelial and eccrine cells of a chilblain-like skin lesion," *J Eur Acad Dermatol Venereol.* 2020, 1, 10: e187-e189. doi: <https://doi.org/10.1111/jdv.16970>
4. Guo Y and V Kanamarlapudi, "Molecular Analysis of SARS-CoV-2 Spike Protein-Induced Endothelial Cell Permeability and vWF Secretion," *Int. J. Mol. Sci.* 2023, 24, 6: 5664. doi: <https://doi.org/10.3390/ijms24065664>
5. Jana S et al., "Cell-free hemoglobin does not attenuate the effects of SARS-CoV-2 spike protein S1 subunit in pulmonary endothelial cells," *Int. J. Mol. Sci.* 2021, 22, 16: 9041. doi: <https://doi.org/10.3390/ijms22169041>
6. Kulkoviene G et al., "Differential Mitochondrial, Oxidative Stress and Inflammatory Responses to SARS-CoV-2 Spike Protein Receptor Binding Domain in Human Lung Microvascular, Coronary Artery Endothelial and Bronchial Epithelial Cells," *Int. J. Mol. Sci.* 2024, 25, 6: 3188. doi: <https://doi.org/10.3390/ijms25063188>

7. Marrone L et al., "Tirofiban prevents the effects of SARS-CoV-2 spike protein on macrophage activation and endothelial cell death," *Heliyon*, 2024, 10, 15, e35341. doi: [10.1016/j.heliyon.2024.e35341](https://doi.org/10.1016/j.heliyon.2024.e35341)
8. Meyer K et al., "SARS-CoV-2 Spike Protein Induces Paracrine Senescence and Leukocyte Adhesion in Endothelial Cells," *J. Virol.* 2021, 95: e0079421. doi: <https://doi.org/10.1128/jvi.00794-21>
9. Nuovo JG et al., "Endothelial Cell Damage Is the Central Part of COVID-19 and a Mouse Model Induced by Injection of the S1 Subunit of the Spike Protein," *Ann. Diagn. Pathol.* 2021, 51, 151682. doi: <https://doi.org/10.1016/j.anndiagpath.2020.151682>
10. Perico L et al., "SARS-CoV-2 and the spike protein in endotheliopathy," *Trends Microbiol.* 2024, 32, 1: 53-67. doi: [10.1016/j.tim.2023.06.004](https://doi.org/10.1016/j.tim.2023.06.004)
11. Perico L et al., "SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation," *Front. Immunol.* 2022, 13, 827146. doi: <https://doi.org/10.3389/fimmu.2022.827146>
12. Raghavan S et al., "SARS-CoV-2 Spike Protein Induces Degradation of Junctional Proteins That Maintain Endothelial Barrier Integrity," *Front. Cardiovasc. Med.* 2021, 8, 687783. doi: <https://doi.org/10.3389/fcvm.2021.687783>
13. Ratajczak MZ et al., "SARS-CoV-2 Entry Receptor ACE2 Is Expressed on Very Small CD45⁺ Precursors of Hematopoietic and Endothelial Cells and in Response to Virus Spike Protein Activates the Nlrp3 Inflammasome," *Stem Cell Rev Rep.* 2021, 17, 1: 266-277. doi: <https://doi.org/10.1007/s12015-020-10010-z>
14. Robles JP et al., "The Spike Protein of SARS-CoV-2 Induces Endothelial Inflammation through Integrin $\alpha 5\beta 1$ and NF- κ B Signaling," *J. Biol. Chem.* 2022, 298, 3: 101695. doi: <https://doi.org/10.1016/j.jbc.2022.101695>
15. Rotoli BM et al., "Endothelial cell activation by SARS-CoV-2 spike S1 protein: A crosstalk between endothelium and innate immune cells," *Biomedicines* 2021, 9, 9: 1220. doi: <https://doi.org/10.3390/biomedicines9091220>
16. Ruben ML et al., "The SARS-CoV-2 spike protein subunit S1 induces COVID-19-like acute lung injury in K18-hACE2 transgenic mice and barrier dysfunction in human endothelial cells," *Am J Physiol Lung Cell Mol Physiol.* 2021, 321, 2: L477-L484. doi: <https://doi.org/10.1152/ajplung.00223.2021>
17. Sano H et al., "A case of persistent, confluent maculopapular erythema following a COVID-19 mRNA vaccination is possibly associated with the intralesional spike protein expressed by vascular endothelial cells and eccrine glands in the deep dermis," *J. Dermatol.* 2023, 50: 1208-1212. doi: <https://doi.org/10.1111/1346-8138.16816>
18. Santonja C et al., "COVID-19 chilblain-like lesion: immunohistochemical demonstration of SARS-CoV-2 spike protein in blood vessel endothelium and sweat gland epithelium in a polymerase chain reaction-negative patient," *Br J Dermatol.* 2020, 183, 4: 778-780. doi: <https://doi.org/10.1111/bjd.19338>
19. Scheim DE et al., "Sialylated Glycan Bindings from SARS-CoV-2 Spike Protein to Blood and Endothelial Cells Govern the Severe Morbidities of COVID-19," *Int. J. Mol. Sci.* 2023, 24, 23: 17039. doi: <https://doi.org/10.3390/ijms242317039>

20. Sirsendu J et al., "Cell-Free Hemoglobin Does Not Attenuate the Effects of SARS-CoV-2 Spike Protein S1 Subunit in Pulmonary Endothelial Cells," *Int. J. Mol. Sci.*, 2021, 22, 16: 9041. doi: <https://doi.org/10.3390/ijms22169041>
21. Stern B et al., "SARS-CoV-2 spike protein induces endothelial dysfunction in 3D engineered vascular networks," *J. Biomed. Mater. Res. A*. 2023, 112, 4: 524-533. doi: <https://doi.org/10.1002/jbm.a.37543>
22. Villacampa A et al., "SARS-CoV-2 S protein activates NLRP3 inflammasome and deregulates coagulation factors in endothelial and immune cells," *Cell Commun. Signal*. 2024, 22, 38. doi: <https://doi.org/10.1186/s12964-023-01397-6>
23. Wu ML et al., "Mast cell activation triggered by SARS-CoV-2 causes inflammation in brain microvascular endothelial cells and microglia," *Front. Cell. Infect. Microbiol*. 2024, 14. doi: <https://doi.org/10.3389/fcimb.2024.1358873>
24. Youn JY et al., "Therapeutic application of estrogen for COVID-19: Attenuation of SARS-CoV-2 spike protein and IL-6 stimulated, ACE2-dependent NOX2 activation, ROS production and MCP-1 upregulation in endothelial cells," *Redox Biol*. 2021, 46: 102099. doi: <https://doi.org/10.1016/j.redox.2021.102099>
25. Zekri-Nechar K et al., "Spike Protein Subunits of SARS-CoV-2 Alter Mitochondrial Metabolism in Human Pulmonary Microvascular Endothelial Cells: Involvement of Factor Xa," *Dis. Markers* 2022, 1118195. doi: <https://doi.org/10.1155/2022/1118195>

M. Gastrointestinal

1. Forsyth CB et al., "The SARS-CoV-2 S1 spike protein promotes MAPK and NF- κ B activation in human lung cells and inflammatory cytokine production in human lung and intestinal epithelial cells," *Microorganisms* 2022, 10, 10: 1996. doi: <https://doi.org/10.3390/microorganisms10101996>
2. Li Z et al., "SARS-CoV-2 pathogenesis in the gastrointestinal tract mediated by Spike-induced intestinal inflammation," *Precis. Clin. Med*. 2024, 7, 1: pbad034. doi: <https://doi.org/10.1093/pcmedi/pbad034>
3. Luo Y et al., "SARS-Cov-2 spike induces intestinal barrier dysfunction through the interaction between CEACAM5 and Galectin-9," *Front. Immunol*. 2024, 15. doi: <https://doi.org/10.3389/fimmu.2024.1303356>
4. Nascimento RR et al., "SARS-CoV-2 Spike protein triggers gut impairment since mucosal barrier to innermost layers: From basic science to clinical relevance," *Mucosal Immunol*. 2024, 17, 4: 565-583. doi: <https://doi.org/10.1016/j.mucimm.2024.03.00>
5. Yilmaz A et al., "Differential proinflammatory responses of colon epithelial cells to SARS-CoV-2 spike protein and *Pseudomonas aeruginosa* lipopolysaccharide," *Turk J Biochem*. 2024. doi: <https://doi.org/10.1515/tjb-2024-0144>
6. Yonker LM et al., "Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier," *J Clin Invest*. 2021, 131, 14: e149633. doi: <https://doi.org/10.1172/JCI149633>

7. Zeng FM et al., "SARS-CoV-2 spike spurs intestinal inflammation via VEGF production in enterocytes," *EMBO Mol Med*. 2022, 14: e14844. doi: <https://doi.org/10.15252/emmm.202114844>
8. Zollner A et al., "Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases," *Gastroenterology* 2022, 163, 2: 495-506.e8. doi: <https://doi.org/10.1053/j.gastro.2022.04.037>

N. Immune dysfunction

1. Baldari CT et al., "Emerging Roles of SARS-CoV-2 Spike-ACE2 in Immune Evasion and Pathogenesis," *Trends Immunol*. 2023, 44, 6. doi: <https://doi.org/10.1016/j.it.2023.04.001>
2. Bocquet-Garcon A, "Impact of the SARS-CoV-2 Spike Protein on the Innate Immune System: A Review," *Cureus* 2024, 16, 3: e57008. doi: [10.7759/cureus.57008](https://doi.org/10.7759/cureus.57008)
3. Delgado JF et al., "SARS-CoV-2 spike protein vaccine-induced immune imprinting reduces nucleocapsid protein antibody response in SARS-CoV-2 infection," *J. Immunol. Res*. 2022: 8287087. doi: <https://doi.org/10.1155/2022/8287087>
4. Freitas RS et al., "SARS-CoV-2 Spike antagonizes innate antiviral immunity by targeting interferon regulatory factor 3," *Front Cell Infect Microbiol*. 2021, 11: 789462. doi: <https://doi.org/10.3389/fcimb.2021.789462>
5. Irrgang P et al., "Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination," *Sci. Immunol*. 2022, 8, 79. doi: [10.1126/sciimmunol.ade2798](https://doi.org/10.1126/sciimmunol.ade2798)
6. Kim MJ et al., "The SARS-CoV-2 spike protein induces lung cancer migration and invasion in a TLR2-dependent manner," *Cancer Commun (London)*, 2023, 44, 2: 273–277. doi: <https://doi.org/10.1002/cac2.12485>
7. Onnis A et al., "SARS-CoV-2 Spike protein suppresses CTL-mediated killing by inhibiting immune synapse assembly," *J Exp Med* 2023, 220, 2: e20220906. doi: <https://doi.org/10.1084/jem.20220906>

O. Macrophages, monocytes, neutrophils

1. Ahn WM et al., "SARS-CoV-2 Spike Protein Stimulates Macropinocytosis in Murine and Human Macrophages via PKC-NADPH Oxidase Signaling," *Antioxidants* 2024, 13, 2: 175. doi: <https://doi.org/10.3390/antiox13020175>
2. Ait-Belkacem I et al., "SARS-CoV-2 spike protein induces a differential monocyte activation that may contribute to age bias in COVID-19 severity," *Sci. Rep*. 2022, 12: 20824. doi: <https://doi.org/10.1038/s41598-022-25259-2>
3. Barhoumi T et al., "SARS-CoV-2 coronavirus Spike protein-induced apoptosis, inflammatory, and oxidative stress responses in THP-1-like-macrophages: potential role of angiotensin-converting enzyme inhibitor (perindopril)," *Front. Immunol*. 2021, 12: 728896. doi: <https://doi.org/10.3389/fimmu.2021.728896>
4. Bortolotti D et al., "SARS-CoV-2 Spike 1 Protein Controls Natural Killer Cell Activation via the HLA-E/NG2A Pathway," *Cells* 2020, 9, 9: 1975. doi: <https://doi.org/10.3390/cells9091975>

5. Cao X et al., "Spike protein of SARS-CoV-2 activates macrophages and contributes to induction of acute lung inflammation in male mice," *FASEB J.* 2021, 35, e21801. doi: <https://doi.org/10.1096/fj.202002742RR>
6. Chiok K et al., "Proinflammatory Responses in SARS-CoV-2 and Soluble Spike Glycoprotein S1 Subunit Activated Human Macrophages," *Viruses* 2023, 15, 3: 754. doi: <https://doi.org/10.3390/v15030754>
7. Cory TJ et al., "Metformin Suppresses Monocyte Immunometabolic Activation by SARS-CoV-2 Spike Protein Subunit 1," *Front. Immunol.* 2021, 12 (Sec. Cytokines and Soluble Mediators in Immunity): 733921. doi: <https://doi.org/10.3389/fimmu.2021.733921>
8. Del Re A et al., "Ultramicronized Palmitoylethanolamide Inhibits NLRP3 Inflammasome Expression and Pro-Inflammatory Response Activated by SARS-CoV-2 Spike Protein in Cultured Murine Alveolar Macrophages," *Metabolites* 2021, 11, 9: 592. doi: <https://doi.org/10.3390/metabo11090592>
9. Duarte C, "Age-dependent effects of the recombinant spike protein/SARS-CoV-2 on the M-CSF- and IL-34-differentiated macrophages in vitro," *Biochem. Biophys. Res. Commun.* 2021, 546: 97–102. doi: <https://doi.org/10.1016/j.bbrc.2021.01.104>
10. Karwaciak I et al., "Nucleocapsid and Spike Proteins of the Coronavirus Sars-Cov-2 Induce Il6 in Monocytes and Macrophages—Potential Implications for Cytokine Storm Syndrome," *Vaccines* 2021, 9, 1, 54: 1–10. doi: <https://doi.org/10.3390/vaccines9010054>
11. Li T et al., "Platelets Mediate Inflammatory Monocyte Activation by SARS-CoV-2 Spike Protein," *J. Clin. Invest.* 2022, 132, 4: e150101. doi: [10.1172/JCI150101](https://doi.org/10.1172/JCI150101)
12. Loh JT et al., "Dok3 restrains neutrophil production of calprotectin during TLR4 sensing of SARS-CoV-2 spike protein," *Front. Immunol.* 2022, 13 (Sec. Molecular Innate Immunity). doi: <https://doi.org/10.3389/fimmu.2022.996637>
13. Marrone L et al., "Tirofiban prevents the effects of SARS-CoV-2 spike protein on macrophage activation and endothelial cell death," *Heliyon*, 2024, 10, 15: e35341. doi: [10.1016/j.heliyon.2024.e35341](https://doi.org/10.1016/j.heliyon.2024.e35341)
14. Miller GM et al., "SARS-CoV-2 and SARS-CoV-2 Spike protein S1 subunit Trigger Proinflammatory Response in Macrophages in the Absence of Productive Infection," *J. Immunol.* 2023, 210 (1_Supplement): 71.30. doi: <https://doi.org/10.4049/jimmunol.210.Supp.71.30>
15. Onnis A et al., "SARS-CoV-2 Spike protein suppresses CTL-mediated killing by inhibiting immune synapse assembly," *J Exp Med* 2023, 220, 2: e20220906. doi: <https://doi.org/10.1084/jem.20220906>
16. Palestra F et al. "SARS-CoV-2 Spike Protein Activates Human Lung Macrophages," *Int. J. Mol. Sci.* 2023, 24, 3: 3036. doi: <https://doi.org/10.3390/ijms24033036>
17. Park C et al., "Murine alveolar Macrophages Rapidly Accumulate intranasally Administered SARS-CoV-2 Spike Protein leading to neutrophil Recruitment and Damage," *Elife* 2024, 12, RP86764. doi: <https://doi.org/10.7554/eLife.86764.3>
18. Park YJ et al., "D-dimer and CoV-2 spike-immune complexes contribute to the production of PGE2 and proinflammatory cytokines in monocytes," *PLoS Pathog.* 2022, 18, 4: e1010468. doi: <https://doi.org/10.1371/journal.ppat.1010468>

19. Park YJ et al., "Pyrogenic and inflammatory mediators are produced by polarized M1 and M2 macrophages activated with D-dimer and SARS-CoV-2 spike immune complexes," *Cytokine* 2024, 173: 156447. doi: <https://doi.org/10.1016/j.cyto.2023.156447>
20. Patterson BK et al., "Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection," *Front. Immunol.* 12 (Sec. Viral Immunology). doi: <https://doi.org/10.3389/fimmu.2021.746021>
21. Pence B, "Recombinant SARS-CoV-2 Spike Protein Mediates Glycolytic and Inflammatory Activation in Human Monocytes," *Innov Aging* 2020, 4, sp. 1: 955. doi: <https://doi.org/10.1093/geroni/igaa057.3493>
22. Satta S et al., "An engineered nano-liposome-human ACE2 decoy neutralizes SARS-CoV-2 Spike protein-induced inflammation in both murine and human macrophages," *Theranostics* 2022, 12, 6: 2639–2657. doi: [10.7150/thno.66831](https://doi.org/10.7150/thno.66831)
23. Schroeder JT and AP Bieneman, "The S1 Subunit of the SARS-CoV-2 Spike protein activates human monocytes to produce cytokines linked to COVID-19: relevance to galectin-3," *Front Immunol.* 2022, 13: 831763. doi: <https://doi.org/10.3389/fimmu.2022.831763>
24. Shirato K and Takako Kizaki, "SARS-CoV-2 Spike Protein S1 Subunit Induces Pro-inflammatory Responses via Toll-Like Receptor 4 Signaling in Murine and Human Macrophages," *Heliyon* 2021, 7, 2: e06187, doi: <https://doi.org/10.1016/j.heliyon.2021.e06187>
25. Theobald SJ et al., "Long-lived macrophage reprogramming drives spike protein-mediated inflammasome activation in COVID-19," *EMBO Mol. Med.* 2021, 13:e14150. doi: <https://doi.org/10.15252/emmm.202114150>
26. Vettori M et al., "Effects of Different Types of Recombinant SARS-CoV-2 Spike Protein on Circulating Monocytes' Structure," *Int. J. Mol. Sci.* 2023, 24, 11, 9373. doi: <https://doi.org/10.3390/ijms24119373>
27. Youn YJ et al., "Nucleocapsid and spike proteins of SARS-CoV-2 drive neutrophil extracellular trap formation," *Immune Netw.* 2021, 21, 2: e16. doi: <https://doi.org/10.4110/in.2021.21.e16>
28. Zaki H and S Khan, "SARS-CoV-2 spike protein induces inflammatory molecules through TLR2 in macrophages and monocytes," *J. Immunol.* 2021, 206 (1_supplement): 62.07. doi: <https://doi.org/10.4049/jimmunol.206.Supp.62.07>

P. MAPK/NF-KB

1. Arjsri P et al., "Hesperetin from root extract of *Clerodendrum petasites* S. Moore inhibits SARS-CoV-2 spike protein S1 subunit-induced Nlrp3 inflammasome in A549 lung cells via modulation of the Akt/Mapk/Ap-1 pathway," *Int. J. Mol. Sci.* 2022, 23, 18: 10346. doi: <https://doi.org/10.3390/ijms231810346>
2. Bhattacharyya S and JK Tobacman, "SARS-CoV-2 spike protein-ACE2 interaction increases carbohydrate sulfotransferases and reduces N-acetylgalactosamine-4-sulfatase by p38 MAPK," *Signal Transduct Target Ther* 2024, 9, 39. doi: <https://doi.org/10.1038/s41392-024-01741-3>

3. Forsyth CB *et al.*, "The SARS-CoV-2 S1 spike protein promotes MAPK and NF- κ B activation in human lung cells and inflammatory cytokine production in human lung and intestinal epithelial cells," *Microorganisms* 2022, 10, 10: 1996. doi: <https://doi.org/10.3390/microorganisms10101996>
4. Johnson EL *et al.*, "The S1 spike protein of SARS-CoV-2 upregulates the ERK/MAPK signaling pathway in DC-SIGN-expressing THP-1 cells," *Cell Stress Chaperones* 2024, 29, 2: 227-234. doi: <https://doi.org/10.1016/j.cstres.2024.03.002>
5. Khan S *et al.*, "SARS-CoV-2 Spike Protein Induces Inflammation via TLR2-Dependent Activation of the NF- κ B Pathway," *eLife* 2021, 10: e68563, doi: <https://doi.org/10.7554/elife.68563>
6. Kircheis R and O Planz, "Could a Lower Toll-like Receptor (TLR) and NF- κ B Activation Due to a Changed Charge Distribution in the Spike Protein Be the Reason for the Lower Pathogenicity of Omicron?" *Int. J. Mol. Sci.* 2022, 23, 11: 5966. doi: <https://doi.org/10.3390/ijms23115966>
7. Kyriakopoulos AM *et al.*, "Mitogen Activated Protein Kinase (MAPK) Activation, p53, and Autophagy Inhibition Characterize the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein Induced Neurotoxicity," *Cureus* 2022, 14, 12: e32361. doi: [10.7759/cureus.32361](https://doi.org/10.7759/cureus.32361)
8. Robles JP *et al.*, "The Spike Protein of SARS-CoV-2 Induces Endothelial Inflammation through Integrin α 5 β 1 and NF- κ B Signaling," *J. Biol. Chem.* 2022, 298, 3: 101695. doi: <https://doi.org/10.1016/j.jbc.2022.101695>
9. Sharma VK *et al.*, "Nanocurcumin Potently Inhibits SARS-CoV-2 Spike Protein-Induced Cytokine Storm by Deactivation of MAPK/NF- κ B Signaling in Epithelial Cells," *ACS Appl. Bio Mater.* 2022, 5, 2: 483–491. doi: <https://doi.org/10.1021/acsbam.1c00874>
10. Bhattacharyya S and JK Tobacman, "SARS-CoV-2 spike protein-ACE2 interaction increases carbohydrate sulfotransferases and reduces N-acetylgalactosamine-4-sulfatase by p38 MAPK," *Signal Transduct Target Ther* 2024, 9, 39. doi: <https://doi.org/10.1038/s41392-024-01741-3>

Q. Mast cells

1. Cao JB *et al.*, "Mast cell degranulation-triggered by SARS-CoV-2 induces tracheal-bronchial epithelial inflammation and injury," *Virol. Sin.* 2024, 39, 2: 309-318. doi: <https://doi.org/10.1016/j.virs.2024.03.001>
2. Fajloun Z *et al.*, "SARS-CoV-2 or Vaccinal Spike Protein can Induce Mast Cell Activation Syndrome (MCAS)," *Infect Disord Drug Targets*, 2025, 25, 1: e300424229561. doi: [10.2174/0118715265319896240427045026](https://doi.org/10.2174/0118715265319896240427045026)
3. Wu ML *et al.*, "Mast cell activation triggered by SARS-CoV-2 causes inflammation in brain microvascular endothelial cells and microglia," *Front. Cell. Infect. Microbiol.*, 2024, 14. doi: <https://doi.org/10.3389/fcimb.2024.1358873>

R. Microglia

1. Chang MH *et al.*, "SARS-CoV-2 Spike Protein 1 Causes Aggregation of α -Synuclein via Microglia-Induced Inflammation and Production of Mitochondrial ROS: Potential Therapeutic Applications of Metformin," *Biomedicines* 2024, 12, 6: 1223. doi: <https://doi.org/10.3390/biomedicines12061223>

2. Clough E et al., "Mitochondrial Dynamics in SARS-CoV2 Spike Protein Treated Human Microglia: Implications for Neuro-COVID," *J. Neuroimmune Pharmacol.* 2021, 16, 4: 770–784. doi: <https://doi.org/10.1007/s11481-021-10015-6>
3. Frank MG et al., "SARS-CoV-2 Spike S1 Subunit Induces Neuroinflammatory, Microglial and Behavioral Sickness Responses: Evidence of PAMP-Like Properties," *Brain Behav. Immun.* 2022, 100: 267277. doi: <https://doi.org/10.1016/j.bbi.2021.12.007>
4. Mishra R and AC Banerjee, "SARS-CoV-2 Spike targets USP33-IRF9 axis via exosomal miR-148a to activate human microglia," *Front. Immunol.* 2021, 12: 656700. doi: <https://doi.org/10.3389/fimmu.2021.656700>
5. Olajide OA et al., "SARS-CoV-2 spike glycoprotein S1 induces neuroinflammation in BV-2 microglia," *Mol. Neurobiol.* 2022, 59: 445-458. doi: <https://doi.org/10.1007/s12035-021-02593-6>
6. Wu ML et al., "Mast cell activation triggered by SARS-CoV-2 causes inflammation in brain microvascular endothelial cells and microglia," *Front. Cell. Infect. Microbiol.* 2024, 14. doi: <https://doi.org/10.3389/fcimb.2024.1358873>

S. Microvascular

1. Avolio E et al., "The SARS-CoV-2 Spike Protein Disrupts Human Cardiac Pericytes Function through CD147 Receptor-Mediated Signalling: A Potential Non-infective Mechanism of COVID-19 Microvascular Disease," *Clin. Sci.* 2021, 135, 24: 2667–2689. doi: <https://doi.org/10.1042/CS20210735>
2. Bhargavan B and GD Kanmogne, "SARS-CoV-2 spike proteins and cell–cell communication inhibits TFPI and induces thrombogenic factors in human lung microvascular endothelial cells and neutrophils: implications for COVID-19 coagulopathy pathogenesis," *Int. J. Mol. Sci.* 2022, 23, 18: 10436. doi: <https://doi.org/10.3390/ijms231810436>
3. Kulkoviene G et al., "Differential Mitochondrial, Oxidative Stress and Inflammatory Responses to SARS-CoV-2 Spike Protein Receptor Binding Domain in Human Lung Microvascular, Coronary Artery Endothelial and Bronchial Epithelial Cells," *Int. J. Mol. Sci.* 2024, 25, 6: 3188. doi: <https://doi.org/10.3390/ijms25063188>
4. Magro N et al., "Disruption of the blood-brain barrier is correlated with spike endocytosis by ACE2 + endothelia in the CNS microvasculature in fatal COVID-19. Scientific commentary on 'Detection of blood-brain barrier disruption in brains of patients with COVID-19, but no evidence of brain penetration by SARS-CoV-2'," *Acta Neuropathol.* 2024, 147, 1: 47. doi: <https://doi.org/10.1007/s00401-023-02681-y>
5. Panigrahi S et al., "SARS-CoV-2 Spike Protein Destabilizes Microvascular Homeostasis," *Microbiol Spectr.* 2021, 9, 3: e0073521. doi: <https://doi.org/10.1128/Spectrum.00735-21>
6. Perico L et al., "SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation," *Front. Immunol.* 2022, 13, 827146. doi: <https://doi.org/10.3389/fimmu.2022.827146>

7. Wu ML et al., "Mast cell activation triggered by SARS-CoV-2 causes inflammation in brain microvascular endothelial cells and microglia," *Front. Cell. Infect. Microbiol.* 2024, 14. doi: <https://doi.org/10.3389/fcimb.2024.1358873>
8. Zekri-Nechar K et al., "Spike Protein Subunits of SARS-CoV-2 Alter Mitochondrial Metabolism in Human Pulmonary Microvascular Endothelial Cells: Involvement of Factor Xa," *Dis. Markers* 2022; 1118195. doi: <https://doi.org/10.1155/2022/1118195>

T. MIS-C, pediatric

1. Colmenero I et al., "SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases," *Br J Dermatol.* 2020, 183: 729-737. doi: <https://doi.org/10.1111/bjd.19327/>
2. De Sousa PMB et al., "Fatal Myocarditis following COVID-19 mRNA Immunization: A Case Report and Differential Diagnosis Review," *Vaccines* 2024, 12, 2: 194. doi: <https://doi.org/10.3390/vaccines12020194>
3. Mayordomo-Colunga J et al., "SARS-CoV-2 spike protein in intestinal cells of a patient with coronavirus disease 2019 multisystem inflammatory syndrome," *J Pediatr.* 2022, 243: 214-18e215. doi: <https://doi.org/10.1016/j.jpeds.2021.11.058>
4. Rivas MN et al., "COVID-19-associated multisystem inflammatory syndrome in children (MIS-C): A novel disease that mimics toxic shock syndrome—the superantigen hypothesis," *J Allergy Clin Immunol* 2021, 147, 1: 57-59. doi: [10.1016/j.jaci.2020.10.008](https://doi.org/10.1016/j.jaci.2020.10.008)
5. Rivas MN et al., "Multisystem Inflammatory Syndrome in Children and Long COVID: The SARS-CoV-2 Viral Superantigen Hypothesis," *Front Immunol.* 2022, 13 (Sec. Molecular Innate Immunity) doi: <https://doi.org/10.3389/fimmu.2022.941009>
6. Sacco K et al., "Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19," *Nat. Med.* 2022, 28: 1050-1062. doi: <https://doi.org/10.1038/s41591-022-01724-3>
7. Yonker LM et al., "Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier," *J Clin Invest.* 2021, 131, 14: e149633. doi: <https://doi.org/10.1172/JCI149633>

U. Mitochondria/metabolism

1. Cao X et al., "The SARS-CoV-2 spike protein induces long-term transcriptional perturbations of mitochondrial metabolic genes, causes cardiac fibrosis, and reduces myocardial contractile in obese mice," *Mol. Metab.* 2023, 74, 101756. doi: <https://doi.org/10.1016/j.molmet.2023.101756>
2. Chang MH et al., "SARS-CoV-2 Spike Protein 1 Causes Aggregation of α -Synuclein via Microglia-Induced Inflammation and Production of Mitochondrial ROS: Potential Therapeutic Applications of Metformin," *Biomedicines* 2024, 12, 6: 1223. doi: <https://doi.org/10.3390/biomedicines12061223>

3. Clough E et al., "Mitochondrial Dynamics in SARS-COV2 Spike Protein Treated Human Microglia: Implications for Neuro-COVID," *Journal of Neuroimmune Pharmacology* 2021, 16, 4: 770–784. doi: <https://doi.org/10.1007/s11481-021-10015-6>
4. Huynh TV et al., "Spike Protein Impairs Mitochondrial Function in Human Cardiomyocytes: Mechanisms Underlying Cardiac Injury in COVID-19," *Cells* 2023, 12, 877. doi: <https://doi.org/10.3390/cells12060877>
5. Kulkoviene G et al., "Differential Mitochondrial, Oxidative Stress and Inflammatory Responses to SARS-CoV-2 Spike Protein Receptor Binding Domain in Human Lung Microvascular, Coronary Artery Endothelial and Bronchial Epithelial Cells," *Int. J. Mol. Sci.* 2024, 25, 6: 3188. doi: <https://doi.org/10.3390/ijms25063188>
6. Mercado-Gómez M et al., "The spike of SARS-CoV-2 promotes metabolic rewiring in hepatocytes," *Commun. Biol.* 2022, 5, 827. doi: <https://doi.org/10.1038/s42003-022-03789-9>
7. Nguyen V, "The Spike Protein of SARS-CoV-2 Impairs Lipid Metabolism and Increases Susceptibility to Lipotoxicity: Implication for a Role of Nrf2," *Cells* 2022, 11, 12: 1916. doi: <https://doi.org/10.3390/cells11121916>
8. Yeung-Luk BH et al., "SARS-CoV-2 infection alters mitochondrial and cytoskeletal function in human respiratory epithelial cells mediated by expression of spike protein," *mBio* 2023, 14, 4: e00820-23. doi: <https://doi.org/10.1128/mbio.00820-23>
9. Zekri-Nechar K et al., "Spike Protein Subunits of SARS-CoV-2 Alter Mitochondrial Metabolism in Human Pulmonary Microvascular Endothelial Cells: Involvement of Factor Xa," *Dis. Markers* 2022, 1118195. doi: <https://doi.org/10.1155/2022/1118195>

V. Myocarditis/cardiac/cardiomyopathy

1. Abdi A et al., "Biomed Interaction of SARS-CoV-2 with cardiomyocytes: Insight into the underlying molecular mechanisms of cardiac injury and pharmacotherapy," *Pharmacother.* 2022, 146: 112518. doi: [10.1016/j.biopha.2021.112518](https://doi.org/10.1016/j.biopha.2021.112518)
2. Avolio E et al., "The SARS-CoV-2 Spike Protein Disrupts Human Cardiac Pericytes Function through CD147 Receptor-Mediated Signalling: A Potential Non-infective Mechanism of COVID-19 Microvascular Disease," *Clin. Sci.* 2021, 135, 24: 2667–2689. doi: <https://doi.org/10.1042/CS20210735>
3. Baumeier C et al., "Intramyocardial Inflammation after COVID-19 Vaccination: An Endomyocardial Biopsy-Proven Case Series," *Int. J. Mol. Sci.* 2022, 23: 6940. doi: <https://doi.org/10.3390/ijms23136940>
4. Bellavite P et al., "Immune response and molecular mechanisms of cardiovascular adverse effects of spike proteins from SARS-coV-2 and mRNA vaccines," *Biomedicines* 2023, 11, 2: 451. doi: <https://doi.org/10.3390/biomedicines11020451>
5. Boretti A. "PQQ Supplementation and SARS-CoV-2 Spike Protein-Induced Heart Inflammation," *Nat. Prod. Commun.* 2022, 17, 1934578x221080929. doi: <https://doi.org/10.1177/1934578X221080929>

6. Buoninfante A et al., "Myocarditis associated with COVID-19 vaccination," *npj Vaccines* 2024, 122. doi: <https://doi.org/10.1038/s41541-024-00893-1>
7. Cao X et al., "The SARS-CoV-2 spike protein induces long-term transcriptional perturbations of mitochondrial metabolic genes, causes cardiac fibrosis, and reduces myocardial contractile in obese mice," *Mol. Metab.* 2023, 74, 101756. doi: <https://doi.org/10.1016/j.molmet.2023.101756>
8. Clemens DJ et al., "SARS-CoV-2 spike protein-mediated cardiomyocyte fusion may contribute to increased arrhythmic risk in COVID-19," *PLoS One* 2023, 18, 3: e0282151. doi: <https://doi.org/10.1371/journal.pone.0282151>
9. De Sousa PMB et al., "Fatal Myocarditis following COVID-19 mRNA Immunization: A Case Report and Differential Diagnosis Review," *Vaccines* 2024, 12, 2: 194. doi: <https://doi.org/10.3390/vaccines12020194>
10. Forte E, "Circulating spike protein may contribute to myocarditis after COVID-19 vaccination," *Nat. Cardiovasc. Res.* 2023, 2: 100. doi: <https://doi.org/10.1038/s44161-023-00222-0>
11. Huang X et al., "Sars-Cov-2 Spike Protein-Induced Damage of hiPSC-Derived Cardiomyocytes," *Adv. Biol.* 2022, 6, 7: e2101327. doi: <https://doi.org/10.1002/adbi.202101327>
12. Hulscher N et al., "Autopsy findings in cases of fatal COVID-19 vaccine-induced myocarditis," *ESC Heart Failure* 2024. doi: <https://doi.org/10.1002/ehf2.14680>
13. Huynh TV et al., "Spike Protein Impairs Mitochondrial Function in Human Cardiomyocytes: Mechanisms Underlying Cardiac Injury in COVID-19," *Cells* 2023, 12, 877. doi: <https://doi.org/10.3390/cells12060877>
14. Huynh TV et al., "Spike Protein of SARS-CoV-2 Activates Cardiac Fibrogenesis through NLRP3 Inflammasomes and NF-κB Signaling," *Cells* 2024, 13, 16: 1331. doi: <https://doi.org/10.3390/cells13161331>
15. Imig JD, "SARS-CoV-2 spike protein causes cardiovascular disease independent of viral infection," *Clin Sci (Lond)* 2022, 136, 6: 431–434. doi: <https://doi.org/10.1042/CS20220028>
16. Kato Y et al., "TRPC3-Nox2 Protein Complex Formation Increases the Risk of SARS-CoV-2 Spike Protein-Induced Cardiomyocyte Dysfunction through ACE2 Upregulation," *Int. J. Mol. Sci.* 2023, 24, 1: 102. doi: <https://doi.org/10.3390/ijms24010102>
17. Kawano H et al., "Fulminant Myocarditis 24 Days after Coronavirus Disease Messenger Ribonucleic Acid Vaccination," *Intern. Med.* 2022, 61, 15: 2319-2325. doi: <https://doi.org/10.2169/internalmedicine.9800-22>
18. Li C. et al., "Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model," *Clin. Infect. Dis.* 2022, 74, 11: 1933-1950. doi: <https://doi.org/10.1093/cid/ciab707>
19. Lin Z, "More than a key—the pathological roles of SARS-CoV-2 spike protein in COVID-19 related cardiac injury," *Sports Med Health Sci* 2023, 6, 3: 209-220. doi: <https://doi.org/10.1016/j.smhs.2023.03.004>
20. Rzymiski P and Andrzej Fal, "To aspirate or not to aspirate? Considerations for the COVID-19 vaccines," *Pharmacol. Rep* 2022, 74: 1223–1227. doi: <https://doi.org/10.1007/s43440-022-00361-4>

21. Schreckenber R et al., “Cardiac side effects of RNA-based SARS-CoV-2 vaccines: Hidden cardiotoxic effects of mRNA-1273 and BNT162b2 on ventricular myocyte function and structure,” *Br. J. Pharmacol.* 2024, 181, 3: 345-361. doi: <https://doi.org/10.1111/bph.16262>
22. Yonker LM et al., “Circulating Spike Protein Detected in Post-COVID-19 mRNA Vaccine Myocarditis,” *Circulation* 2023, 147, 11. doi: <https://doi.org/10.1161/CIRCULATIONAHA.122.061025>

W. NLRP3

1. Albornoz EA et al., “SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein,” *Mol. Psychiatr.* 2023, 28: 2878–2893. doi: <https://doi.org/10.1038/s41380-022-01831-0>
2. Arjsri P et al., “Hesperetin from root extract of *Clerodendrum petasites* S. Moore inhibits SARS-CoV-2 spike protein S1 subunit-induced Nlrp3 inflammasome in A549 lung cells via modulation of the Akt/Mapk/Ap-1 pathway,” *Int. J. Mol. Sci.* 2022, 23, 18: 10346. doi: <https://doi.org/10.3390/ijms231810346>
3. Chittasupho C et al., “Inhibition of SARS-CoV-2-Induced NLRP3 Inflammasome-Mediated Lung Cell Inflammation by Triphala-Loaded Nanoparticle Targeting Spike Glycoprotein S1,” *Pharmaceutics* 2024, 16, 6: 751. <https://doi.org/10.3390/pharmaceutics16060751>
4. Chittasupho C et al., “Targeting spike glycoprotein S1 mediated by NLRP3 inflammasome machinery and the cytokine releases in A549 lung epithelial cells by nanocurcumin,” *Pharmaceutics* (Basel) 2023, 16, 6: 862. doi: <https://doi.org/10.3390/ph16060862>
7. Corpetti C et al., “Cannabidiol inhibits SARS-Cov-2 spike (S) protein-induced cytotoxicity and inflammation through a PPAR γ -dependent TLR4/NLRP3/Caspase-1 signaling suppression in Caco-2 cell line,” *Phytother. Res.* 2021, 35, 12: 6893–6903. doi: <https://doi.org/10.1002/ptr.7302>
8. Del Re A et al., “Ultramicrosized Palmitoylethanolamide Inhibits NLRP3 Inflammasome Expression and Pro-Inflammatory Response Activated by SARS-CoV-2 Spike Protein in Cultured Murine Alveolar Macrophages.” *Metabolites* 2021, 11, 9: 592. doi: <https://doi.org/10.3390/metabo11090592>
9. Dissook S et al., “Luteolin-rich fraction from *Perilla frutescens* seed meal inhibits spike glycoprotein S1 of SARS-CoV-2-induced NLRP3 inflammasome lung cell inflammation via regulation of JAK1/STAT3 pathway: A potential anti-inflammatory compound against inflammation-induced long-COVID,” *Front. Med.* 2023, 9: 1072056. doi: <https://doi.org/10.3389/fmed.2022.1072056>
10. Huynh TV et al., “Spike Protein of SARS-CoV-2 Activates Cardiac Fibrogenesis through NLRP3 Inflammasomes and NF- κ B Signaling,” *Cells* 2024, 13, 16: 1331. doi: <https://doi.org/10.3390/cells13161331>
11. Jiang Q et al., “SARS-CoV-2 spike S1 protein induces microglial NLRP3-dependent neuroinflammation and cognitive impairment in mice,” *Exp. Neurol.* 2025, 383: 115020. doi: <https://doi.org/10.1016/j.expneurol.2024.115020>
12. Kucia M et al. “An evidence that SARS-Cov-2/COVID-19 spike protein (SP) damages hematopoietic stem/progenitor cells in the mechanism of pyroptosis in Nlrp3 inflammasome-dependent manner,” *Leukemia* 2021, 35: 3026-3029. doi: <https://doi.org/10.1038/s41375-021-01332-z>

13. Ratajczak MZ et al., "SARS-CoV-2 Entry Receptor ACE2 Is Expressed on Very Small CD45⁺ Precursors of Hematopoietic and Endothelial Cells and in Response to Virus Spike Protein Activates the Nlrp3 Inflammasome," *Stem Cell Rev Rep*. 2021, 17, 1: 266-277. doi: <https://doi.org/10.1007/s12015-020-10010-z>
14. Semmarath W et al., "Cyanidin-3-O-glucoside and Peonidin-3-O-glucoside-Rich Fraction of Black Rice Germ and Bran Suppresses Inflammatory Responses from SARS-CoV-2 Spike Glycoprotein S1-Induction In Vitro in A549 Lung Cells and THP-1 Macrophages via Inhibition of the NLRP3 Inflammasome Pathway," *Nutrients* 2022, 14, 13: 2738. doi: <https://doi.org/10.3390/nu14132738>
15. Villacampa A et al., "SARS-CoV-2 S protein activates NLRP3 inflammasome and deregulates coagulation factors in endothelial and immune cells," *Cell Commun. Signal*. 2024, 22, 38. doi: <https://doi.org/10.1186/s12964-023-01397-6>

X. Ocular, ophthalmic, conjunctival

1. Golob-Schwarzl N et al., "SARS-CoV-2 spike protein functionally interacts with primary human conjunctival epithelial cells to induce a pro-inflammatory response," *Eye* 2022, 36: 2353–5. doi: <https://doi.org/10.1038/s41433-022-02066-7>
2. Grishma K and Das Sarma, "The Role of Coronavirus Spike Protein in Inducing Optic Neuritis in Mice: Parallels to the SARS-CoV-2 Virus," *J Neuroophthalmol* 2024, 44, 3: 319-329. doi: [10.1097/WNO.0000000000002234](https://doi.org/10.1097/WNO.0000000000002234)
3. Zhu G et al., "SARS-CoV-2 spike protein-induced host inflammatory response signature in human corneal epithelial cells," *Mol. Med. Rep*. 2021, 24: 584. doi: <https://doi.org/10.3892/mmr.2021.12223>

Y. Other cell signaling

1. Caohuy H et al., "Inflammation in the COVID-19 airway is due to inhibition of CFTR signaling by the SARS-CoV-2 spike protein," *Sci. Rep*. 2024, 14: 16895. doi: <https://doi.org/10.1038/s41598-024-66473-4>
2. Choi JY et al., "SARS-CoV-2 spike S1 subunit protein-mediated increase of beta-secretase 1 (BACE1) impairs human brain vessel cells," *Biochem. Biophys. Res. Commun*. 2022, 625, 20: 66-71. doi: <https://doi.org/10.1016/j.bbrc.2022.07.113>
3. Corpetti C et al., "Cannabidiol inhibits SARS-Cov-2 spike (S) protein-induced cytotoxicity and inflammation through a PPAR γ -dependent TLR4/NLRP3/Caspase-1 signaling suppression in Caco-2 cell line," *Phytother. Res*. 2021, 35, 12: 6893–6903. doi: <https://doi.org/10.1002/ptr.7302>
4. Gracie NP et al., "Cellular signalling by SARS-CoV-2 spike protein," *Microbiology Australia* 2024, 45, 1: 13-17. doi: <https://doi.org/10.1071/MA24005>
5. Li F et al., "SARS-CoV-2 Spike Promotes Inflammation and Apoptosis Through Autophagy by ROS-Suppressed PI3K/AKT/mTOR Signaling," *Biochim Biophys Acta BBA - Mol Basis Dis* 2021, 1867: 166260. doi: <https://doi.org/10.1016/j.bbadis.2021.166260>

6. Li K et al., "SARS-CoV-2 Spike protein promotes vWF secretion and thrombosis via endothelial cytoskeleton-associated protein 4 (CKAP4)," *Signal Transduct Targ Ther* 2022, 7, 332. doi: <https://doi.org/10.1038/s41392-022-01183-9>
7. Moutal A et al., "SARS-CoV-2 Spike protein co-opts VEGF-A/Neuropilin-1 receptor signaling to induce analgesia," *Pain* 2020, 162, 1: 243–252. doi: [10.1097/j.pain.0000000000002097](https://doi.org/10.1097/j.pain.0000000000002097)
8. Munavilli GG et al., "COVID-19/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to hyaluronic acid dermal fillers: a challenging clinical conundrum in diagnosis and treatment," *Arch. Dermatol. Res.* 2022, 314: 1-15. doi: <https://doi.org/10.1007/s00403-021-02190-6>
9. Prieto-Villalobos J et al., "SARS-CoV-2 spike protein S1 activates Cx43 hemichannels and disturbs intracellular Ca²⁺ dynamics," *Biol Res.* 2023, 56, 1: 56. doi: <https://doi.org/10.1186/s40659-023-00468-9>
10. Rotoli BM et al., "Endothelial cell activation by SARS-CoV-2 spike S1 protein: A crosstalk between endothelium and innate immune cells," *Biomedicines* 2021, 9, 9: 1220. doi: <https://doi.org/10.3390/biomedicines9091220>
11. Singh N and Anuradha Bharara Singh, "S2 Subunit of SARS-nCoV-2 Interacts with Tumor Suppressor Protein p53 and BRCA: An in Silico Study," *Translational Oncology* 2020, 13, 10: 100814. doi: <https://doi.org/10.1016/j.tranon.2020.100814>
12. Singh RD, "The spike protein of sars-cov-2 induces heme oxygenase-1: pathophysiologic implications," *Biochim Biophys Acta, Mol Basis Dis* 2022, 1868, 3: 166322. doi: <https://doi.org/10.1016/j.bbadis.2021.166322>
13. Solis O et al., "The SARS-CoV-2 spike protein binds and modulates estrogen receptors," *Sci. Adv.* 2022, 8, 48: eadd4150. doi: [10.1126/sciadv.add4150](https://doi.org/10.1126/sciadv.add4150)
14. Suzuki YJ et al., "SARS-CoV-2 spike protein-mediated cell signaling in lung vascular cells," *Vascul. Pharmacol.* 2021, 137: 106823. doi: <https://doi.org/10.1016/j.vph.2020.106823>
15. Suzuki YJ and SG Gychka, "SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines," *Vaccines* 2021, 9, 1: 36. doi: <https://doi.org/10.3390/vaccines9010036>
16. Tillman TS et al., "SARS-CoV-2 Spike Protein Downregulates Cell Surface alpha7nAChR through a Helical Motif in the Spike Neck," *ACS Chem. Neurosci.* 2023, 14, 4: 689–698. doi: <https://doi.org/10.1021/acchemneuro.2c00610>

Z. PASC, post COVID, long COVID

1. Bellucci M et al., "Post-SARS-CoV-2 infection and post-vaccine-related neurological complications share clinical features and the same positivity to anti-ACE2 antibodies," *Front. Immunol.* 2024, 15 (Sec. Multiple Sclerosis and Neuroimmunology). doi: <https://doi.org/10.3389/fimmu.2024.1398028>
2. Craddock V et al., "Persistent circulation of soluble and extracellular vesicle-linked Spike protein in individuals with postacute sequelae of COVID-19," *J Med. Virol.* 2023, 95, 2: e28568. doi: <https://doi.org/10.1002/jmv.28568>

3. Dissook S et al., "Luteolin-rich fraction from *Perilla frutescens* seed meal inhibits spike glycoprotein S1 of SARS-CoV-2-induced NLRP3 inflammasome lung cell inflammation via regulation of JAK1/STAT3 pathway: A potential anti-inflammatory compound against inflammation-induced long-COVID," *Front. Med.* 2023, 9: 1072056. doi: <https://doi.org/10.3389/fmed.2022.1072056>
4. Frank MG et al., "Exploring the immunogenic properties of SARS-CoV-2 structural proteins: PAMP:TLR signaling in the mediation of the neuroinflammatory and neurologic sequelae of COVID-19," *Brain Behav Immun* 2023, 111. doi: <https://doi.org/10.1016/j.bbi.2023.04.009>
5. Frank MG et al., "SARS-CoV-2 S1 subunit produces a protracted priming of the neuroinflammatory, physiological, and behavioral responses to a remote immune challenge: A role for corticosteroids," *Brain Behav. Immun.* 2024, 121: 87-103. doi: <https://doi.org/10.1016/j.bbi.2024.07.034>
6. Fraser ME et al., "SARS-CoV-2 Spike Protein and Viral RNA Persist in the Lung of Patients With Post-COVID Lung Disease (abstract)," *Am J Respir Crit Care Med* 2024, 209: A4193. doi: https://doi.org/10.1164/ajrccm-conference.2024.209.1_MeetingAbstracts.A4193
7. Goh D et al., "Case report: Persistence of residual antigen and RNA of the SARS-CoV-2 virus in tissues of two patients with long COVID," *Front. Immunol.* 2022, 13 (Sec. Viral Immunology). doi: <https://doi.org/10.3389/fimmu.2022.939989>
8. Halma MTJ et al., "Exploring autophagy in treating SARS-CoV-2 spike protein-related pathology," *Endocrinol Metab (EnM)* 2024, 14: 100163. doi: <https://doi.org/10.1016/j.endmts.2024.100163>
9. Halma MTJ et al., "Strategies for the Management of Spike Protein-Related Pathology," *Microorganisms* 2023, 11, 5: 1308, doi: <https://doi.org/10.3390/microorganisms11051308>
10. Hano S et al., "A case of persistent, confluent maculopapular erythema following a COVID-19 mRNA vaccination is possibly associated with the intralesional spike protein expressed by vascular endothelial cells and eccrine glands in the deep dermis," *J Dermatol* 2023, 50, 9: 1208-1212. doi: <https://doi.org/10.1111/1346-8138.16816>
11. Patterson BK et al., "Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection," *Front. Immunol.* 12 (Sec. Viral Immunology). doi: <https://doi.org/10.3389/fimmu.2021.746021>
12. Peluso MJ et al., "Plasma-based antigen persistence in the post-acute phase of COVID-19," *Lancet* 2024, 24, 6: E345-E347. doi: [10.1016/S1473-3099\(24\)00211-1](https://doi.org/10.1016/S1473-3099(24)00211-1)
13. Rong Z et al., "Persistence of spike protein at the skull-meninges-brain axis may contribute to the neurological sequelae of COVID-19," *Cell Host Microbe* 2024, 26: S1931-3128(24)00438-4. doi: [10.1016/j.chom.2024.11.007](https://doi.org/10.1016/j.chom.2024.11.007)
14. Scholkmann F and CA May, "COVID-19, post-acute COVID-19 syndrome (PACS, 'long COVID') and post-COVID-19 vaccination syndrome (PCVS, 'post-COVIDvac-syndrome'): Similarities and differences," *Pathol Res Pract.* 2023, 246: 154497. doi: <https://doi.org/10.1016/j.prp.2023.154497>
15. Schultheiss C et al., "Liquid biomarkers of macrophage dysregulation and circulating spike protein illustrate the biological heterogeneity in patients with post-acute sequelae of COVID-19," *J Med Virol* 2023, 95, 1: e28364. doi: <https://doi.org/10.1002/jmv.28364>

16. Swank Z, et al. "Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae," *Clin. Infect. Dis.* 2023, 76, 3: e487–e490. doi: <https://doi.org/10.1093/cid/ciac722>
17. Theoharides TC, "Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome?" *Mol. Neurobiol.* 2022, 59, 3: 1850–1861. doi: <https://doi.org/10.1007/s12035-021-02696-0>
18. Visvabharathy L et al., "Case report: Treatment of long COVID with a SARS-CoV-2 antiviral and IL-6 blockade in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence," *Front. Med.* 2022, 9 (Sec. Infectious Diseases – Surveillance). doi: <https://doi.org/10.3389/fmed.2022.1003103>
19. Yamamoto M et al., "Persistent varicella zoster virus infection following mRNA COVID-19 vaccination was associated with the presence of encoded spike protein in the lesion," *J. Cutan Immunol. Allergy.* 2022:1–6. doi: <https://doi.org/10.1002/cia2.12278>
20. Zollner A et al., "Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases," *Gastroenterology* 2022, 163, 2: 495-506.e8. doi: <https://doi.org/10.1053/j.gastro.2022.04.037>

AA. Pregnancy

1. Erdogan MA, "Prenatal SARS-CoV-2 Spike Protein Exposure Induces Autism-Like Neurobehavioral Changes in Male Neonatal Rats," *J Neuroimmune Pharmacol.* 2023, 18, 4: 573-591. doi: [10.1007/s11481-023-10089-4](https://doi.org/10.1007/s11481-023-10089-4)
2. Guo X et al., "Regulation of proinflammatory molecules and tissue factor by SARS-CoV-2 spike protein in human placental cells: implications for SARS-CoV-2 pathogenesis in pregnant women," *Front. Immunol.* 2022, 13: 876555–876555. doi: <https://doi.org/10.3389/fimmu.2022.876555>
3. Kammala AK et al., "In vitro mRNA-S maternal vaccination induced altered immune regulation at the maternal-fetal interface," *Am. J. Reprod. Immunol.* 2024, 91, 5: e13861. doi: <https://doi.org/10.1111/aji.13861>
4. Karrow NA et al., "Maternal COVID-19 Vaccination and Its Potential Impact on Fetal and Neonatal Development," *Vaccines* 2021, 9: 1351. doi: <https://doi.org/10.3390/vaccines9111351>
5. Parcial ALN et al., "SARS-CoV-2 Is Persistent in Placenta and Causes Macroscopic, Histopathological, and Ultrastructural Changes," *Viruses* 2022, 14, 9: 1885. doi: <https://doi.org/10.3390/v14091885>
6. Wu H et al., "Molecular evidence suggesting the persistence of residual SARS-CoV-2 and immune responses in the placentas of pregnant patients recovered from COVID-19," *Cell Prolif.* 2021, 54, 9: e13091. doi: <https://doi.org/10.1111/cpr.13091>
7. Zurlow M et al., "The anti-SARS-CoV-2 BNT162b2 vaccine suppresses mithramycin-induced erythroid differentiation and expression of embryo-fetal globin genes in human erythroleukemia K562 cells." *Exp Cell Res* 2023, 433, 2: 113853. doi: <https://doi.org/10.1016/j.yexcr.2023.113853>

BB. Pulmonary, respiratory

1. Bhargavan B and GD Kanmogne, "SARS-CoV-2 spike proteins and cell-cell communication inhibits TFPI and induces thrombogenic factors in human lung microvascular endothelial cells and neutrophils: implications for COVID-19 coagulopathy pathogenesis," *Int. J. Mol. Sci.* 2022, 23, 18: 10436. doi: <https://doi.org/10.3390/ijms231810436>
2. Biancatelli RMLC et al., "The SARS-CoV-2 spike protein subunit S1 induces COVID-19-like acute lung injury in Kappa18-hACE2 transgenic mice and barrier dysfunction in human endothelial cells," *Am. J. Physiol. Lung Cell. Mol. Physiol.* 2021, 321: L477-L484. doi: <https://doi.org/10.1152/ajplung.00223.2021>
3. Cao JB et al., "Mast cell degranulation-triggered by SARS-CoV-2 induces tracheal-bronchial epithelial inflammation and injury," *Viol. Sin.* 2024, 39, 2: 309-318. doi: <https://doi.org/10.1016/j.virs.2024.03.001>
4. Cao X et al., "Spike protein of SARS-CoV-2 activates macrophages and contributes to induction of acute lung inflammation in male mice," *FASEB J.* 2021, 35, e21801. doi: <https://doi.org/10.1096/fj.202002742RR>
5. Caohuy H et al., "Inflammation in the COVID-19 airway is due to inhibition of CFTR signaling by the SARS-CoV-2 spike protein," *Sci. Rep.* 2024, 14: 16895. doi: <https://doi.org/10.1038/s41598-024-66473-4>
6. Chittasupho C et al., "Inhibition of SARS-CoV-2-Induced NLRP3 Inflammasome-Mediated Lung Cell Inflammation by Triphala-Loaded Nanoparticle Targeting Spike Glycoprotein S1," *Pharmaceutics* 2024, 16, 6: 751. <https://doi.org/10.3390/pharmaceutics16060751>
7. Chittasupho C et al., "Targeting spike glycoprotein S1 mediated by NLRP3 inflammasome machinery and the cytokine releases in A549 lung epithelial cells by nanocurcumin," *Pharmaceuticals* (Basel) 2023, 16, 6: 862. doi: <https://doi.org/10.3390/ph16060862>
8. Del Re A et al., "Intranasal delivery of PEA-producing *Lactobacillus paracasei* F19 alleviates SARS-CoV-2 spike protein-induced lung injury in mice," *Transl. Med. Commun.* 2024, 9, 9. doi: <https://doi.org/10.1186/s41231-024-00167-x>
9. Forsyth CB et al., "The SARS-CoV-2 S1 spike protein promotes MAPK and NF-κB activation in human lung cells and inflammatory cytokine production in human lung and intestinal epithelial cells," *Microorganisms* 2022, 10, 10: 1996. doi: <https://doi.org/10.3390/microorganisms10101996>
10. Fraser ME et al., "SARS-CoV-2 Spike Protein and Viral RNA Persist in the Lung of Patients With Post-COVID Lung Disease (abstract)," *Am J Respir Crit Care Med* 2024, 209: A4193. doi: https://doi.org/10.1164/ajrccm-conference.2024.209.1_MeetingAbstracts.A4193
11. Greenberger JS et al., "SARS-CoV-2 Spike Protein Induces Oxidative Stress and Senescence in Mouse and Human Lung," *In Vivo* 2024, 38, 4: 1546-1556; doi: <https://doi.org/10.21873/invivo.13605>
12. Jana S et al., "Cell-free hemoglobin does not attenuate the effects of SARS-CoV-2 spike protein S1 subunit in pulmonary endothelial cells," *Int. J. Mol. Sci.* 2021, 22, 16: 9041. doi: <https://doi.org/10.3390/ijms22169041>
13. Kulkoviene G et al., "Differential Mitochondrial, Oxidative Stress and Inflammatory Responses to SARS-CoV-2 Spike Protein Receptor Binding Domain in Human Lung Microvascular, Coronary Artery Endothelial and Bronchial Epithelial Cells," *Int. J. Mol. Sci.* 2024, 25, 6: 3188. doi: <https://doi.org/10.3390/ijms25063188>

14. Liang S et al., "SARS-CoV-2 spike protein induces IL-18-mediated cardiopulmonary inflammation via reduced mitophagy," *Signal Transduct Target Ther* 2023, 8, 103. doi: <https://doi.org/10.1038/s41392-023-01368-w>
15. Liu T et al., "RS-5645 attenuates inflammatory cytokine storm induced by SARS-CoV-2 spike protein and LPS by modulating pulmonary microbiota," *Int J Biol Sci*. 2021, 17, 13: 3305–3319. doi: [10.7150/ijbs.63329](https://doi.org/10.7150/ijbs.63329)
16. Palestra F et al. "SARS-CoV-2 Spike Protein Activates Human Lung Macrophages," *Int. J. Mol. Sci*. 2023, 24, 3: 3036. doi: <https://doi.org/10.3390/ijms24033036>
17. Park C et al., "Murine alveolar Macrophages Rapidly Accumulate intranasally Administered SARS-CoV-2 Spike Protein leading to neutrophil Recruitment and Damage," *Elife* 2024, 12: RP86764. doi: <https://doi.org/10.7554/eLife.86764.3>
18. Puthia MTL et al., "Experimental model of pulmonary inflammation induced by SARS-CoV-2 spike protein and endotoxin," *ACS Pharmacol Transl Sci*. 2022, 5, 3: 141–8. doi: <https://doi.org/10.1021/acspsci.1c00219>
19. Rahman M et al., "Differential Effect of SARS-CoV-2 Spike Glycoprotein 1 on Human Bronchial and Alveolar Lung Mucosa Models: Implications for Pathogenicity," *Viruses* 2021, 13, 12: 2537. doi: <https://doi.org/10.3390/v13122537>
20. Ruben ML et al., "The SARS-CoV-2 spike protein subunit S1 induces COVID-19-like acute lung injury in K18-hACE2 transgenic mice and barrier dysfunction in human endothelial cells," *Am J Physiol Lung Cell Mol Physiol*. 2021, 321, 2: L477-L484. doi: <https://doi.org/10.1152/ajplung.00223.2021>
21. Segura-Villalobos D et al., "Jacareubin inhibits TLR4-induced lung inflammatory response caused by the RBD domain of SARS-CoV-2 Spike protein," *Pharmacol. Rep*. 2022, 74: 1315–1325. doi: <https://doi.org/10.1007/s43440-022-00398-5>
22. Semmarath W et al., "Cyanidin-3-O-glucoside and Peonidin-3-O-glucoside-Rich Fraction of Black Rice Germ and Bran Suppresses Inflammatory Responses from SARS-CoV-2 Spike Glycoprotein S1-Induction In Vitro in A549 Lung Cells and THP-1 Macrophages via Inhibition of the NLRP3 Inflammasome Pathway," *Nutrients* 2022, 14, 13: 2738. doi: <https://doi.org/10.3390/nu14132738>
23. Sirsendu J et al., "Cell-Free Hemoglobin Does Not Attenuate the Effects of SARS-CoV-2 Spike Protein S1 Subunit in Pulmonary Endothelial Cells," *Int. J. Mol. Sci*. 2021, 22, 16: 9041. doi: <https://doi.org/10.3390/ijms22169041>
24. Sui Y et al., "SARS-CoV-2 Spike Protein Suppresses ACE2 and Type I Interferon Expression in Primary Cells From Macaque Lung Bronchoalveolar Lavage," *Front. Immunol*. 2021, 12. doi: <https://doi.org/10.3389/fimmu.2021.658428>
25. Sung PS et al., "CLEC5A and TLR2 Are Critical in SARS-CoV-2-Induced NET Formation and Lung Inflammation," *J. Biomed. Sci*. 2022, 29, 52. doi: <https://doi.org/10.1186/s12929-022-00832-z>
26. Suzuki YJ et al., "SARS-CoV-2 spike protein-mediated cell signaling in lung vascular cells," *Vascul. Pharmacol*. 2021, 137: 106823. doi: <https://doi.org/10.1016/j.vph.2020.106823>

27. Yeung-Luk BH et al., "SARS-CoV-2 infection alters mitochondrial and cytoskeletal function in human respiratory epithelial cells mediated by expression of spike protein," *mBio* 2023, 14, 4: e00820-23. doi: <https://doi.org/10.1128/mbio.00820-23>
28. Zekri-Nechar K et al., "Spike Protein Subunits of SARS-CoV-2 Alter Mitochondrial Metabolism in Human Pulmonary Microvascular Endothelial Cells: Involvement of Factor Xa," *Dis. Markers* 2022, 1118195. doi: <https://doi.org/10.1155/2022/1118195>

CC. Renin-Angiotensin-Aldosterone System

1. Burnett FN et al., "SARS-CoV-2 Spike Protein Intensifies Cerebrovascular Complications in Diabetic hACE2 Mice through RAAS and TLR Signaling Activation," *Int. J. Mol. Sci.* 2023, 24, 22: 16394. doi: <https://doi.org/10.3390/ijms242216394>
2. Lehmann KJ, "SARS-CoV-2-Spike Interactions with the Renin-Angiotensin-Aldosterone System – Consequences of Adverse Reactions of Vaccination," *J Biol Today's World* 2023, 12/4: 001-013. doi: <https://doi.org/10.31219/osf.io/27g5h>
3. Matsuzawa Y et al., "Impact of Renin–Angiotensin–Aldosterone System Inhibitors on COVID-19," *Hypertens. Res.* 2022, 45, 7: 1147–1153, doi: <https://doi.org/10.1038/s41440-022-00922-3>

DD. Senescence/aging

1. Duarte C, "Age-dependent effects of the recombinant spike protein/SARS-CoV-2 on the M-CSF- and IL-34-differentiated macrophages in vitro," *Biochem. Biophys. Res. Commun.* 2021, 546: 97–102. doi: <https://doi.org/10.1016/j.bbrc.2021.01.104>
2. Greenberger JS et al., "SARS-CoV-2 Spike Protein Induces Oxidative Stress and Senescence in Mouse and Human Lung," *In Vivo* 2024, 38, 4: 1546-1556. doi: <https://doi.org/10.21873/invivo.13605>
3. Meyer K et al., "SARS-CoV-2 Spike Protein Induces Paracrine Senescence and Leukocyte Adhesion in Endothelial Cells," *J. Virol.* 2021, 95, e0079421. doi: <https://doi.org/10.1128/jvi.00794-21>

EE. Stem cells

1. Balzanelli MG et al., "The Role of SARS-CoV-2 Spike Protein in Long-term Damage of Tissues and Organs, the Underestimated Role of Retrotransposons and Stem Cells, a Working Hypothesis," *Endocr Metab Immune Disord Drug Targets* 2025, 25, 2: 85-98. doi: [10.2174/0118715303283480240227113401](https://doi.org/10.2174/0118715303283480240227113401)
2. Kucia M et al. "An evidence that SARS-Cov-2/COVID-19 spike protein (SP) damages hematopoietic stem/progenitor cells in the mechanism of pyroptosis in Nlrp3 inflammasome-dependent manner," *Leukemia* 2021, 35: 3026-3029. doi: <https://doi.org/10.1038/s41375-021-01332-z>
3. Ropa J et al., "Human Hematopoietic Stem, Progenitor, and Immune Cells Respond Ex Vivo to SARS-CoV-2 Spike Protein," *Stem Cell Rev Rep.* 2021, 17, 1: 253-265. doi: <https://doi.org/10.1007/s12015-020-10056-z>

FF. Syncytia/cell fusion

1. Braga L et al., “Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia,” *Nature* 2021, 594: 88–93. doi: <https://doi.org/10.1038/s41586-021-03491-6>
2. Cattin-Ortolá J et al., “Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate expression at the cell surface and syncytia formation,” *Nat Commun* 2021, 12, 1: 5333. doi: <https://doi.org/10.1038/s41467-021-25589-1>
3. Clemens DJ et al., “SARS-CoV-2 spike protein-mediated cardiomyocyte fusion may contribute to increased arrhythmic risk in COVID-19,” *PLoS One* 2023, 18, 3: e0282151. doi: <https://doi.org/10.1371/journal.pone.0282151>
4. Lazebnik Y, “Cell fusion as a link between the SARS-CoV-2 spike protein, COVID-19 complications, and vaccine side effects,” *Oncotarget* 2021, 12, 25: 2476-2488. doi: <https://doi.org/10.18632/oncotarget.28088>
5. Liu X et al., “SARS-CoV-2 spike protein-induced cell fusion activates the cGAS-STING pathway and the interferon response,” *Sci Signal*. 2022, 15, 729: eabg8744. doi: [10.1126/scisignal.abg8744](https://doi.org/10.1126/scisignal.abg8744)
6. Martinez-Marmol R et al., “SARS-CoV-2 infection and viral fusogens cause neuronal and glial fusion that compromises neuronal activity,” *Sci. Adv.* 2023, 9, 23. doi: [10.1126/sciadv.adg2248](https://doi.org/10.1126/sciadv.adg2248)
7. Rajah MM et al., “SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced spike-mediated syncytia formation,” *EMBO J.* 2021, 40: e108944. doi: <https://doi.org/10.15252/embj.2021108944>
8. Shirato K and Takako Kizaki, “SARS-CoV-2 Spike Protein S1 Subunit Induces Pro- inflammatory Responses via Toll-Like Receptor 4 Signaling in Murine and Human Macrophages,” *Heliyon* 2021, 7, 2: e06187. doi: <https://doi.org/10.1016/j.heliyon.2021.e06187>
9. Theuerkauf SA et al., “Quantitative assays reveal cell fusion at minimal levels of SARS-CoV-2 spike protein and fusion from without,” *iScience* 2021, 24, 3: 102170. doi: <https://doi.org/10.1016/j.isci.2021.102170>
10. Zhang Z et al., “SARS-CoV-2 spike protein dictates syncytium-mediated lymphocyte elimination,” *Cell Death Differ.* 2021, 28: 2765–2777. doi: <https://doi.org/10.1038/s41418-021-00782-3>

GG. Therapeutics

1. Almejdi AM et al., “SARS-CoV-2 Spike Protein: Pathogenesis, Vaccines, and Potential Therapies,” *Infection* 2021, 49, 5: 855–876. doi: <https://doi.org/10.1007/s15010-021-01677-8>
2. Boretti A, “PQQ Supplementation and SARS-CoV-2 Spike Protein-Induced Heart Inflammation,” *Nat. Prod. Commun.* 2022, 17, 1934578x221080929. doi: <https://doi.org/10.1177/1934578X221080929>
3. Boschi C et al., “SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects,” *Int. J. Biol. Macromol.* 2022, 23, 24: 15480. doi: <https://doi.org/10.3390/ijms232415480>

4. Braga L et al., "Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia," *Nature* 2021, 594: 88–93. doi: <https://doi.org/10.1038/s41586-021-03491-6>
5. Chang MH et al., "SARS-CoV-2 Spike Protein 1 Causes Aggregation of α -Synuclein via Microglia-Induced Inflammation and Production of Mitochondrial ROS: Potential Therapeutic Applications of Metformin," *Biomedicines* 2024, 12, 6: 1223. doi: <https://doi.org/10.3390/biomedicines12061223>
6. Chittasupho C et al., "Inhibition of SARS-CoV-2-Induced NLRP3 Inflammasome-Mediated Lung Cell Inflammation by Triphala-Loaded Nanoparticle Targeting Spike Glycoprotein S1," *Pharmaceutics* 2024, 16, 6: 751. doi: <https://doi.org/10.3390/pharmaceutics16060751>
7. Chittasupho C et al., "Targeting spike glycoprotein S1 mediated by NLRP3 inflammasome machinery and the cytokine releases in A549 lung epithelial cells by nanocurcumin," *Pharmaceutics* (Basel) 2023, 16, 6: 862. doi: <https://doi.org/10.3390/ph16060862>
8. Corpetti C et al., "Cannabidiol inhibits SARS-Cov-2 spike (S) protein-induced cytotoxicity and inflammation through a PPAR γ -dependent TLR4/NLRP3/Caspase-1 signaling suppression in Caco-2 cell line," *Phytother. Res.* 2021, 35, 12: 6893–6903. doi: <https://doi.org/10.1002/ptr.7302>
9. Cory TJ et al., "Metformin Suppresses Monocyte Immunometabolic Activation by SARS-CoV-2 Spike Protein Subunit 1," *Front. Immunol.* 2021, 12 (Sec. Cytokines and Soluble Mediators in Immunity): 733921. doi: <https://doi.org/10.3389/fimmu.2021.733921>
10. Del Re A et al., "Intranasal delivery of PEA-producing *Lactobacillus paracasei* F19 alleviates SARS-CoV-2 spike protein-induced lung injury in mice," *Transl. Med. Commun.* 2024, 9, 9. doi: <https://doi.org/10.1186/s41231-024-00167-x>
11. Del Re A et al., "Ultramicronized Palmitoylethanolamide Inhibits NLRP3 Inflammasome Expression and Pro-Inflammatory Response Activated by SARS-CoV-2 Spike Protein in Cultured Murine Alveolar Macrophages," *Metabolites* 2021, 11, 9: 592. doi: <https://doi.org/10.3390/metabo11090592>
12. Ferrer MD et al., "Nitrite Attenuates the In Vitro Inflammatory Response of Immune Cells to the SARS-CoV-2 S Protein without Interfering in the Antioxidant Enzyme Activation," *Int. J. Mol. Sci.* 2024, 25, 5: 3001. <https://doi.org/10.3390/ijms25053001>
13. Frank MG et al., "SARS-CoV-2 S1 subunit produces a protracted priming of the neuroinflammatory, physiological, and behavioral responses to a remote immune challenge: A role for corticosteroids," *Brain Behav. Immun.* 2024, 121: 87-103. doi: <https://doi.org/10.1016/j.bbi.2024.07.034>
14. Frühbeck G et al., "FNDC4 and FNDC5 reduce SARS-CoV-2 entry points and spike glycoprotein S1-induced pyroptosis, apoptosis, and necroptosis in human adipocytes," *Cell Mol Immunol.* 2021, 18, 10: 2457–9. doi: <https://doi.org/10.1038/s41423-021-00762-0>
15. Gasparello J et al., "Sulforaphane inhibits the expression of interleukin-6 and interleukin-8 induced in bronchial epithelial IB3-1 cells by exposure to the SARS-CoV-2 Spike protein," *Phytomedicine* 2021, 87: 153583. doi: <https://doi.org/10.1016/j.phymed.2021.153583>
16. Halma MTJ et al., "Exploring autophagy in treating SARS-CoV-2 spike protein-related pathology," *Endocrinol Metab (EnM)* 2024, 14: 100163. doi: <https://doi.org/10.1016/j.endmts.2024.100163>
17. Halma MTJ et al., "Strategies for the Management of Spike Protein-Related Pathology," *Microorganisms* 2023, 11, 5: 1308. doi: <https://doi.org/10.3390/microorganisms11051308>

18. Jana S et al., "Cell-free hemoglobin does not attenuate the effects of SARS-CoV-2 spike protein S1 subunit in pulmonary endothelial cells," *Int. J. Mol. Sci.* 2021, 22, 16: 9041. doi: <https://doi.org/10.3390/ijms22169041>
19. Jugler C et al., "SARS-CoV-2 Spike Protein-Induced Interleukin 6 Signaling Is Blocked by a Plant-Produced Anti-Interleukin 6 Receptor Monoclonal Antibody," *Vaccines* 2021, 9, 11: 1365. doi: <https://doi.org/10.3390/vaccines9111365>
20. Ken W et al., "Low dose radiation therapy attenuates ACE2 depression and inflammatory cytokines induction by COVID-19 viral spike protein in human bronchial epithelial cells," *Int J Radiat Biol.* 2022, 98, 10:1532-1541. doi: <https://doi.org/10.1080/09553002.2022.2055806>
21. Kumar N et al., "SARS-CoV-2 spike protein S1-mediated endothelial injury and pro-inflammatory state Is amplified by dihydrotestosterone and prevented by mineralocorticoid antagonism," *Viruses* 2021, 13, 11: 2209. doi: <https://doi.org/10.3390/v13112209>
22. Liu T et al., "RS-5645 attenuates inflammatory cytokine storm induced by SARS-CoV-2 spike protein and LPS by modulating pulmonary microbiota," *Int J Biol Sci.* 2021, 17, 13: 3305–3319. doi: [10.7150/ijbs.63329](https://doi.org/10.7150/ijbs.63329)
23. Loh D, "The potential of melatonin in the prevention and attenuation of oxidative hemolysis and myocardial injury from cd147 SARS-CoV-2 spike protein receptor binding," *Melatonin Research* 2020, 3, 3: 380-416. doi: <https://doi.org/10.32794/mr11250069>
24. Loh JT et al., "Dok3 restrains neutrophil production of calprotectin during TLR4 sensing of SARS-CoV-2 spike protein," *Front. Immunol.* 2022, 13 (Sec. Molecular Innate Immunity). doi: <https://doi.org/10.3389/fimmu.2022.996637>
25. Marrone L et al., "Tirofiban prevents the effects of SARS-CoV-2 spike protein on macrophage activation and endothelial cell death," *Heliyon* 2024, 10, 15: e35341. doi: [10.1016/j.heliyon.2024.e35341](https://doi.org/10.1016/j.heliyon.2024.e35341)
26. Norris B et al., "Evaluation of Glutathione in Spike Protein of SARS-CoV-2 Induced Immunothrombosis and Cytokine Dysregulation," *Antioxidants* 2024, 13, 3: 271. doi: <https://doi.org/10.3390/antiox13030271>
27. Oka N et al., "SARS-CoV-2 S1 protein causes brain inflammation by reducing intracerebral acetylcholine production," *iScience* 2023, 26, 6: 106954. doi: [10.1016/j.isci.2023.106954](https://doi.org/10.1016/j.isci.2023.106954)
28. Olajide OA et al., "Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone," *Inflammation* 2021, 44: 1865–1877. doi: <https://doi.org/10.1007/s10753-021-01464-5>
29. Petrosino S and N Matende, "Elimination/Neutralization of COVID-19 Vaccine-Produced Spike Protein: Scoping Review," *Mathews Journal of Nutrition & Dietetics* 2024, 7, 2. doi: <https://doi.org/10.30654/MJND.10034>
30. Satta S et al., "An engineered nano-liposome-human ACE2 decoy neutralizes SARS-CoV-2 Spike protein-induced inflammation in both murine and human macrophages," *Theranostics* 2022, 12, 6: 2639–2657. doi: [10.7150/thno.66831](https://doi.org/10.7150/thno.66831)

31. Segura-Villalobos D et al., “Jacareubin inhibits TLR4-induced lung inflammatory response caused by the RBD domain of SARS-CoV-2 Spike protein,” *Pharmacol. Rep.* 2022, 74: 1315–1325. doi: <https://doi.org/10.1007/s43440-022-00398-5>
32. Semmarath W et al., “Cyanidin-3-O-glucoside and Peonidin-3-O-glucoside-Rich Fraction of Black Rice Germ and Bran Suppresses Inflammatory Responses from SARS-CoV-2 Spike Glycoprotein S1-Induction In Vitro in A549 Lung Cells and THP-1 Macrophages via Inhibition of the NLRP3 Inflammasome Pathway,” *Nutrients* 2022, 14, 13: 2738. doi: <https://doi.org/10.3390/nu14132738>
33. Suprewicz L et al., “Recombinant human plasma gelsolin reverses increased permeability of the blood-brain barrier induced by the spike protein of the SARS-CoV-2 virus,” *J Neuroinflammation* 2022, 19, 1: 282. doi: <https://doi.org/10.1186/s12974-022-02642-4>
34. Vargas-Castro R et al., “Calcitriol prevents SARS-CoV spike-induced inflammation in human trophoblasts through downregulating ACE2 and TMPRSS2 expression,” *J Steroid Biochem Mol Biol* 2025, 245: 106625. doi: <https://doi.org/10.1016/j.jsbmb.2024.106625>
35. Visvabharathy L et al., “Case report: Treatment of long COVID with a SARS-CoV-2 antiviral and IL-6 blockade in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence,” *Front. Med.* 2022, 9 (Sec. Infectious Diseases – Surveillance). doi: <https://doi.org/10.3389/fmed.2022.1003103>
36. Yonker LM et al., “Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier,” *J Clin Invest.* 2021, 131, 14: e149633. doi: <https://doi.org/10.1172/JCI149633>
37. Youn JY et al., “Therapeutic application of estrogen for COVID-19: Attenuation of SARS-CoV-2 spike protein and IL-6 stimulated, ACE2-dependent NOX2 activation, ROS production and MCP-1 upregulation in endothelial cells,” *Redox Biol.* 2021, 46: 102099. doi: <https://doi.org/10.1016/j.redox.2021.102099>
38. Yu J et al., “Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition,” *Blood* 2020, 136, 18: 2080–2089. doi: <https://doi.org/10.1182/blood.2020008248>

HH. Toll-like receptors (TLRs)

1. Aboudounya MM and RJ Heads, “COVID-19 and Toll-Like Receptor 4 (TLR4): SARS-CoV-2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation,” *Mediators Inflamm.* 2021: 8874339. doi: <https://doi.org/10.1155/2021/8874339>
2. Burnett FN et al., “SARS-CoV-2 Spike Protein Intensifies Cerebrovascular Complications in Diabetic hACE2 Mice through RAAS and TLR Signaling Activation,” *Int. J. Mol. Sci.* 2023, 24, 22: 16394. doi: <https://doi.org/10.3390/ijms242216394>
3. Carnevale R et al., “Toll-Like Receptor 4-Dependent Platelet-Related Thrombosis in SARS-CoV-2 Infection,” *Circ. Res.* 2023, 132, 3: 290–305. doi: <https://doi.org/10.1161/CIRCRESAHA.122.321541>
4. Corpetti C et al., “Cannabidiol inhibits SARS-Cov-2 spike (S) protein-induced cytotoxicity and inflammation through a PPARγ-dependent TLR4/NLRP3/Caspase-1 signaling suppression in Caco-2 cell line,” *Phytother. Res.* 2021, 35, 12: 6893–6903. doi: <https://doi.org/10.1002/ptr.7302>

5. Fontes-Dantas FL, "SARS-CoV-2 Spike Protein Induces TLR4-Mediated Long- Term Cognitive Dysfunction Recapitulating Post-COVID-19 Syndrome in Mice," *Cell Reports* 2023, 42, 3: 112189, doi: <https://doi.org/10.1016/j.celrep.2023.112189>
6. Khan S et al., "SARS-CoV-2 Spike Protein Induces Inflammation via TLR2-Dependent Activation of the NF-κB Pathway," *eLife* 2021, 10: e68563. doi: <https://doi.org/10.7554/elife.68563>
7. Kim MJ et al., "The SARS-CoV-2 spike protein induces lung cancer migration and invasion in a TLR2-dependent manner," *Cancer Commun (London)* 2023, 44, 2: 273–277. doi: <https://doi.org/10.1002/cac2.12485>
8. Kircheis R and O Planz, "Could a Lower Toll-like Receptor (TLR) and NF-κB Activation Due to a Changed Charge Distribution in the Spike Protein Be the Reason for the Lower Pathogenicity of Omicron?" *Int. J. Mol. Sci.* 2022, 23, 11: 5966. doi: <https://doi.org/10.3390/ijms23115966>
9. Loh JT et al., "Dok3 restrains neutrophil production of calprotectin during TLR4 sensing of SARS-CoV-2 spike protein," *Front. Immunol.* 2022, 13 (Sec. Molecular Innate Immunity). doi: <https://doi.org/10.3389/fimmu.2022.996637>
10. Segura-Villalobos D et al., "Jacareubin inhibits TLR4-induced lung inflammatory response caused by the RBD domain of SARS-CoV-2 Spike protein," *Pharmacol. Rep.* 2022, 74: 1315–1325. doi: <https://doi.org/10.1007/s43440-022-00398-5>
11. Sirsendu J et al., "Cell-Free Hemoglobin Does Not Attenuate the Effects of SARS-CoV-2 Spike Protein S1 Subunit in Pulmonary Endothelial Cells," *Int. J. Mol. Sci.*, 2021, 22, 16: 9041. doi: <https://doi.org/10.3390/ijms22169041>
12. Sung PS et al., "CLEC5A and TLR2 Are Critical in SARS-CoV-2-Induced NET Formation and Lung Inflammation," *J. Biomed. Sci.* 2022, 29, 52. doi: <https://doi.org/10.1186/s12929-022-00832-z>
13. Zaki H and S Khan, "SARS-CoV-2 spike protein induces inflammatory molecules through TLR2 in macrophages and monocytes," *J. Immunol.* 2021, 206 (1_supplement): 62.07. doi: <https://doi.org/10.4049/jimmunol.206.Supp.62.07>
14. Zaki H and S Khan, "TLR2 senses spike protein of SARS-CoV-2 to trigger inflammation," *J. Immunol.* 2022, 208 (1_Supplement): 125.30. doi: <https://doi.org/10.4049/jimmunol.208.Supp.125.30>
15. Zhao Y et al., "SARS-CoV-2 spike protein interacts with and activates TLR4," *Cell Res.* 2021, 31: 818–820. doi: <https://doi.org/10.1038/s41422-021-00495-9>